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Summary 
BACKGROUND: Testosterone is vital to the development of normal male characteristics and function. 
However, chemicals present in foods and products in everyday use can impair the production of testosterone 
in experimental animals. Studies in Danish men have shown declining sperm production over several 
decades, and as environmental factors are suspected of being part of the cause, research in the link between 
chemical exposure and reproductive function is necessary. Certain phthalates, which are abundantly used in 
PVC and other materials such as paints and glue, are known to reduce testosterone production in fetal male 
rats leading to malformations of the reproductive system and impaired reproductive function later in life.  
AIMS AND METHODS: This PhD project investigated prenatal exposure of male rats to phthalates and 
other chemicals suspected of affecting fetal testosterone production in order to gain more knowledge on 
these chemicals and thereby improve risk assessment. Several rat studies were performed using similar study 
designs: Pregnant Wistar rats were gavaged with test compounds from gestation day (GD) 7 to GD 21, when 
their male offspring was examined and compared to controls. In a few studies, other dams gave birth and 
were dosed until postnatal day 17, and male offspring was examined at various ages thereafter. 
Diethylhexyl phthalate (DEHP) affects testicular development and function in rats and is increasingly being 
substituted with alternative plasticizers in consumer products. We investigated whether DEHP-like fetal 
testicular effects could be induced with diisononyl phthalate (DINP) or diisobutyl phthalate (DIBP), which 
are increasingly being used as substitutes for DEHP and other toxic phthalates. Furthermore, effects of 
different mixtures were examined: a) a mixture of DEHP and DINP, and b) a mixture of DEHP and another 
plasticizer, diethylhexyl adipate (DEHA), having a common metabolite. Additionally, the hormonal and 
histopathological effects of perinatal DEHP exposure of male rats were examined with focus on how the 
effects progress during the lifespan of the rat. Studies on testicular gene expression and 
immunohistochemistry were performed to elaborate on the mechanisms behind the reproductive effects of  
phthalates as well as the fungicide prochloraz.  
Based on a hypothesis on the possible involvement of peroxisome proliferators-activated receptors (PPARs) 
in the downregulation of testosterone production by phthalates and other chemicals, a reporter gene assay 
was developed for screening of chemicals for interaction with PPARα and PPARγ. Additionally, PPAR-
activating chemicals were tested for effects on testosterone production in fetal rat studies. 
RESULTS AND DISCUSSION: DINP and DIBP reduced fetal testicular testosterone production and –
content and affected fetal testicular histopathology similarly to the known reproductive toxicant DEHP, 
pointing to a similar adverse effect pattern for these phthalates. Combined exposure to DEHP and DINP 
induced accumulated effects compared to the effects seen with each compound alone. 
The studies have elaborated on the temporal development of the testicular histopathological effects of DEHP, 
supporting the findings described for di-n-butyl phthalate (DBP) by other investigators. These findings 
include effects on Leydig cells, gonocytes and Sertoli cells in fetal testes. Later in life, some testes 
degenerated while most regenerated. However, dysgenetic areas were present in otherwise normal testes of 
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DEHP-exposed young and adult rats. No modulating effects of DEHA on the reproductive effects of DEHP 
were observed. 
The testosterone-reducing effect of DEHP and DIBP is related to reduced levels of factors related to steroid 
synthesis. Protein levels of cytochrome P450 side chain cleavage (P450scc), steroidogenic acute regulatory 
protein (StAR), cytochrome P450c17 (CYP17) and PPARγ were less abundant in testes from phthalate-
exposed fetuses as evaluated by immunohistochemistry. Correspondingly, mRNA levels of genes coding for 
these factors as well as scavenger receptor B-1 (SR-B1), steroidogenic factor-1 (SF1), and PPARα were 
reduced in testes of phthalate-exposed fetal rats. Based on literature studies and indications from in vivo 
studies, it is suggested that the phthalate mechanism of action may involve the nuclear receptors SF1, PPARγ 
and PPARα, although further studies are needed.  
Immunohistochemical studies on expression levels of factors involved in steroid synthesis elaborated on the 
mode of action of prochloraz. Prochloraz-exposed male fetuses had reduced testosterone synthesis, but no 
differences in the immunostaining intensity for P450scc or StAR in Leydig cells. On the other hand, 
increased immunostaining intensity for CYP17 was seen in Leydig cells of prochloraz-exposed fetuses, 
emphasizing the importance of CYP17 in the mode of action of this compound. Additionally, a possible role 
of the enzyme 17β-hydroxysteroid dehydrogenase (17βHSD) type 10 in the mechanism of action of 
prochloraz was suggested due to reduced expression of 17βHSD type 10 in Leydig cells of prochloraz-
exposed fetuses. It is not clear whether this is a cause or an effect of the low testosterone production in 
prochloraz-exposed males. 
The widely used preservatives butylparaben and propylparaben were shown to be weak agonists of PPARα 
and PPARγ in vitro. Further studies may reveal whether the interaction of parabens with PPARs can interfere 
with normal physiological processes in testes or other tissues. If these receptors are indeed involved in the 
testosterone-reducing effects of certain chemicals, reporter gene assays for PPARα and PPARγ such as those 
employed in the current studies may be valuable tools for screening chemicals for similar modes of action as 
phthalates, and may thus reveal other chemicals with potentially harmful effects. 
CONCLUSIONS AND PERSPECTIVES: DINP and DIBP had similar effects on fetal rat testicular 
development and function as DEHP, and there is thus a reason for concern for the use of DINP and DIBP as 
substitutes for the reproductive toxicants DEHP or DBP. Furthermore, the observation of an accumulating 
effect when exposing rats to a mixture of DEHP and DINP indicates an increased risk in case of exposure to 
mixtures of chemicals with similar effects. Therefore, risk assessment should take into account the collective 
contribution of exposure to several reproductive toxic phthalates.  
New insights have been made regarding phthalate and prochloraz mechanisms of action. It is not evident 
whether exposure to phthalates or other compounds interfering with fetal testosterone production or 
androgen function contributes to the testicular dysgenesis syndrome observed in humans. There appears to be 
a reason for concern that several chemicals have antiandrogenic effects and that the increasing incidence of 
male reproductive dysfunction may be due to combined exposure to antiandrogens. It is therefore highly 
relevant to be able to detect chemicals with antiandrogenic effects by use of adequate regulatory test 
guidelines and subsequently to be able to reduce human exposure to antiandrogens by regulatory initiatives.
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Dansk resumé 
BAGGRUND: Testosteron er vigtig for reguleringen af den mandlige udvikling. I de senere år har det vist 
sig, at kemikalier i fødevarer og forbrugerprodukter kan virke hormonforstyrrende ved bl.a. at hæmme 
dannelsen af testosteron hos forsøgsdyr. Samtidig har undersøgelser vist, at sædkvaliteten hos danske mænd 
er faldende og forekomsten af misdannelser i reproduktionssystemet stigende, og en sammenhæng med 
hormonforstyrrende stoffer er foreslået. For eksempel er visse phthalater, som anvendes i blandt andet PVC, 
lim og maling, mistænkt for at virke hormonforstyrrende hos mennesker, idet disse phthalater kan hæmme 
testosteronproduktionen hos hanrotter i fostertilstanden og medføre misdannelser samt nedsætte 
reproduktionsevnen senere i livet. 
FORMÅL OG METODER: I dette PhD-projekt er foretaget en række studier af hanrotter, der i foster-
tilstanden er eksponeret for phthalater og andre forurenende kemikalier mistænkt for at påvirke testosteron-
produktionen. Øget viden om disse stoffer og mekanismerne bag deres skadelige effekter ønskes for at kunne 
forbedre risikovurderingen. En række rottestudier er udført med udgangspunkt i et fælles forsøgsdesign: 
Drægtige Wistar rotter er oralt doseret med mulige hormonforstyrrende stoffer fra gestationsdag (GD) 7 til 
21, hvor deres hanunger blev undersøgt og sammenlignet med ikke-doserede dyr. I enkelte studier er 
doseringen fortsat til dag 17 efter fødslen, og hanungerne er undersøgt i forskellige aldersgrupper. 
Diethylhexyl phthalat (DEHP) påvirker testiklernes udvikling og funktion hos rotter og bliver i stigende grad 
erstattet med andre plastblødgørere i forbrugerprodukter. Vi har derfor undersøgt om DEHP-lignende 
effekter ses ved eksponering med diisononyl phthalat (DINP) eller diisobutyl phthalat (DIBP), der anvendes 
som erstatning for bl.a. DEHP. Desuden undersøgtes effekterne af kombineret eksponering for to kemikalier: 
a) en kombination af DEHP og DINP og b) en kombination af DEHP med en anden plastblødgører, 
diethylhexyl adipat, DEHA, som har visse træk tilfælles med DEHP. Desuden blev det undersøgt, hvordan 
de histologiske og hormonelle forandringer forårsaget af DEHP udviklede sig igennem rottens levetid. 
Immunhistokemiske studier samt genekspressionsanalyser blev udført for at øge kendskabet til 
mekanismerne bag de reproduktionsskadelige effekter af phthalaterne samt af sprøjtegiften prochloraz. 
Da peroxisom proliferator-aktiverede receptorer (PPARs) kan tænkes at være involveret i phthalaternes 
testosteron-hæmmende virkning, er et reportergen assay udviklet for at kunne screene kemikalier for deres 
evne til at aktivere eller hæmme PPARs. I forlængelse af denne hypotese blev PPAR- som PFOA, 
rosiglitazon og butylparaben undersøgt for mulig påvirkning af testosteronproduktionen hos rottefostre. 
RESULTATER OG DISKUSSION: DINP og DIBP havde samme virkning som DEHP, idet de reducerede 
testosteronproduktionen og forårsagede histopatologiske forandringer i testiklerne hos doserede rottefostre. 
Disse fund hos rottefostre tyder på, at DINP og DIBP kan have samme skadelige effekter som DEHP også 
senere i livet og derfor vil være uegnede som erstatninger for DEHP. Desuden medførte dosering med en 
kombination af DEHP og DINP en samlet effekt som var mere markant end effekten af de enkelte stoffer. 
Undersøgelserne af den tidsmæssige udvikling i de histologiske forandringer som følge af DEHP 
eksponering viste ligheder med observationer i forsøg med di-n-butyl phthalat beskrevet i litteraturen. Hos 
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DEHP-eksponerede fostre sås forandringer af Leydig celler, Sertoli celler og kønsceller i næsten alle 
testikler, mens der hos voksne rotter snarere sås et alt-eller-intet respons, idet visse testikler var degenererede 
og uden sædceller, mens de fleste forekom normale. Endvidere sås dysgene områder i testiklerne hos unge 
og voksne DEHP-doserede rotter. Eksponering for en kombination af DEHP og DEHA tydede ikke på at 
DEHA modulerede effekten af DEHP. 
Den lave testosteronproduktion hos phthalat-doserede rotter er relateret til en nedregulering af gener og 
proteiner i steroidsyntesen. Immunhistokemiske studier påviste lavere proteinniveauer af cytochrome P450 
side chain cleavage (P450scc), steroidogenic acute regulatory protein (StAR), cytochrome P450c17 (CYP17) 
og PPARγ i Leydig celler hos phthalat-eksponerede fostre. Ligeledes var mRNA for disse faktorer såvel som 
for scavenger receptor B-1 (SR-B1), steroidogenic factor-1 (SF1) og PPARα reduceret i testikler fra 
phthalat-eksponerede dyr. Forandringerne i protein- eller genekspression for SF1, PPARγ og PPARα 
understøtter hypotesen om, at disse kernereceptorer er involveret i phthalaternes virkningsmekanisme, men 
yderligere studier ønskes for at belyse dette. 
Virkningsmekanismen for prochloraz er belyst ved hjælp af immunhistokemiske studier, der påviste øget 
niveau af CYP17 i Leydig celler i testes hos prochloraz-doserede fostre i forhold til kontroldyr. Desuden sås 
et reduceret proteinniveau af enzymet 17β-hydroxysteroid dehydrogenase (17βHSD) type 10, som dermed 
kan tiltænkes en rolle i prochloraz’ virkningsmekanisme, selvom det endnu ikke er afklaret, hvorvidt det lave 
proteinniveau er en årsag til eller en følge af det lave testosteronniveau hos de prochloraz-doserede fostre. 
Reportergen assays blev anvendt til at undersøge transaktivering af PPARγ og PPARα. Butylparaben og 
propylparaben viste svag agonisme til begge receptorer, men det er endnu uafklaret om denne interaktion kan 
påvirke de normale fysiologiske processer i testes eller andre væv. Hvis disse receptorer er involveret i den 
testosteron-hæmmende virkning af phthalater og andre kemikalier, vil reportergen assays som de her 
anvendte være et værdifuldt værktøj til at screene en mængde kemikalier for, om de har 
virkningsmekanismer, der ligner phthalaternes, og dermed muligvis er sundhedsskadelige. 
KONKLUSIONER OG PERSPEKTIVER: Rottestudier viste at DINP og DIBP forstyrrer testiklernes 
udvikling ligesom DEHP, og disse stoffer bør derfor ikke anvendes som erstatning for de 
reproduktionsskadelige phthalater. Eksponering for en kombination af DEHP og DINP medførte mere 
markante hormonforandringer end observeret for de enkelte stoffer. Risikovurderingen bør derfor tage 
hensyn til menneskets samlede eksponering for mange forskellige phthalater med samme effekter. 
Studierne har desuden belyst nye aspekter af mekanismerne bag den lave testosteronproduktion i 
fostertestikler efter eksponering for phthalater eller prochloraz. Det er næppe sandsynligt, at eksponering for 
phthalater eller andre enkeltstoffer med antiandrogen virkning er direkte årsag til den øgede forekomst af 
misdannelser i reproduktionssystemet og nedsat sædkvalitet hos mennesker. Der synes dog at være grund til 
bekymring for, at mennesket er eksponeret for en del kemikalier med antiandrogen virkning, og at den 
samlede antiandrogene påvirkning kan medføre hormonforstyrrelser og skader på mænds 
reproduktionssystem. Det er derfor yderst relevant at udvikle metoder til at detektere kemikalier med 
antiandrogene effekter, samt efterfølgende at gøre det muligt at reducere den humane eksponering for 
antiandrogener ved hjælp af regulatoriske tiltag. 
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1 Introduction 
Testosterone is vital to the development of normal male characteristics and function. However, chemicals 
present in foods and products in everyday use can impair the production of testosterone in experimental 
animals. Studies in Danish men have shown declining sperm production over several decades, and as 
environmental factors are suspected of being part of the cause, research in the link between chemical 
exposure and reproductive function is necessary. Of special interest are the phthalates, which are abundantly 
used in PVC and other materials such as paints and glue. Certain phthalates are known to reduce testosterone 
production in fetal male rats leading to impaired reproductive function later in life.  
 
This PhD project aimed to investigate prenatal exposure of male rats to phthalates and other chemicals 
suspected of affecting fetal testosterone production. This is important in order to gain more knowledge on 
these chemicals and thereby improve risk assessment. Another perspective is that knowledge on the 
mechanism of action of phthalates may be applied in the development of in vitro methods to screen other 
environmental compounds for similar effects. Additionally, mechanistic knowledge can be a key to 
understanding whether the effects are relevant to humans.  
This project mainly focused on phthalate effects in vivo. The hormonal and histopathological effects were 
examined in male rats perinatally exposed to phthalates and other compounds (prochloraz, butylparaben, 
perfluorooctanoate, rosiglitazone) suspected of disrupting reproductive development. The phthalate studies 
examined mechanisms of action, dose-response relationships and effects of mixtures. Additionally, a 
hypothesis on the possible involvement of peroxisome proliferators-activated receptors (PPARs) in the 
testosterone-reducing effect of phthalates encouraged the development and application of reporter gene 
assays for screening of chemicals for interactions with PPARα and PPARγ. 
2 – Background 
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2 Background 
The following sections describe the hypothesis of environmental influences on male reproductive function. 
As this area has received much attention during the last decade, focus will mainly be on studies on phthalate 
effects in order to form a background for the performed studies. 
2.1 Declining male reproductive function and endocrine disrupters 
The number of children born per person in the industrialized and the developmental world has been declining 
within the last decades (reviewed in 1;2). Obviously, the majority of this decline can be related to changing 
family patterns and new possibilities in birth control. In theory, the reduced fertility rate in industrialized 
countries may not be important on a global level, as many developing countries still have rapidly growing 
populations. However, social factors may not be the only explanation. Studies have indicated that incidences 
of disorders in the male reproductive system have been rising within the last 50 years in Denmark 3. If these 
trends are due to environmental and lifestyle influences on reproductive health, the “westernization” of 
developing countries may be associated with global consequences for the human population in the future.  
Testis cancer and malformations of the external male genitalia are now very frequent in Danish young men 
among whom 15 per 100,000 develop testicular cancer and up to 20 % have low semen quality in the 
infertile range 4;5. Incidences of hypospadias and cryptorchidism have been increasing since the 1960’es in 
many countries 3. In Denmark, 5 % of boys exhibit some degree of hypospadia, 9% are born with 
cryptorchidism and 2% are cryptorchid at the age of 3 months 6;7. As cryptorchidism is a risk factor for 
reduced semen quality and development of testis cancer, these statistics seem alarming.  
The testicular dysgenesis syndrome has recently been suggested as a pattern of human reproductive disorders 
presumed to have a common origin 8. Fig. 1 illustrates this hypothesis, i.e. how reduced semen quality, testis 
cancer, hypospadia and testicular maldescent may be related to testicular dysgenesis interfering with Sertoli 
and Leydig cell function. In some cases, testicular dysgenesis is associated with genetic defects, while the 
hypothesis that this syndrome may be related to environmental contaminants (endocrine disrupting 
chemicals) has been investigated and debated intensely in recent years. 
2 – Background 
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Fig. 1. Model of associations between components of the testicular dysgenesis syndrome. Genetic and environmental 
factors may contribute to testicular dysgenesis, i.e. disturbed development of Leydig, Sertoli and germ cells. 
Malfunction of these cell types may lead to reduced semen quality, testis cancer development, hypospadias and 
cryptorchidism. From Skakkebæk et al., 2001 2. 
 
Animal studies confirm that endocrine disrupting chemicals are able to induce the testicular dysgenesis 
syndrome. In order to evaluate the plausibility of an environmental influence on the development of the 
testicular dysgenesis syndrome, information on human exposure to endocrine disrupting chemicals is 
important. 
Historically, the effects of chemical exposure in humans have mainly been studied in work exposure settings. 
Studies have revealed effects of occupational exposures to metals, solvents and pesticides on human male 
reproduction (reviewed in 9). Recent studies in the normal population have aimed to correlate the 
reproductive development of infants to chemical exposure of the mother and child. A study on 100 children 
from the US showed associations between high urinary levels of certain phthalate metabolites and a low 
anogenital index, a marker of “masculinization” of male external genitalia 10. Additionally, a study on Danish 
and Finnish children indicated correlations between reproductive hormone levels in serum of 3 months old 
boys and levels of certain phthalate esters in their mothers’ breast milk 11. Breast milk levels of some 
phthalates were found to be negatively associated with free testosterone levels and positively correlated with 
LH:testosterone levels in boys’ serum 11. This points to poor function of the testosterone producing cells in 
boys exposed to high levels of phthalates. Further investigations are necessary in order to confirm whether 
these correlations are indeed signs of adverse effects of phthalates on male reproductive development. 
2.2 Phthalates – use and toxicity 
Phthalates are produced in very high volumes and are present in materials in everyday use. Although 
phthalates and their primary metabolites have a short half-life and thus may not accumulate in the body, the 
abundance of the chemicals leads to measurable levels in human blood and breast milk 11. The main route of 
exposure is via food, as phthalates present in the environment end up in e.g. water, fish and plants 12. Oral 
Environmental factors
incl. endocrine disrupters
Androgen insufficiency
Disturbed 
Sertoli cell function
Testicular dysgenesis
Genetic defects
e.g. 45,X/46XY, point mutations etc.
Impaired 
germ cell differentiation
Decreased 
Leydig cell function
Reduced semen quality
CIS → Testicular cancer
Hypospadias
Testicular maldescent
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exposure of young children via mouthing of toys containing phthalates is also considerable, although the use 
of certain phthalates in infant toys has recently been banned in the EU. Additionally, humans may be 
exposed via inhalation of dust from indoor air containing phthalates from building materials and consumer 
products or via dermal exposure caused by contact with e.g. clothes and gloves containing phthalates 12. In 
addition to the general abundance of phthalates in consumer products, medical products such as tubes and 
tablet coating can contain extremely high levels of phthalates.  
Phthalates are present as diesters in materials, but after ingestion these are rapidly metabolized to their 
monoesters. Phthalate monoesters are absorbed in the gut and further modified by hydroxylation, oxidation 
and glucoronidation before urinary excretion 13;14. Phthalate monoesters are also transported across the 
placenta 15 and can be measured in amniotic fluid of humans as well as phthalate-exposed rats 13;16. 
It has been well documented that certain phthalates have adverse effects on male rat reproduction with 
particular risk in case of perinatal exposure. The adverse reproductive effects seen in adult rats after perinatal 
exposure is very similar for phthalate esters with side chain lengths of 4 to 6 carbons in the ortho-
configurations (diethyl hexyl phthalate (DEHP), benzylbutyl phthalate (BBP), di-n-butyl phthalate (DBP) 
and diisononyl phthalate (DINP)) 17. In contrast, phthalates with shorter ester side chain lengths (diethyl 
phthalate (DEP) and dimethyl phthalate (DMP)) or a para-configuration (dioctyl tere phthalate (DOTP)) do 
not alter reproductive development 17.  
The first evidence that certain phthalates such as DEHP, DBP and BBP are testicular toxicants was reported 
around 1980 18-20. As these earliest studies were performed in prepubertal or adult rats, high doses were 
required to induce adverse effects. Studies performed in the 1990’es revealed that the intrauterine period is 
more sensitive to phthalate exposure, and that exposure to these phthalates in late gestation can induce 
adverse reproductive effects at lower doses 21;22. However, it was not until 2005 that these three compounds 
were permanently banned for use in all toys and childcare products in the EU 23. DINP, DiDP (diisodecyl 
phthalate) and DnOP (di-n-octyl phthalate) were concomitantly banned for use in toys for children under 3 
years of age 23. This was an extention of a temporary ban of these six phthalates in infant toys decided in 
1999 24. As a result of the increasing awareness of the effects of these compounds, DEHP, DBP and BBP are 
currently being phased out in certain materials, while the industrial use of less well-investigated phthalates 
may be increasing 25.  
Adult male rats exposed to the reproductive toxic phthalates during development have an increased incidence 
of hypospadias, cryptorchidism, testicular atrophy, reduced sperm counts and malformations or hypoplasia of 
epididymis, vasa deferentia, seminal vesicles and prostate 17;26;27. This pattern of effects is very similar to the 
human testicular dysgenesis syndrome, and causal relations between phthalate exposure and development of 
testicular dysgenesis have thus been suggested, but also other chemicals can induce similar types of effects in 
rats.  
2.3 Mechanisms of antiandrogenic effects in male rats  
Many different types of chemicals can affect male reproductive development in animal studies. Some of 
these chemicals can be categorized as having estrogen-like effects in tissues, while others rather appear to 
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disrupt the production or function of androgens and are called antiandrogens. The observed effects in male 
rat offspring perinatally exposed to antiandrogens include reduced weights of reproductive organs, increased 
incidences of cryptorchidism and malformations of external genitalia, alteration of hormone levels, and 
decreased sperm quality. Among the antiandrogenic chemicals, some are known to be antagonists to the 
androgen receptor (AR), while others inhibit 5α-reductase, an enzyme converting testosterone to the 
metabolite dihydrotestosterone, which has strong affinity for the AR. Direct or indirect influences on steroid 
converting enzymes can also lead to reduced testosterone production.  
Table 1 compares the antiandrogenic effects of various chemicals in perinatally exposed rats. Some act 
through inhibition of the AR and others inhibit fetal testosterone synthesis, but they all affect the androgen 
dependent development of male external genitalia. The anogenital distance (AGD) is longer in normal males 
than in females, and a reduced AGD is thus a sensitive marker for antiandrogenicity and is affected by all 
these chemicals. The pattern of malformations such as the degree of hypospadias or cryptorchidism and the 
epididymal agenesis or underdevelopment appears to differ between these compounds and may in part 
depend on other factors than androgens. For example, the development of cryptorchidism is also related to 
altered levels of Insulin-like factor 3 (Insl3). 
 
Table 1. The listed chemicals induce antiandrogenic effects in rats. AR antagonism, reduced fetal testosterone 
production and/or reduced Insl3 levels lead to reduced anogenital distance and malformations such as hypospadias, 
cryptorchidism, and epididymal dysgenesis. Modified from Gray et al. (2006) 28. 
Chemical AR 
effect 
Fetal T 
synthesis 
Insl3 
mRNA 
level 
AGD 
effect 
Hypospadia Cryptorchidism Epididymal 
dysgenesis 
Vinclozolin 
Procymidone 
p,p’-DDE 
Linuron 
Prochloraz 
DEHP 
BBP 
DBP 
↓ 
↓ 
↓ 
↓ 
↓ 
- 
- 
- 
- 
- 
? 
↓ 
↓ 
↓ 
↓ 
↓ 
- 
- 
? 
- 
- 
↓ 
↓ 
↓ 
↓ 
↓ 
↓ 
↓ 
↓ 
↓ 
↓ 
↓ 
+ + + 
+ + + 
+ 
+ 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
- 
- 
- 
+ + + 
+ + + 
+ 
- 
- 
- 
+ + 
- 
+ + + 
+ + 
+ + 
 
Among the AR antagonists are five pesticides, vinclozolin, procymidone, p,p’-DDE, linuron and prochloraz 
(Table 1). Some phthalates and at least two of the mentioned AR antagonists (linuron and prochloraz) also 
reduce fetal testosterone synthesis (Table 1). The fungicide prochloraz is an example of a compound that is 
both an AR antagonist and inhibits fetal testicular testosterone production 29;30. In contrast, neither the 
phthalate diesters nor their primary monoester metabolites are strong AR antagonists despite similarities to 
other antiandrogens regarding their effects in vivo. However, recent studies indicate that secondary DEHP 
metabolites are able to antagonize the AR 31. As will be discussed in the following, it is well described that 
some phthalates reduce fetal testosterone production, but the underlying cause has not been determined.  
Thus, several classes of chemicals have the potential to be involved in the observed increase in male 
reproductive disorders in the industrialized world. The level of exposure to each chemical or chemical group 
alone may not be sufficient to induce adverse effects in humans, but as humans are exposed to numerous 
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chemicals with various effects on the reproductive system, the combined effect of these chemicals may be a 
cause for concern.  
2.4 Effects of perinatal phthalate exposure of rats   
As mentioned, perinatal exposure to certain phthalates can induce hypospadias, cryptorchidism, testicular 
atrophy, reduced sperm counts and malformations of reproductive organs. These effects originate in fetal 
life, when testosterone production is reduced and the development of fetal testes is disrupted 32. Fetal testes 
of rats exposed to DEHP or DBP show characteristic morphological changes not observed with any other 
chemicals than phthalates. Seminiferous chords appear larger with more gonocytes, which are centrally 
located and some are multinucleated. Leydig cells are small and aggregated into large clusters 33;34.  
This abnormal morphology of the Leydig cells correlates with their low production of testosterone. 
Normally, testicular testosterone production peaks from gestation day (GD) 17 to PND 2, but this peak is 
absent in phthalate-exposed males 33-35 (Fig. 2). 
 
Fig. 2. Testicular testosterone production peaks around gestation day (GD) 20 in normal male rat fetuses, but this peak 
is not seen in DEHP-exposed rats. From Parks et al 2000 34. 
 
The molecular origin of the testosterone-reducing effects of phthalates has been examined in several studies 
in recent years. In 2001, Shultz et al. described how fetal testicular expression of genes coding for factors 
involved in testosterone synthesis, fatty acid and cholesterol synthesis, cell death and proliferation was 
affected by DBP exposure from GD 12 to GD 21. They emphasized the down-regulation of scavenger 
receptor B-1 (SR-B1) and steroidogenic acute regulatory protein (StAR), which code for proteins 
transporting cholesterol across the Leydig cell membrane and the mitochondrial membranes, respectively 35. 
In addition, the gene expression of cytochrome P450 side chain cleavage (P450scc) and cytochrome P450c17 
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(CYP 17), which are important enzymatic steps in the conversion of cholesterol to testosterone, were down-
regulated 35 (Fig. 3). 
  
 
Fig. 3. Model of phthalate effects on factors involved in steroid synthesis. DBP affects the mRNA expression of SR-
B1, StAR, P450scc and CYP17 genes in fetal testes thereby reducing testosterone levels. In contrast, androgen 
receptor antagonists such as flutamide rather acts by disrupting the effects of androgens in tissues, but may also 
reduce testosterone synthesis via the influence of AR on factors involved in cholesterol synthesis. From Shultz et al. 
(2001)35. 
 
As several steps in the steroidogenic pathway were affected by DBP, it appears likely that these effects are 
secondary and downstream to a common primary target still waiting to be identified. The transcription of 
genes coding for proteins involved in steroid synthesis are regulated by several ligand-activated nuclear 
receptors, which are activated by ligand binding and subsequently bind to response elements on their target 
genes. The androgen receptor (AR), steroidogenic factor 1 (SF1) and peroxisome proliferator activated 
receptors (PPARs) regulate some of the genes coding for proteins involved in steroid synthesis. SF1 
regulates the transcription of several factors involved in steroid synthesis including SR-B1, StAR, P450scc, 
3β-hydroxysteroid dehydrogenase (3βHSD) and CYP17 36;37. AR regulates the activity of sterol regulatory 
element binding proteins (SREBPs), which regulate the transcription of genes for SR-B1, StAR and other 
enzymes involved in the maintenance of cholesterol homeostasis 38-40. In addition to regulating the hepatic 
cholesterol homeostasis and thereby the substrate availability to steroid synthesis, PPARs regulate the 
transcription of SR-B1 and the cholesterol transporter peripheral benzodiazepine receptor (PBR), which 
cooperates with StAR in mitochondrial cholesterol uptake 41. It is therefore relevant to examine whether 
these nuclear receptors interact with phthalates or other chemicals influencing fetal testosterone production. 
In vitro studies have not revealed substantial evidence for interaction between phthalate monoesters and AR 
or SF131;42, while it is well known that PPARs are activated by certain phthalates 43.  
Corton and Lapinskas (2005) have reviewed the literature on the possible involvement of PPARs on the 
testicular effects of phthalates. They find some degree of correlation between the reproductive effects of 
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phthalate esters and the ability to transactivate PPARα or PPARγ in reporter gene assays44. However, the 
authors find that the hypothesis has some weaknesses as some phthalates do not fit into this relationship, and 
they conclude that further studies are required to clarify PPAR-dependent and –independent events involved 
in the testicular toxicity of phthalates.  
In addition to phthalates, industrial chemicals such as perfluorinated compounds and medical products such 
as fibrates and thiazolidinediones are also known to activate PPARα or PPARγ as well as affect steroid 
production in testes and ovaries of rats and humans in vitro and in vivo41;45-49. Bearing this in mind, it is a 
plausible hypothesis that PPARs may be involved in the testicular toxicity of not only phthalates, but also 
other PPAR activating chemicals. 
2.5 Other PPAR activating chemicals affecting testosterone levels 
For several compounds there appears to be a link between PPAR activation and impaired testosterone 
production. Perfluorooctanoate (PFOA) and perfluorooctanesulfonate were previously used for surface 
treatment and emulsification, and PFOA is known to activate PPARα in transactivation studies 50. Human 
blood levels of PFOA and similar compounds have increased since the 1970s, but due to their accumulation 
in the environment, some of these compounds have recently been phased out for certain applications by the 
manufacturer 51. Ammonium PFOA exposure for 14 days reduced hCG-stimulated serum testosterone levels 
in adult male rats in a study by Cook et al (1992) and reduced testosterone levels in rat serum and testicular 
interstitial fluid in another study by Biegel et al (1995)45;46. 
Another compound linking PPAR activation and impaired testosterone production is the PPARγ agonist 
rosiglitazone, a thiazolidinedione drug, which was found to reduce testosterone levels in normal men 49. 
Rosiglitazone is used for treatment of women with polycystic ovary syndrome and reduces 
hyperandrogenism in these patients52;53. These observations indicate that it is plausible that testicular effects 
in rats exposed to PPAR activating environmental compounds may also be relevant to humans. 
Also certain parabens, which are abundantly used in moisturizers and cosmetics, have been found to reduce 
testosterone production in rats. Exposure of young male rats to either butylparaben or propylparaben reduced 
serum testosterone levels and decreased sperm production 54;55, while a third study showed that butylparaben 
reduced sperm number in perinatally exposed rats 56. Some parabens are also known to be estrogenic in vitro 
and in vivo, and as parabens have been measured in human breast tumor samples, a causal relation to breast 
cancer has been speculated57. No studies on the interaction of parabens with PPARs have yet been reported, 
but due to the potentially high levels of human exposure, it is relevant to examine their toxicological effects 
further. 
The evidence for effects of PFOA and butylparaben on testosterone production in young or adult rats have 
lead to speculations that these compounds may also affect fetal testicular testosterone production as seen for 
certain phthalates. If testicular testosterone production is indeed affected by several types of chemicals at this 
critical time of reproductive development, this may be highly relevant for risk evaluation for these chemicals. 
Not only will their individual levels of effect need to be considered, but also the effect of several compounds 
with similar mechanisms of action may need to be taken into account.  
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2.6 Mixture effects and risk assessment 
Evidently, humans are environmentally exposed to a mixture of various chemicals some of which may have 
endocrine activity, and it is conceivable that the overall effect of mixed exposure will result in more severe 
effects than observed for each chemical alone. Risk assessment of toxicological effects is currently based on 
determination of thresholds for effects of single compounds, i.e. the lowest observed adverse effect levels 
(LOAELs) and the no observed adverse effect levels (NOAELs). However, it is highly relevant to consider 
combination effects of compounds with similar modes of actions, but a useful approach needs to be 
developed before this can be incorporated in risk assessment. 
Combination effects have been studied intensely in cell-based studies, which have shown that combined 
exposure to several endocrine disrupting chemicals with similar modes of actions leads to increased effects. 
Most often, these combined effects have been shown to be concentration-additive (dose-additive). In animal 
studies, chemicals often have more complex effects and the interpretation of combination studies may be 
difficult. For example, various enzymatic processes drive the uptake and metabolism of chemicals, and as 
two chemicals may inhibit the uptake or metabolism of each other, combined exposure to the chemicals may 
not show dose-addition despite similar effects on their molecular target, e.g. at receptor level.  
DEHP is hydrolyzed in the gut to its monoester, mono(2-ethylhexyl) phthalate (MEHP), and 2-ethylhexanol 
(2-EH). The metabolite 2-EH is also produced by hydrolyzation of another plasticizer, di(2-ethylhexyl) 
aditpate (DEHA), which is being used as a substitute for DEHP. If part of the reproductive effects of DEHP 
can be attributed to the metabolite 2-EH, exposure to DEHA may induce adverse effects comparable to those 
seen with DEHP. Additionally, it may be hypothesized that combined exposure to DEHA and DEHP leads to 
increased effects compared to the effects of DEHP alone.  
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3 Aims of the studies 
The purpose of the performed studies was to improve the knowledge basis for risk assessment by examining 
the following main topics: 
o Identification of which phthalate esters affect reproductive development in the male rat and 
examination of dose-response relationships and effects of different mixtures: a) a mixture of two 
phthalates, and b) a mixture of a phthalate (DEHP) and another plasticizer (DEHA) having a 
common metabolite 
o Hormonal and histopathological effects of perinatal phthalate exposure of male rats – focus on how 
the effects progress during the lifespan of the rat 
o Mechanistic studies on the effects of phthalates on reproductive development in male rats  
o Mechanistic studies on the effects of prochloraz on reproductive development in male rats  
o Evaluation of a reporter gene assay for screening of chemicals for interaction with PPARα and 
PPARγ 
o Test of PPAR activating compounds for effects on testosterone production in fetal rat studies 
 
Effects of different phthalate esters - dose-response and combination studies:  
Studies on the effects of phthalates have often been made with doses of 500 to 1000 mg/kg bw per day of 
DEHP or DBP. Other phthalates have been studied less than e.g. DEHP, but are suspected of having similar 
adverse effects. As DINP and diisobutyl phthalate (DIBP) are increasingly used industrially as substitutes for 
DEHP and DBP, we have tested these two phthalates for effects on testosterone production and 
histopathology of fetal testes, as well as the effect of mixed exposure to DEHP and DINP administered 
together.  
Additionally, a hypothesis that DEHA may modulate the effects of DEHP when these compounds are 
administered in combination was examined by comparing the effects of mixed exposure to DEHP and 
DEHA to the effects observed with DEHP alone. 
Furthermore, we aimed to examine the fetal testicular effects of lower doses of DEHP. 
 
Hormones and histology – temporal development: 
The fetal period is generally believed to be particularly vulnerable to chemicals interfering with hormonal 
balances 58. We wished to examine how perinatal phthalate exposure would affect male rats in fetal life 
compared to prepuberty and adulthood by examining testicular histopathology, apoptosis levels and various 
immunohistochemical markers in different age groups of DEHP-exposed rats.  
 
Mechanistic studies:  
Reduced fetal testosterone production is considered to be a biologically plausible as a mode of action for 
phthalate-induced reproductive effects 32. However, the events leading to reduced fetal testosterone 
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production are not evident. Most likely, the reduction of fetal testosterone production is a result of reduced 
expression of genes coding for proteins/enzymes involved in steroid synthesis. As mentioned, PPARs and 
SF1 regulate some of these genes, and interaction of these receptors with phthalate metabolites may be 
hypothesized of playing a role in the downregulation of steroidogenesis. In the current project, we examined 
whether PPARα, PPARγ or SF1 gene and/or protein expression in testes of fetal rats were affected by 
phthalates.  
The antiandrogenic fungicide prochloraz also reduces fetal testosterone production, and by methods 
comparable to those applied in the phthalate studies we wished to examine the gene and protein expression 
of factors involved in steroid synthesis 
 
Screening of chemicals for PPAR interaction: 
By developing a reporter gene assay, we wished to be able to identify some PPAR activating chemicals. In 
line with the hypothesis of a role of PPARs in the testosterone-reducing effect of phthalates and other PPAR 
agonists, we wished to examine whether other chemicals with effects on testosterone synthesis also interact 
with PPARs. As certain parabens reduce testosterone levels in rats, these parabens were tested for interaction 
with PPARα and PPARγ in reporter gene assays. 
 
Test of PPAR activators for effects on fetal testosterone production 
We hypothesized that if the interaction of phthalates with PPARs is causally involved in the reduction of 
fetal testosterone production, then other PPAR ligands may have similar effects in fetal rats. In a similar 
setup to the phthalate studies, testicular testosterone production, histopathology, gene and protein expression 
was examined in rat fetuses exposed to the PPAR ligands PFOA and rosiglitazone. In the same study, a 
group of rats exposed to butylparaben was included. 
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4 Experimental setup 
Detailed descriptions of in vivo studies can be found in the papers I to VI (appendix X). The in vivo and in 
vitro studies on PPAR agonists are described in appendix Y. As listed in Table 2, a number of rat studies 
were performed with comparable study designs. Pregnant rats were gavaged with single doses or mixtures of 
test compounds from gestation day (GD) 7 to 21 and male fetuses were examined at GD 21. In other studies, 
exposure continued from postnatal day (PND) 1 to 17 and pups were examined in prepuberty and adulthood. 
 
The offspring were then examined with different methods: 
o Pathological and immunohistochemical investigations in testes  
o Gene expression studies in testes  
o Hormone measurements in testes and blood 
In addition to these rat studies, an in vitro assay for analysis of PPARα and PPARγ transactivation was 
developed as described in appendix Y. Some of the chemicals tested in this assay were similar to those tested 
in vivo, as listed in Table 3.  
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Table 2. Purpose and main endpoints of in vivo studies.   
The last column refers to papers presented in appendix X, and additional contributions presented in appendix Y. 
Compounds 
(dose, mg/kg bw per day) 
Animals Purpose Endpoints related to 
this thesis 
Reference 
DEHP (750), 
DEHP (750) +  DEHA (400) 
Fetal rats exposed 
in utero 
Investigate combination 
effects and fetal 
testicular effects  
Hormones, histology, 
apoptosis 
I, II 
DEHP (300), 
DEHP (750), 
DEHP (750) +  DEHA (400) 
Perinatally 
exposed 
prepubertal and 
adult rats  
Investigate combination 
effects and 
antiandrogenic effects  
Hormones, histology, 
apoptosis, 
immunohistochemistry 
I, II, III 
DEHP (300), 
DINP (750), 
DEHP (300) + DINP (750) 
Fetal rats exposed 
in utero 
Investigate combination 
effects and fetal 
testicular effects  
Hormones, histology, 
immunohistochemistry 
I  
+ poster 
appendix Y 
DEHP (300, 100, 30, 10) Fetal rats exposed 
in utero 
Investigate mechanism 
of action and dose-
dependency  
Hormones, histology, 
immunohistochemistry, 
gene expression 
IV 
DIBP (600) Fetal rats exposed 
in utero 
Investigate fetal 
testicular effects  
Hormones, histology, 
immunohistochemistry 
gene expression 
V 
+ poster 
appendix Y 
Prochloraz (150, 50) Perinatally 
exposed fetal and 
prepubertal rats  
Investigate mechanism 
of action 
Immunohistochemisty  
 
VI  
Butylparaben (100), 
Perfluorooctanoate (20),  
Rosiglitazone (1) 
Fetal rats exposed 
in utero 
Test whether other 
PPAR ligands have 
similar effects to 
phthalates in vivo 
Hormones, histology, 
gene expression 
Appendix Y 
 
Table 3. In vitro studies 
Compounds Type of study Purpose Reference 
Butylparaben 
Propylparaben 
Perfluorooctanoate 
MEHP 
Rosiglitazone 
Prochloraz 
PPAR reporter 
gene assay 
Detect compounds interacting with PPARα and 
PPARγ 
Appendix Y 
 
My main contributions to paper III (DEHP and DEHA young and adult animals) and paper VI (Prochloraz) 
were the analyses of testicular histopathology and immunohistochemistry in fetal rats.  
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5 Results 
The main results of the rat studies have been published in paper I to VI (Appendix X). Additionally, fetal 
testicular histopathology was examined in the combination study of DEHP and DINP, and gene expression 
was examined on DIBP-exposed fetal testes. The results of these studies can be found on theposters 
presented in Appendix Y as well as in the tables below. The results of the in vivo and in vitro studies on 
PPAR agonists (butylparaben, perfluorooctanoate, rosiglitazone) are described in appendix Y and 
summarized in Table 7. 
Apoptosis assessment in the combination studies on DEHP and DEHA did not reveal any important effects 
(Paper II), and as this was the topic of my MSc thesis 59, the results on apoptosis assessments will not be 
discussed thoroughly in this PhD thesis. 
5.1 Comparison of in vivo studies 
As study designs and endpoints were comparable for most of the studies, results of the different studies are 
summarized in Table 4 to Table 7. For simplicity, only the results in the highest dose group from dose-
response studies are listed. DEHA did not appear to modulate the effects of DEHP and only results from the 
DEHP group in that study are listed here.  
Testes of phthalate exposed rat fetuses exhibited some very characteristic alterations including the presence 
of multinuclear gonocytes, presence of enlarged tubules with centrally located gonocytes, clustering of 
Leydig cells with altered appearance and vacuolization of Sertoli cells, as listed in Table 4. DEHP-, DINP- 
and DIBP-exposed animals all exhibited these alterations to varying degrees.  
Interestingly, the effects on gonocytes and Sertoli cells were not as prevalent on GD 19 as on GD 21 in testes 
of DIBP-exposed animals, while Leydig cell effects were present already at GD 19 (Table 4).  
No histopathological effects were observed in fetal testes following exposure to prochloraz, butylparaben, 
PFOA, or rosiglitazone at GD 21. 
 
Table 4. Histopathological alterations in fetal testes of phthalate-exposed rats.  
Numbers indicate the percentage of exposed animals with a certain histological phenotype observed when examining 
one section per testis. The percentage of control animals with that phenotype is listed in parentheses. See papers II, IV 
and V for further explanations of the observed alterations. 
Compound (dose, 
mg/kg bw/day) 
Age of 
animal 
Multinuclear 
gonocytes 
Enlarged 
tubules with 
centrally located 
gonocytes 
Clustering of 
Leydig cells with 
altered 
appearance 
Sertoli cell 
vacuolization 
Paper 
DEHP (750) GD 21 64% (0%) 100% (0%) 50% (12%) 100% (6%) II 
DEHP (300)  
DINP (750) 
DEHP (300) +  
DINP (750) 
GD 21 
GD 21 
GD 21 
100% (0%) 
83% (0%) 
95% (0%) 
68% (0%) 
22% (0%) 
76% (0%) 
 
72% (18%) 
52% (18%) 
70% (18%) 
 
 Poster, 
app. Y 
DEHP (300) GD 21 Yes Yes Yes Yes IV 
DIBP (600) 
DIBP (600) 
GD 19 
GD 21 
0% (8%) 
62% (10%) 
22% (0%) 
88% (0%) 
100% (15%) 
87% (0%) 
11% (0%) 
88% (0%) 
V 
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The three tested phthalates DEHP, DINP and DIBP all reduced fetal testosterone production and testicular 
testosterone content (Table 5). Concomitantly, serum testosterone levels were reduced, though not as 
significantly as testicular testosterone levels. As the masculinization of male external genitalia is stimulated 
by testosterone, compounds that impair testosterone production or -function can reduce the anogenital 
distance. This was observed with DEHP and DIBP, but was not assessed in the study on DINP. Serum 
luteinizing hormone (LH) was increased by DEHP in one study, while the observed tendencies to increases 
in LH levels were not statistically significant in the combination study on DEHP and DINP (Table 5).  
Comparable reductions of testosterone levels and anogenital distance (AGD) in males were seen with 
prochloraz, but not with any of the other compounds tested.  
In prepubertal and adult DEHP-exposed rats, tendencies to hormonal changes similar to those observed in 
DEHP exposed fetuses (i.e. reduced testosterone and increased LH levels) were observed, but the changes 
were not statistically significant. 
 
Table 5. Changes in hormone levels and anogenital distance (AGD) in fetal male rats. Percent of control mean value 
(control mean = 100%).  
T: testosterone, NS: not statistically significant. ↓ or ↑ indicates statistically significant reductions or increases of the 
listed parameters.  # at PND 3 
Compound (dose, mg/kg 
bw/day) 
Age of 
animal 
Plasma/ 
serum T 
Testicular 
T content 
Testicular T 
production 
ex vivo 
Plasma/ 
serum 
LH 
Change in 
AGD 
Paper 
DEHP (750) GD 21 ↓ 13%  ↓ 23% ↓ 18% ↑ 216% ↓ 86%# I 
DEHP (300) 
DINP (750) 
DEHP (300) + DINP (750) 
GD 21 
GD 21 
GD 21 
70% NS 
71% NS 
↓ 48% 
↓ 30% 
↓ 27% 
↓ 16% 
↓ 21% 
↓ 31% 
↓ 10% 
149% NS 
136% NS 
↑ 186%  
 I 
 
DEHP (300) GD 21 ↓ 50% ↓ 21% ↓ 37%   IV 
DIBP (600) 
DIBP (600) 
GD 19 
GD 20/21 
 ↓ 30% 
↓ 9% 
79% NS 
↓ 4% 
 ↓ 85% 
↓ 84% 
V 
Prochloraz (150) GD 21 ↓ 34% ↓ 17% ↓ 13% 158% NS ↓ 88% VI 
Butylparaben (100) 
PFOA (20) 
Rosiglitazone (1) 
GD 21 
GD 21 
GD 21 
 105% NS 
136% NS 
109% NS 
106% NS 
115% NS 
106% NS 
 ↔ 
↔ 
↔ 
 
DEHP (750) 
DEHP (750) 
PND 22 
PND 190 
72% NS 
68% NS 
 
83% NS 
 571% NS  II 
 
Immunohistochemistry reveals not only the localization of proteins in tissues, but also to some extent the 
amount of the examined protein. Some of the proteins involved in steroid synthesis were less abundant in 
testes with low testosterone production. Scoring of immunostaining intensity revealed that particularly 
P450scc, StAR and CYP17 were less abundant in testes from phthalate-exposed fetuses (Table 6). 
Additionally, all three phthalates decreased the immunostaining intensity for PPARγ. 
Prochloraz-exposed animals did not show any differences in immunostaining intensity for P450scc or StAR 
despite the observed reduction of testosterone synthesis. On contrary, the enzyme CYP17 appeared to be 
upregulated in prochloraz-exposed testes. The intensity of 17βHSD (17β-hydroxysteroid dehydrogenase) 
type 10 appeared to be reduced in testes of prochloraz-exposed rats (Table 6). 
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Table 6. Summary of effects on immunohistochemistry in fetal rat testes (GD 21). 
↓, ↑ or ↔ indicates reduced, increased or unchanged intensity of immunostaining in Leydig cells of exposed rat fetuses 
compared to controls. * indicates results published in the listed papers, while the remaining results are yet unpublished. 
Compound 
(dose, mg/kg bw/day) 
PPARγ Star  PBR P450scc 3βHSD CYP17 17βHSD type 10 Paper 
DEHP (750)     ↔*   I 
DEHP (300) 
DINP (750) 
DEHP (300) + DINP (750) 
↓ 
↓ 
↓ 
↓ 
↓ 
↓ 
 ↓ 
↓ 
↓ 
↔ 
↔ 
↔ 
↓ 
↓ 
↓ 
  
DEHP (300) ↓* ↓* ↓* ↓*  ↓  IV 
DIBP (600) GD 19 
DIBP (600) GD 21 
↓  
↓ 
 
↓* 
 
 
 
↓* 
 ↓  
↓  
 V 
Prochloraz (150) ↔ ↔*  ↔* ↔* ↑* ↓* VI 
Butylparaben (100) 
PFOA (20) 
Rosiglitazone (1) 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
    
 
Corresponding to the results on immunohistochemistry for factors involved in steroid synthesis, mRNA 
levels of genes coding for these factors (SR-B1, StAR, PBR, P450scc, CYP17) were reduced in testes of 
phthalate-exposed fetal rats (Table 7). In contrast to the immunostaining results, PPARγ mRNA levels were 
unaffected by DEHP or DIBP, whereas PPARα mRNA levels were reduced at GD 19 in testes of DIBP 
exposed animals. No statistically significant effects of prochloraz on mRNA levels were observed for any of 
these factors (Table 7). The discrepancies between results of immunostaining and gene expression studies 
may indicate that the observations of increased CYP17 protein levels in prochloraz-exposed animals and 
decreased PPARγ protein levels in phthalate-exposed animals are due to effects at protein level rather than at 
transcription level. Alternatively, changes in gene expression may occur at an earlier age than the changes in 
protein expression are observed.  
In addition to the listed effects, testicular mRNA levels of SF1 and Insl3 were reduced by DEHP and DIBP, 
but were not measured in studies on other test compounds. 
 
Table 7. Summary of effects on gene expression in fetal rat testes (GD 21). 
↓, ↑ or ↔ indicates reduced, increased or unchanged mRNA levels in testes of exposed rat fetuses compared to 
controls. * indicates results published in the listed papers, while the remaining results are yet unpublished 
Compound  
(dose, mg/kg bw/day) 
PPAR γ PPARα SR-B1 Star  PBR P450scc CYP17  Paper 
DEHP (300) ↔* ↔* ↓* ↓* ↓* ↓* ↔*  IV 
DIBP (600) GD 19 
DIBP (600) GD 21 
↔ 
↔ 
↓ 
↔   
↓* 
↓* 
↓*  
↓* 
↔* 
↔* 
↓*  
↓* 
↓*  
↓* 
Poster, app. Y 
Prochloraz (150)   ↔* ↔*  ↔* ↔* VI 
Butylparaben (100) 
PFOA (20) 
Rosiglitazone (1) 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
 ↔ 
↔ 
↔ 
↔ 
↔ 
↔ 
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5.2 Comparison of PPAR transactivation in vitro with effects on fetal 
testosterone levels in vivo 
Reporter gene assays were developed in order to detect chemicals transactivating PPARα and/or PPARγ. As 
mentioned, certain PPARα- or PPARγ-agonists can also reduce testosterone production in rats. In Table 8, 
the ability of chemicals to transactivate PPARα or PPARγ in vitro is compared to their ability to reduce fetal 
testicular testosterone levels in vivo. DEHP reduced testosterone production in vivo, and its primary 
metabolite MEHP was also able to transactivate PPARα and PPARγ in vitro. Prochloraz did not appear to 
activate PPARs, but was able to reduce fetal testicular testosterone levels in vivo. Butylparaben, PFOA and 
rosiglitazone transactivated PPARα and PPARγ to varying degrees, but did not affect testosterone production 
in fetal male rats at the applied doses, although similar doses had been found to reduce testosterone levels in 
young or adult rats in other studies 45;54.  
This comparison does not indicate any association between PPAR activation and fetal testosterone 
production, but cannot rule out the possibility of a connection either. 
 
Table 8. Comparison of results of in vitro studies on PPARα and PPARγ transactivation and in vivo studies on fetal 
testicular testosterone production (see appendix Y for further description).  
+++ indicates a high degree of effect, + indicates a moderate degree of effect, and - indicates no effect of the compound 
on the listed endpoint at the applied dose- or concentration levels. 
Compound 
(dose in vivo, mg/kg 
bw/day) 
PPARα transactivation
 
PPARγ transactivation 
 
Reduces fetal 
testicular 
testosterone levels 
in vivo 
Paper 
(in vivo data) 
MEHP/DEHP (300) 
Prochloraz (150) 
Butylparaben (100) 
PFOA (20) 
Rosiglitazone (1) 
+++ 
- 
+ 
+++ 
+ 
+++ 
- 
+ 
+ 
+++ 
+++ 
+++ 
- 
- 
- 
IV 
VI 
Appendix Y 
Appendix Y 
Appendix Y 
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6 Discussion 
6.1 DINP and DIBP have similar effects as DEHP in fetal rat testis 
In order to examine whether DINP and DIBP are safer substitutes for the reproductive toxicant DEHP, we 
compared the effects of these compounds on fetal testicular testosterone production and testicular 
development. Prenatal exposure to DEHP, DINP and DIBP reduced testosterone levels and induced fetal 
testicular histopathological effects similar to those observed with DEHP (Table 4 and 5) and described for 
DBP by other groups 33;34. Multinucleated germ cells, enlarged chords with centrally located germ cells, large 
clusters of small Leydig cells, and Sertoli cells with cytoplasmic vacuolization were present in most DEHP-, 
DIBP- or DINP-exposed animals (Paper II, V and appendix Y). As these effects in fetal life are related to 
adverse long-term reproductive effects (discussed in section 6.2), this indicates a reason for concern for the 
use of DINP and DIBP as substitutes for DEHP and DBP.  
The observations in young and adult DEHP-exposed rats (Paper III) confirm the findings described for DBP 
by other groups. As for DBP60;61, severe degeneration of seminiferous tubules was seen in some animals, 
while others appeared largely normal. Some of the effects observed with DEHP and DBP have not been 
described for any other types of chemicals, namely the presence of dysgenetic tubules with intratubular 
Leydig cells in areas of Leydig cell hyperplasia. It is therefore remarkable that this phenomenon is not solely 
a result of DBP exposure, but also occurs with DEHP (Paper II). 
Our studies on DIBP and DINP investigated endpoints in male fetuses and the effects may not be considered 
adverse as such. However, these effects on fetal histopathology and testosterone production are likely related 
to the adverse effects observed in adult phthalate-exposed rats as discussed in the following. 
6.2 Temporal differences in the toxic effects of phthalates 
Fundamentally, the most important effects caused by chemical exposure of experimental animals are adverse 
effects with relevance to humans. For the phthalates, the adverse and relevant effects seen in rats are 
hypospadias and low sperm quality. Reduced anogenital distance and presence of nipples in males are also 
characteristic signs of antiandrogenicity, but these endpoints are less well related to adverse effects in 
humans. Cryptorchidism and degeneration of epididymis and seminiferous tubules are likely causal factors 
for the low sperm quality. But what causes these malformations of reproductive organs? And why are some 
animals severely affected while others appear completely normal? 
The testosterone peak in late gestation is essential for the normal formation of the external genitalia, and 
Insl3, a hormone produced in Leydig cells, appears to be essential for testicular descent at birth, and some of 
the effects of phthalates can be explained by reduced production of these two hormones 32. In the following 
will be discussed how the testicular and epididymal degeneration may be related to the observed fetal effects 
and what may be causing the low testosterone and Inls-3 levels.  
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6.2.1 How is fetal testicular histopathology related to impaired spermatogenesis later in 
life? 
Leydig cells of phthalate-exposed fetal rats are located in large clusters centrally in the testes and have 
smaller cytoplasm and smaller, more irregular nuclei than normal testes. This “inactive” appearance of the 
Leydig cells is very likely related to the low testosterone levels in phthalate-exposed males at this age. The 
peak in testosterone levels in late gestation is considered to be essential for the normal masculinization of 
males, as androgen receptors in the reproductive organs induce growth and differentiation of tissues 62. Thus, 
the link between fetal Leydig cell effects and the effects on reproductive organ weights (prostate, levator 
ani/bulbocavernosus muscle) later in life is quite clear (Paper III).  
Also the changes in the morphology of the testicular interstitial space and the occurrence of Sertoli cells 
outside the seminiferous tubules in fetal testes may be related to the development of dysgenetic tubules later 
in life, as discussed in Paper II. The alteration of interstitial “architecture” in fetal testes has also been 
observed with DBP and was related to the formation of incomplete tubules formed within dysgenetic areas at 
PND 461. In that study it was shown that Leydig cells could be “trapped” inside the tubular structures and 
affect the function of Sertoli cells and spermatogenesis in that section of the seminiferous tubule later in 
life61. In our studies as well as the DBP studies, apparently normal testicular tissue surrounds the dysgenic 
areas in prepuberty and adulthood. These testes have likely gained full function and are capable of producing 
normal sperm. However, certain parallels can be drawn between the dysgenetic areas in phthalate-exposed 
rat testes and the development of testis cancer in humans. In human testes, Sertoli cells in areas with cancer 
precursor carcinoma-in-situ cells are immature and do not express certain markers of Sertoli cell maturity. 
Likewise, these markers are absent in dysgenetic areas of testes of DBP-exposed rats61;63. If human testis 
cancer development is indeed related to Sertoli cell dysfunction, it may be speculated that the disruption of 
Sertoli cell function in dysgenetic areas of phthalate-exposed rat testes is a sign of a relationship between 
phthalate exposure and human testis cancer development.  
In contrast to the effects on Leydig and Sertoli cells, the observed alterations of gonocytes in fetal testes are 
not as readily related to the effects observed later in life. Multinucleated germ cells are not observed later 
than PND 7 with a maximal incidence at GD 21 60;64. Despite the apparent increase in germ cell numbers and 
enlargement of seminiferous chords at GD 21, our studies did not indicate any alterations in the expression 
of apoptosis and proliferation markers at GD 21 in DEHP exposed testes (Paper II).  
In a study on prenatal exposure to DBP, reduced germ cell numbers were observed from GD 21 to PND 25 
65. Increased expression of markers for proliferation and apoptosis was observed at GD 17, but not GD 21 65. 
Thus, the low germ cell number at GD 21 observed in that study was explained by an increased apoptosis 
rate around GD 17. The low germ cell numbers observed postnatally were explained by a low proliferation 
rate, which was seen at PND 6 65. At PND 25, the proliferation rate increased and germ cell numbers were 
restored in adulthood in scrotal testes. Collectively, the changes in germ cell numbers in scrotal testes 
appeared to be transient in rats and thus not directly related to the testicular toxicity of these phthalates. This 
conclusion is also supported by our studies showing no considerable changes of apoptosis rates at GD 21, 
PND 22, 27 or in adulthood in most testes of DEHP-exposed rats (Paper II). 
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In our studies, prepubertal testes (PND 22) of DEHP exposed rats were slightly smaller and appeared slightly 
delayed in their development, similarly to the findings with DBP described by Ferrara (2005) 65 and Barlow 
& Foster (2003) 60. This may be related to delayed Sertoli cell development, as also serum levels of the 
Sertoli cell product Inhibin B was reduced by DEHP at PND 22 (Paper I). These Sertoli cell effects appeared 
to be transient, as there was no general reduction of testis size, and testis size reflects the number and 
function of Sertoli cells 63. Furthermore, in adult DEHP-exposed testes sperm quality and histopathology 
appeared largely normal in most adult testes in our study (Paper III).  
A few DEHP-exposed testes, however, were completely degenerated. Likewise, a clear difference between 
scrotal and cryptorchid testes of exposed animals was found in the DBP study 65. This difference emerged 
postnatally, as germ cell numbers of scrotal and cryptorchid testes of DBP exposed animals were similar 
until PND 25, whereas cryptorchid testes did not exhibit full spermatogenesis in adulthood65.  
However, other studies have shown that degeneration in adult testes was not associated with cryptorchidism, 
but rather with epididymal malformation. Barlow & Foster (2003) examined the pathogenesis of testicular 
and epididymal effects of prenatal DBP exposure of rats from fetal life to adulthood. Fetal epididymides of 
DBP-exposed animals exhibited decreased coiling of ducts - an effect, which progressed to malformation and 
degeneration in adulthood 60. As certain other antiandrogenic compounds such as linuron have similar 
epididymal effects as listed in Table 1, this may be related to low testosterone production or -function. In 
contrast to the epididymal effects, the testicular effects of DBP observed in late gestation (multinucleated 
gonocytes, increased numbers of gonocytes and clustering of Leydig cells) resolved, while a different set of 
morphological alterations appeared later on (focal dysgenesis in the seminiferous epithelium in some testes 
and general degeneration in others) 60, as also seen in our DEHP study. The severity of testicular 
degeneration progressed with age and was suggested to result from the progressing epididymal lesions 
causing obstruction of flow from the testes 60.  
In our study on DEHP, the observed testicular degeneration in a few testes was to some degree associated 
with epididymal degeneration, as four of the six animals with degenerated testes also had small epididymides 
(Paper III). It is possible that the two remaining animals with small testes were in fact cryptorchid, thus 
explaining the testicular degeneration, but we did not register whether testes were cryptorchid or not in that 
study. Apparently, there are rat strain differences in the reponse to DBP, as Sprague-Dawley rats mainly 
develop epididymal effects 27;60 whereas Wistar rats rather become cryptorchid 61. 
Apparently, two or three pathways may be leading to the testicular degeneration later in life, as illustrated in 
Fig. 4. Low Insl3 and/or testosterone production may induce cryptorchidism, which prevents normal 
testicular function and is a risk factor for testis cancer and low sperm count. Low testosterone production by 
Leydig cells may either induce epididymal malformation causing testicular degeneration or impair Sertoli 
cell function. Impaired Sertoli cell function or a reduced number of Sertoli cells is known to reduce the 
number of germ cells and thus sperm production. The characteristic “all or none” response with regard to 
testis degeneration after perinatal phthalate exposure may indicate that the subtle effects on Sertoli cell 
function are transient and probably not causally related to the testicular degeneration.  
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Fig. 4. Development of the adverse effects of phthalates related to the testicular dysgenesis syndrome. Perinatal 
phthalate exposure induces hypospadia, testicular degeneration, low sperm counts and cryptorchidism in rats, while 
testis cancer is not seen in rats but is causally related to cryptorchidism in humans. Arrows indicate well-described 
relationships between these effects, while dotted arrows indicate more uncertain relationships. 
 
Collectively, the impaired fetal testosterone and Insl3 production are central events in the development of 
adverse effects of perinatal phthalate exposure. It is also possible that the alterations of germ cell 
development and fetal testicular structure may influence adult reproductive function. Thus, our observations 
of reduced testosterone production in addition to alterations of fetal testicular histopatholgy in testes of 
DINP- and DIBP-exposed rats indicate that adverse effects of perinatal exposure can be expected in 
adulthood.  
6.2.2 Prepubertal and adult phthalate exposure 
This thesis deals mainly with the effects of perinatal phthalate exposure, but phthalates are also toxic to the 
testes of young and adult rats. As discussed in Paper II, phthalate exposure disrupts Sertoli cell structure and 
function and leads to apoptosis of germ cells. The direct interactions leading to these effects are not clear, but 
among the observed events are interferences with Sertoli cell proliferation and induction of germ cell 
apoptosis by disruption of signals from Sertoli cells, as well as disruption of gap junctional intercellular 
communication between Sertoli cells 32. Due to the persistence of stem cell spermatogonia, the effects on 
spermatogenesis seen with prepubertal or adult phthalate exposure appear to be reversible when Sertoli cells 
recover after ended exposure 66.  
Collectively, the prenatal or early postnatal period appears to be more sensitive to phthalate exposure than 
prepuberty or adulthood in rats. Children may also be exposed to higher levels of phthalates than adults, as 
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will be discussed later. This, together with the increased sensitivity, emphasizes why the major concern for 
adverse effects is with perinatal phthtalate exposure.  
6.3 Phthalate mechanisms of action in fetal rat testes 
As previously mentioned, perinatal exposure to DBP, DEHP, BBP or DINP was found to induce adverse 
reproductive effects in rats 17. Recently, Liu et al (2005) has compared the gene targets of different phthalates 
and found that DBP, DEHP, BBP and dipentyl phthalate (DPP) all reduced anogenital distance and affected 
the expression of a common group of genes in fetal testes, while DEP, DMP and DOTP did not affect 
anogenital distance and altered the testicular expression of a different group of genes 67. Mechanistic studies 
on phthalate mechanism of action have mainly been investigated with perinatal DBP exposure as described 
in numerous papers, and due to the mentioned similarities for the antiandrogenic phthalates, these 
mechanisms can be regarded as representative for other antiandrogenic phthalates as well. 
6.3.1 Protein and gene expression changes causing low fetal testicular testosterone levels 
In addition to measuring testicular testosterone content and –production, the testicular expression of proteins 
and genes involved in steroid synthesis was assessed in fetal rats exposed to phthalates (Paper IV and V). In 
correspondence with the low testosterone production, mRNA expression levels of genes coding for factors 
related to steroid synthesis were reduced in fetal testes of DEHP- and DIBP-exposed animals (Table 7, Fig. 
5). Immunohistochemistry can be used as a marker for protein levels of these factors, although quantification 
can be difficult. Our results showed reduced protein levels of StAR and P450scc in testes of fetal rats 
exposed to DEHP, DIBP, or DINP (Table 6). In DEHP-exposed testes, reduced protein and mRNA levels 
were observed for PBR, a protein that assists StAR in the mitochondrial cholesterol transport. The 
downregulation of PBR expression by DEHP in fetal rat testes had not previously been described, but PBR 
was reduced in testes of DEHP exposed adult mice in a study by Gazouli et al., 2002 41. Lehmann et al. 
(2004) found that DBP reduced PBR protein expression and increased PBR mRNA levels in fetal rat testes68. 
StAR, P450scc, and SR-B1 appeared to be more sensitive to phthalate exposure than the other genes 
examined, as mRNA expression for these three genes were reduced by 300 mg/kg of DEHP as well as by 
600 mg/kg of DIBP. In contrast, P450c17 was only affected by DIBP, and PBR was only affected by DEHP. 
At 100 mg/kg bw/day of DEHP, only the reduction of StAR expression was statistically significant, 
indicating that StAR is more sensitive than the other genes. A similar pattern was described by Lehmann et al 
(2004)68, who found statistically significant effects of DBP on StAR, P450scc, and SR-B1, but not P450c17 at 
doses down to 50 mg/kg per day. However, the relative sensitivities of these genes appear to vary between 
different studies on DBP35;42;67-69.  
In our study on DIBP, the effects on gene expression were generally more marked at GD 19 than at GD 21, 
whereas testosterone levels were clearly more reduced at GD 21 than GD 19 (Paper V). Similarly, a study on 
DBP showed that P450scc and P450c17 expression levels were only reduced at GD 19 and not at GD 2135. 
On the contrary, StAR and SR-B1 expression levels were reduced more at GD 21 than GD19 in that study35. 
At GD 16, only StAR and SR-B1 expression levels were reduced, when P450scc and P450c17 expression 
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levels were similar to controls35. Overall, the downregulation of genes coding for factors involved in steroid 
synthesis may precede the low testosterone levels, but in order to search for factors inducing the low steroid 
synthesis, it may be necessary to examine gene expression even before GD 19.  
In a study by Thompson et al. (2004), the exposure period was narrowed down to one single day and effects 
on testosterone synthesis related genes were examined42. It was shown that effects of treatment with DBP on 
GD 19 only were comparable to the effects of exposure from GD 12 to GD 19 42. Treatment from GD 12 to 
GD 18 induced similar effects as GD 12 to GD 19 treatment, while the effects observed at GD 17 were 
subtle42. This indicates that GD 17 to 19 is a critical time period for repressing testosterone and gene 
expression levels with DBP. Another study by Thompson et al (2005) revealed that exposure to one dose of 
DBP on GD 19 reduced testosterone levels already 1 hour after exposure by oral gavage, while reduced 
expression of SR-B1, StAR, P450scc, and P450c17 was not evident until 6 hours after exposure69. 
Interestingly, StAR expression was downregulated already after 3 hours further indicating a central role for 
this protein in the series of events. From 12 hours onwards, testosterone levels were reduced even further69. 
Apparently, there is an initial direct effect of DBP on testosterone production and later an indirect effect 
caused by reduced expression of genes and proteins involved in steroidogenesis. The authors speculate that 
the acute effect may be due to interaction with a fetal Leydig cell specific transcriptional regulator69. 
Collectively, the effect of phthalate exposure on StAR expression and cholesterol transfer across the 
mitochondrial membrane to P450scc may be central in the chain of events leading to reduced testosterone 
production (Fig. 5). As reviewed by Stocco et al., 2005, the regulation of StAR expression involves a very 
complex pathway and can be divided into an acute and a chronic response70. Hypothetically, many factors 
can thus be suggested as targets for phthalates. The acute regulation of StAR function is via LH/hCG 
stimulation activating the cAMP/protein kinase A pathway by which phosphorylation of the StAR protein 
induces changes in steroid synthesis within minutes70. Additionally, cAMP is involved in regulating StAR 
expression levels, but several cAMP-independent regulators of StAR expression have also been described70. 
The more chronic regulation of StAR gene expression (i.e. changes within hours) involves activation of 
specific membrane receptors by growth factors inducing different intracellular pathways in addition to the 
nuclear receptor steroidogenic factor-1 (SF1), which acts as a transcription factor for the StAR gene70;71. An 
effect of phthalates on these receptors could in part explain the downregulation of StAR in fetal testes. 
According to Liu et al. (2006), the complex formation of StAR and PBR is central in the acute regulation of 
steroidogenesis, and disruption of this complex reduces hCG-induced steroid synthesis dramatically72. It may 
be hypothesized that phthalates interact with StAR, PBR and/or other proteins in the complex, thereby 
preventing its interaction with and transport of cholesterol.  
Reduced fetal testicular SF1 expression following phthalate exposure (Paper IV) has not previously been 
described. In Fig. 5 an interaction between phthalate metabolites and SF1 is suggested, but in a study by 
Thompson et al., 2004, no interaction between SF1 and the DBP metabolite monobutyl phthalate (MBP) was 
observed 42. This does not exclude the possibility that other phthalate metabolites may be able to interact 
with SF1. 
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In summary, several hypotheses can explain the testosterone-reducing effects of phthalates in late gestation, 
but it remains speculative which mechanism is true. Fig. 5 illustrates the possible mechanisms by which 
nuclear receptors may be involved in the downregulation of testosterone production by phthalates. 
Additionally, the two-step downregulation of testosterone levels in fetal DBP-exposed testes described by 
Thompson et al. (2004) points to different mechanisms causing the acute versus the long-term 
downregulation of steroidogenesis42.  
 
Fig. 5. Model of phthalate mechanisms of action.  
A) MEHP is known to interact with PPARs, which are involved in regulation of cellular and mitochondrial cholesterol 
uptake. This interaction may be related to the reduction of testosterone production by phthalates. 
B) It may be hypothesized that MEHP or other metabolites interact with SF1, a regulator of several steps in steroido-
genesis, thereby reducing testosterone production. 
C) It may be hypothesized that MEHP or other metabolites interrupts the function of StAR or the related mitochondrial 
cholesterol transport complex, as this StAR is an acute regulator of steroidogenesis. 
D) Studies have shown that the DEHP metabolites VI and IX interact with the androgen receptor in vitro31. 
(Ð) indicates factors reduced (at protein or gene expression level) in fetal rat testes by DEHP or DBP.  
Dotted arrows indicate pathways of regulation of various steps in steroid synthesis and androgen function. 
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In addition to the described indirect effects on mitochondrial cholesterol uptake and steroid synthesis, 
phthalates may directly inhibit enzymes in steroidogenesis, affect the metabolism of testosterone, or alter the 
systemic cholesterol availability or lipid metabolism. Fan et al. (2004) showed an upregulation of steroid 
metabolic P450 enzymes in rat livers after exposure to DBP or other PPAR agonists, indicating increased 
steroid breakdown 73. However, increased hepatic steroid breakdown is not likely the primary mechanism of 
reduced testosterone levels by phthalates, as culturing primary Leydig cells with phthalates reduces 
testosterone production directly 41;74. Similarly, the current findings of reduced testicular testosterone content 
and testosterone production ex vivo following phthalate exposure demonstrate that the possible influence of 
increased hepatic steroid breakdown is limited. 
6.3.2 Insl3 regulation by nuclear receptors 
As previously mentioned, Insl3 production is critical for the normal male development of mice and rats, in 
particular testicular descent. In humans, mutations of the Insl3 gene are related to symptoms of the testicular 
dysgenesis syndrome, but the exact role of Insl3 has not been determined75;76. Insl3 is produced by the 
Leydig cells, and similarly to the factors involved in steroidogenesis the transcription of Insl3 is regulated by 
SF1 77. Additionally, the orphan nuclear receptor Nur77 regulates Insl3 transcription 78, but it is not known 
whether SF1 or Nur77 are involved in the pathways by which phthalates affect Insl3 levels (Fig. 5). Maternal 
exposure to the synthetic estrogen diethylstilbestrol induces cryptorchidism in the offspring of humans as 
well as rodents. In mice prenatally exposed to diethylstilbestrol, testicular Insl3 mRNA expression was 
reduced at GD16 and GD18, whereas SF1 expression was unaltered, indicating an SF1-independent 
regulation of Insl3 79. In contrast, SF1 expression was reduced on GD18 in rats prenatally exposed to 
diethylstilbestrol 80. Thus, it remains to be elucidated by which mechanism the expression of Insl3 is 
downregulated by chemical exposure. 
6.3.3 Involvement of PPARs? 
PPARs are known to regulate factors involved in cellular and mitochondrial cholesterol transport as well as 
hepatic cholesterol metabolism, and as phthalates are known to activate PPARs a role for these receptors in 
the downregulation of fetal steroidogenesis can be hypothesized (Fig. 5).  
This hypothesis was based on the fact that the degree of testis toxicity of various phthalates correlates well 
with their potency of PPAR activation44. Additionally, other PPARα or PPARγ ligands affect steroid 
production in testes and ovaries of rats and humans in vitro and in vivo 41;45-49. Several PPAR agonists 
(phthalates, ammonium perfluorooctanoate, clofibrate, WY14,643) have been found to reduce testosterone 
production in primary Leydig cell culture 41;45;48. Neonatal exposure of rats to clofibrate reduced testosterone 
levels in adulthood 47, and ammonium perfluorooctanoate exposure reduced hCG-stimulated testosterone 
production in adult male rats 46. The PPARγ agonist rosiglitazone is known to reduce testosterone levels in 
normal men 49. Rosiglitazone is used for treatment of women with polycystic ovary syndrome and reduces 
hyperandrogenism in these patients 52;53. Thus, it is plausible that the testicular effects in rats exposed to 
PPAR-activating environmental compounds are also of human relevance.  
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The impact of phthalate exposure on PPAR expression was studied as described in Paper IV. Changes in 
fetal testicular PPARα and PPARγ mRNA levels and PPARγ protein expression was assessed at GD 21 in 
DEHP-exposed rats. Animals exposed to 300 mg/kg bw per day of DEHP had a reduced intensity of 
immunostaining for PPARγ in fetal Leydig cells, indicating reduced PPARγ protein levels compared to 
controls (Paper IV). Similarly, PPARγ staining was reduced in Leydig cells at GD 19 and 21 in rats exposed 
to DIBP and at GD 21 in DINP exposed rats (Table 6). The reduced Leydig cell staining for PPARγ in 
phthalate-exposed fetal testes may point to an involvement of PPARγ in the mechanism of action of 
phthalates. However, no alterations in mRNA levels of PPARγ were observed in DEHP- or DIBP-exposed 
testes at GD 21 (Table 7 and Paper IV). DIBP-exposed fetal testes had lower levels of PPARα on GD 19, but 
not GD 21. If PPARs are indeed involved in the mechanisms of action of phthalates, it may be relevant to 
examine changes in gene expression even before GD 19. 
No previous studies have described the distribution of PPARs in fetal testes. Furthermore, the distribution of 
PPARs in adult testes has been poorly described with one study describing weak PPARγ expression (based 
on in situ hybridization) in rat testes 81 and another study describing absence of PPARγ mRNA in mouse 
Leydig tumor cells 41. PPARα expression, however, has been detected in human and rat testes as well as 
mouse Leydig tumor cells41;81;82. Our studies have shown PPARγ staining also in Leydig cells of prepubertal 
and adult rat testes. As this staining pattern partly contradicted the observations described in the literature, 
we confirmed these findings using a monoclonal PPARγ antibody from another manufacturer showing 
similar staining of rat Leydig cells at various ages (results not shown). These studies appear to strengthen the 
evidence that PPARγ is present in fetal Leydig cells. However, the results regarding the impact of phthalate 
exposure on testicular PPAR protein and gene expression show that protein expression changes are not 
always preceded by detectable gene expression changes. It is possible that PPAR interactions may be 
involved in the downregulation of testosterone production in phthalate-exposed rats without any measurable 
changes in PPAR gene expression. 
In addition to the nuclear receptors SF1 and the PPARs, cells contain several orphan nuclear receptors, some 
of which may be involved in the regulation of steroidogenesis. One example is the nuclear receptor DAX-1, 
which interacts with SF, AR and the estrogen receptor and regulates the transcription of several genes for 
factors involved in steroid synthesis including StAR, P450scc, 3βHSD and CYP17 83. The testicular 
expression of DAX-1 mRNA is reduced by phthalate exposure 67, but it is presently unknown whether DAX-
1 or other orphan nuclear receptors interact with phthalates and whether they are related to the testosterone- 
and Insl3-reducing effect of phthalates. 
6.3.4 In vitro studies on phthalate mechanism of action  
In vitro studies have certain advantages compared to animal studies, as they can be more informative about 
mechanisms of action. Steroidogenesis can be studied in various Leydig cell lines, though the Leydig tumor 
cell lines do not produce high levels of testosterone. Instead, progesterone levels can be assessed. Gazouli et 
al. (2002) observed reduced progesterone production in MA-10 mouse Leydig tumor cells and R2C rat 
Leydig tumor cells incubated with 10 µM of MEHP 41. Recent studies in mouse Leydig tumor cells (MLTC-
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1) has shown that hCG–stimulated progesterone production was decreased with high levels (50 to 800 µM) 
of MBP, the monoester metabolite of DBP, while low levels of MBP (1 nM to 1 µM) increased progesterone 
production 84. Addtionally, these studies showed reduced StAR expression at high MBP concentrations and 
increased StAR protein and mRNA expression at lower concentrations corresponding to the effects on 
progesterone levels and further demonstrating an important role of StAR in the mechanism of action of 
phthalates 84.  
In isolated adult rat Leydig cells 1 µM of MEHP reduced testosterone production 41, whereas studies in 
primary cultures of fetal rat Leydig cells have not been able to reveal any effects of phthalates or their 
monoesters on testosterone production 85. A study on DEHP and some of its metabolites (MEHP, metabolite 
VI and XI) on fetal rat testis in culture showed no effects on testosterone production with doses up to 1 or 10 
µM 85. In that study, Stroheker et al. (2006) measured concentrations of DEHP metabolites in testes of 
DEHP-exposed rats and aimed to apply similar concentrations to a fetal rat testis culture. An average 
concentration of 37 nmol/g tissue of DEHP-metabolites were measured in DEHP-exposed fetal testes, and 
this was considered to correspond to a “local” concentration of 37 µM present at the cellular level 85. 
However, they only tested up to 1 µM of MEHP in vitro, which is much lower than the proposed “local” 
concentration. Thus, the concentrations applied in the study on fetal rat testis culture may be too low to 
observe an effect of the DEHP metabolites. 
The study by Stroheker et al. (2006) interestingly enters a field of phthalate-research that has not yet been 
investigated thoroughly. New studies on the metabolism of DEHP reveal that the well-investigated primary 
metabolite MEHP may not be the most prevalent or active metabolite in vivo. Rather, secondary oxidized 
metabolites have longer half-lives and may even be able to accumulate in the body 14. Some of the in vitro 
studies previously made with MEHP may need to be repeated with these secondary metabolites and may 
reveal effects that cannot be found with MEHP. For example, it was previously mentioned that none of the 
reproductive toxic phthalate diesters or their primary monoester metabolites are strong AR antagonists in 
vitro. However, two metabolites of DEHP, metabolite VI and IX have been shown to antagonize the AR 
weakly 31. 
The studies in Leydig tumor cells point to effects of phthalates directly on the Leydig cells, and in particular 
on mitochondrial cholesterol uptake by StAR and/or PBR. In the above mentioned study by Gazouli et al. 
(2002), PBR mRNA levels were reduced by DEHP in MA-10 cells. It was concluded that the reduced 
progesterone level in MA-10 cells could not be due to PPARγ interactions, as no PPARγ mRNA could be 
measured in this cell type 41. They concluded that PPARα mediated the downregulating effect of MEHP on 
the cholesterol transporter PBR, as DEHP reduced PBR expression in wild-type mice, but not in PPARα 
knockout mice 41. As cholesterol transport by PBR is essential for steroid synthesis, the authors thus 
suggested that PPARα may be responsible for the effect of MEHP on testosterone production. On the other 
hand, the lack of PPARγ in MA-10 cells does not exclude the possibility that this cell type differs from rat 
Leydig cells, which (according to our studies) do express PPARγ. The study did not reveal whether PPARγ 
was expressed in the applied rat R2C Leydig tumor cells 41. 
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In order to study whether the effect of phthalates is related to PPARs, it would be relevant to investigate if 
concomitant incubation of Leydig cells with a PPAR antagonist would decrease the effect of the phthalate. 
Additionally, if other PPAR agonists or antagonists affect the same steroidogenic targets as the phthalates in 
vitro, this may further strengthen the hypothesis of involvement of PPARs in the phthalate mechanism of 
action. Studies on the effects of PPARα ligands versus PPARγ ligands on steroid production in Leydig tumor 
cell lines and fetal rat Leydig cell culture may further elaborate on which PPAR subtype may be involved. 
If PPAR-activating chemicals do indeed affect fetal testosterone production, this may be of concern for 
human reproduction, as humans are exposed to several types of chemicals interacting with PPARs 50. 
Additionally, it may be hypothesized that PPAR activation by endogenous sources (e.g. imbalances in the 
metabolic system) may be related to symptoms of the testicular dysgenesis syndrome, as has been suggested 
for phthalates. In line with this, research in the possible links between metabolic disorders and reproductive 
function has recently been attracting increased attention 86.  
6.4 Other chemicals affecting testosterone production in vivo 
6.4.1 In vitro and in vivo studies on PPAR activating chemicals 
The hypothesis of involvement of PPARs in the mechanism of phthalate toxicity inspired our study on fetal 
testicular testosterone production after exposure to the PPAR agonists PFOA and rosiglitazone, which are 
known to reduce testosterone production in young or adult rats or humans. Additionally, we wished to 
examine whether other chemicals with effects on testosterone synthesis (i.e. parabens) were able to interact 
with PPARs.  
Reporter gene assays for PPAR interaction revealed that butylparaben and propylparaben were weak 
activators of PPARα and PPARγ in vitro (Appendix Y). PFOA transactivated PPARα rather strongly and 
was a weak activator of PPARγ, while MEHP was a strong activator of both PPARα and PPARγ, supporting 
the findings by other groups 43;50. Prochloraz did not appear to transactivate either PPAR subtype. Antagonist 
assays were performed by exposing cells to test compounds concomitantly with the specific control ligands 
WY14,643 or rosiglitazone. Butylparaben appeared to be an antagonist of PPARγ, and prochloraz appeared 
to antagonize both PPARα and PPARγ. Little is known about the endogenous ligands for PPARs or the 
human tissue levels of parabens, and it is thus unknown whether the PPAR activating effects of parabens and 
the antagonistic effects of butylparaben and prochloraz may be able to interfere with the activity of the 
endogenous ligands at physiologically relevant concentrations.  
Our rat study showed no alteration of fetal testosterone production or anogenital distance by butylparaben, 
PFOA or rosiglitazone at the applied doses (Table 5 and Appendix Y). This study was not designed for 
studying whether PPARs are involved or not in chemically induced reduction of testosterone. If the 
compounds had been affecting fetal testosterone levels, this effect could be caused by interactions with other 
factors than PPARs. On the other hand, it cannot be excluded that PPAR interactions indeed do lead to 
reduced testosterone production, despite the lack of effects on testicular testosterone production of the 
applied doses of PFOA, butylparaben and rosiglitazone in the current study.  
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When comparing the potencies of the chemicals on PPAR transactivation in vitro, it becomes clear that much 
higher concentrations of PFOA and butylparaben are required for a certain response compared with MEHP 
in this assay (Appendix Y). Thus, the lack of effect in vivo may not be surprising, as the doses of chemicals 
applied in the rat studies are much lower for PFOA (20 mg/kg bw/day) and butylparaben (100 mg/kg 
bw/day) than the dose of DEHP (300 mg/kg bw/day), which reduced fetal testicular testosterone levels in our 
previous study (Paper IV). Rosiglitazone is more potent than MEHP with respect to PPARγ transactivation 
in vitro, but still there is quite a gap between the applied dose of 1 mg/kg bw/day of rosiglitazone and the 
300 mg/kg bw/day of DEHP required to see an effect on testosterone levels in vivo. For all the test 
compounds in the current study, however, higher doses than the applied were expected to be teratogenic or 
toxic to the dam according to studies described in the literature. Further studies may reveal whether higher 
doses of these compounds or other routes of administration will lead to antiandrogenic effects in fetal rats. 
Additionally, studies on distribution and metabolism of the compounds may reveal differences between fetal 
and adult exposure and metabolism, explaining why studies on other age groups of rats have revealed effects 
on testosterone levels at the applied doses.  
As mentioned in relation to the phthalates, in vitro studies may be more adequate for determining whether 
the testosterone-reducing effect of these chemicals is related to their interaction with PPARs. If there is 
indeed a causal relation between PPAR activation and inhibition of testosterone production, reporter gene 
assays as those described here may be adequate for screening chemicals for PPAR activation and may 
thereby reveal other chemicals with potentially harmful effects adverse effects. 
6.4.2 Prochloraz in vivo studies 
The studies on the fungicide prochloraz presented in Paper VI are included as an example of an antiandrogen 
with a different mode of action compared to phthalates but with qualitatively rather similar effects. 
Prochloraz belongs to a group of widely used fungizides, the azoles, which may be suspected to have similar 
actions as prochloraz, but have not yet been thoroughly examined for endocrine effects. Prochloraz is 
presently being evaluated for classification as a reproductive toxicant due to its antiandrogenic effects. As 
mentioned, this compound is both an antagonist of the androgen receptor and reduces fetal testosterone 
production in rats 29. This induces reduced anogenital distance, increased nipple retention and altered 
behaviour of male rats exposed in utero 30. The impact of prochloraz on factors involved in steroidogenesis 
was examined by similar methods as the studies on DEHP and DIBP. Although prochloraz reduced 
testosterone production significantly in fetal testes similarly to the phthalates, prochloraz-exposed testes 
showed no alterations in expression of the examined genes, although immunohistochemical studies revealed 
altered protein expression of some of these factors.  
The observed increase of testicular progesterone level indicates that prochloraz inhibits CYP17 activity, but 
the current immunohistochemical studies revealed an increased CYP17 expression (Paper VI). This indicates 
that the expression of CYP17 may be regulated by feedback mechanisms increasing CYP17 expression in 
response to the impaired activity of the enzyme. We also observed a reduced expression of 17βHSD type 10 
in Leydig cells of prochloraz exposed fetuses. 17βHSD type 10 is highly expressed in fetal Leydig cells and 
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involved in the conversion of 3 -androstanediol into dihydrotestosterone, which is an androgen with high 
affinity to the AR 87. The reduced expression in prochloraz-exposed fetal testes may indicate yet another 
pathway leading to low androgen levels and in turn to the antiandrogenic effects observed with prochloraz 
exposure. Alternatively, 17βHSD type 10 may be activated as a reaction to the low testosterone levels and/or 
impaired androgen function. The observed low expression of the protein may be associated with this increase 
in enzyme activity. Whether the low expression of 17βHSD type 10 is an effect or a cause of the low 
testosterone levels remains unclear, but enzyme activity measurements would be relevant in order to reveal 
which of these hypotheses is true. Further studies may reveal whether reduced expression of this enzyme in 
fetal testes may be generally involved in the antiandrogenic effects and/or reduced testosterone production 
induced by other chemicals than prochloraz.  
6.5 Dose-response and mixture studies - implications for risk 
assessment 
The described studies on the mechanisms of action of endocrine disrupters are important in order to be able 
to detect other potential endocrine disrupters affecting the same targets. Furthermore, mechanistic knowledge 
may be important for determining whether the observed effects are relevant to humans and thus whether 
human exposure to the compound may pose a risk. Risk assessment is also based on knowledge on the dose 
levels at which adverse effects are observed in animal studies in comparison to the human exposure levels of 
the compound. Some vulnerable human population groups may be at risk of being exposed to phthalates at 
levels close to the dose levels inducing adverse effects in rat studies, as will be discussed in the following. 
Furthermore, as several phthalates and other compounds have comparable effects, there may be an increased 
risk with mixed exposure to all these compounds. 
6.5.1 DEHP dose-response studies 
The effects of gestational exposure to 0, 10, 30, 100 and 300 mg/kg bw/day of DEHP were examined in fetal 
rat testes at GD 21 (Paper IV). The studied endpoints seemed to be affected at different dose levels. The most 
sensitive endpoints were changes in gonocyte location and morphology as well as changes in mRNA levels 
of the steroidogenic regulator StAR, as the effects on these parameters were statistically significant at 100 
mg/kg bw/day. Testicular testosterone levels and -production were reduced only in the highest dose group. 
However, for some endpoints such as testicular testosterone production and expression of other genes, 
changes seemed to be present at 30 and 100 mg/kg bw/day, but were not statistically significant with the 
selected number of animals. PBR and StAR mRNA levels were slightly, but not significantly, reduced 
already from 10 mg/kg bw/day of DEHP. Thus, if an increased number of litters had been used, statistically 
significant effects might have been revealed at lower dose levels. However, it can be difficult to interpret 
whether e.g. changes in gene expression at low dose levels are directly related to adverse effects and thereby 
relevant to risk assessment. 
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Risk assessment is generally based on dose-response studies examining endpoints that can be directly related 
to potentially adverse effects in humans. When rats were exposed to DEHP in gestation as well as in 
lactation, we observed adverse reproductive effects in adulthood such as small testes and epididymides and 
malformed secondary sexual organs at 300 and 750 mg/kg bw/day of DEHP (Paper III). Sperm quality was 
affected in a few animals in both dose groups. As no other doses were applied in that study, we could not 
determine a no-observed effect level (NOEAL) applicable for risk assessment.  
Andrade et al. (2006) examined adult Wistar rats exposed to DEHP in utero and via lactation. In that study, 
daily sperm production was reduced at doses from 15 mg/kg bw/day, while cryptorchidism was induced 
already at 5 mg/kg bw/day88. In comparison, Gray et al. (2006) have reported abnormalities of male 
reproductive organs at doses from 11 mg/kg bw per day of DEHP (unpublished work reviewed by the same 
authors in 28). The most recent risk assessment report by the European Chemical Bureau has agreed on a 
tolerable daily intake (TDI) of 48 µg/kg bw/day for DEHP based on a NOAEL of 4.8 mg/kg bw/day 89. This 
NOAEL was determined in a two-generation reproductive study showing reduced size of testes, 
epididymides and seminal vesicles and minimal testis atrophy at dose levels above 300 ppm corresponding to 
4.8 mg/kg bw/day 90. Collectively, the NOAELs and LOAELs determined in these studies appear to be 
comparable. As some of the adverse effects are assumed to be caused by the low fetal testosterone level, it is 
remarkable that the adverse effects observed in the adults are actually found at lower dose levels than those 
reducing testosterone levels in our study. 
In our combination study of DEHP and DINP, 750 mg/kg bw/day DINP induced slightly milder effects than 
300 mg/kg bw/day of DEHP on fetal testicular testosterone levels and histopathology in our studies, 
indicating a lower potency of DINP than DEHP (Paper I and Table 4). This is also reflected in the risk 
assessment of these compounds, as DEHP is more strictly regulated than DINP regarding e.g. use in toys. 
Currently, DINP is not classified as toxic due to a relatively high NOAEL of 88 mg/kg bw/day based on 
adverse hepatic effects, but the EU scientific committee has recently suggested to use instead a NOAEL of 
15 mg/kg bw/day giving a TDI of 150 µg/kg bw/day, which would lead to classification as a potential health 
hazard with prolonged exposure 91. In contrast, our study on DIBP showed that DIBP is at least as potent as 
DEHP and DBP in reducing testosterone levels (Paper V), but DIBP is currently not classified, whereas 
DEHP and DBP are both classified as reproductive toxicants 92. 
6.5.2 Comparison to human exposure levels 
These TDIs based on effects in animals studies can be used for comparison to human exposure levels and 
thereby assessment of risk. For phthalates, relatively high exposure levels have led to concern about the 
abundant use. Generally, mean exposure levels of adult humans are estimated to be in the range of 1 to 8 
µg/kg bw/day, while maximal or 95th percentile exposure have been estimated to be in the range of 5 to 26 
µg/kg bw/day25. Another report determined an exposure level for DEHP by multiple pathways for consumers 
of 12 µg/kg bw/day for adults and 233 µg/kg bw/day for children89. A recent study based on urinary 
metabolite levels has determined an exposure level of up to 74 µg/kg bw/day of DEHP (median 2 µg/kg 
bw/day) in a US study population of pregnant women93.  
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Children are exposed to even higher levels of DEHP per kg body weight. Exposure levels of human infants 
are estimated to be in the range of 2 to 26 µg/kg bw/day with maximal or 95th percentile exposure levels 
between 16 and 285 µg/kg bw/day 25. A recent report by the Danish Environmental Protection Agency 
(2006) on chemicals in consumer products reported a typical intake of 10-20 µg/kg bw/day of DEHP for 
children compared with a worst-case scenario of 50-250 µg/kg bw/day of DEHP for a very exposed child 
playing on a PVC floor. This indicates a narrow safety factor for DEHP for the highly exposed children, 
even without considering the concomitant exposure to other phthalates 94. Collectively, maternal and infant 
exposure levels are close to or even exceed the TDI of 48 µg/kg bw/day 89. Based on the high exposure 
levels, the US National Toxicology Program Centre for the Evaluation of Risks to Human Reproduction 
have expressed concern for effects of DEHP exposure on development of the male reproductive tract for 
infants 95. 
Due to high levels of DEHP in medical products, infants in neonatal intensive care are among the most 
exposed population groups. Infants in neonatal intensive care units have been estimated to have a median 
daily DEHP exposure of 42 µg/kg bw/day with 95th percentile at 1780 µg/kg bw/day 96. These infants are 
thus exposed to levels near the TDI with some infants exceeding TDI several fold during a sensitive period 
of susceptibility. Additionally, adults receiving medical treatment can be exposed to very high levels of 
phthalates as certain tablets are coated with DBP. If these tablets are given to pregnant women, this may pose 
a risk to their unborn children. No studies on correlations between high neonatal or maternal phthalate 
exposure and reproductive function later in life have yet been reported.  
This uncertainty factor of 100 between the NOEALs and the tolerable daily intake is aimed at taking into 
account the interpersonal differences in sensitivity to chemical exposure and species differences in metabolic 
rate and sensitivity between rats and humans. Humans are known to have a more vulnerable reproductive 
system than rats, and minor defects of sperm production or function in men may render them infertile, 
whereas rats can reproduce even with large reductions of sperm production or quality 97. 
6.5.3 Human relevance of phthalate effects 
It is remarkable that some of the phthalates, which were found to be associated with symptoms of the 
testicular dysgenesis syndrome in human studies 10;11, do not induce adverse reproductive effects in rats. 
High urinary concentrations of metabolites of DBP, DIBP, DEP and dibenzyl phthalate were associated with 
reduced anogenital distance in boys 10, and high levels of monoester metabolites of DBP, DINP, DEP and 
DMP in mothers’ breast milk were correlated with altered blood levels of reproductive hormone levels in 
their infant sons 11. However, DEP and DMP do not affect reproductive development in male rats 17. This 
could indicate that the effects observed in the human studies are merely statistical coincidences. However, it 
is also possible that species differences lead to different mechanisms of action or different vulnerability to 
phthalates in humans compared to rats. An alternative explanation is that the levels of the primary monoester 
metabolites of DEP and DMP are markers of general phthalate exposure.  
A comparison of measurements on maximal MEHP concentrations in blood in different species exposed to 
DEHP revealed that rats, marmosets and humans had a similar maximum MEHP concentration despite a 50 
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times larger dose given to rats and marmosets than humans 14. This points to rather high “internal doses 
levels” in humans compared to rats even with low exposure levels. Additionally, the total MEHP exposure 
determined as the area under the concentration-time curves was several fold higher in humans despite the 
lower dose 14. These species differences indicate an increased risk of phthalate toxicity in humans compared 
to rats or marmosets. 
On the other hand, other species differences may imply that the mechanisms leading to adverse effects of 
phthalates in rats are not relevant to humans. Studies in marmosets have shown no reproductive effects of 
DEHP exposure of young and adult animals 98;99. On the other hand, boars prepubertally exposed to 50 mg 
DEHP/kg bw twice weekly had elevated testosterone levels and boars exposed to 300 mg DEHP/kg bw three 
times weekly had slight effects on sperm quality later in life 100;101. Rabbit studies have highlighted the 
importance of performing studies on perinatal phthalate exposure, as rabbits exposed to 400 mg/kg bw/day 
of DBP in utero had much more marked and permanent reproductive effects than rabbits exposed in 
adolescence or adulthood 102. However, no studies on perinatal phthalate exposure of marmosets or boars 
have yet been reported why adverse reproductive effects of phthalates in these species cannot be excluded. 
6.5.4 Mixture studies 
The concept of using TDIs based on NOAELs takes only single chemicals into consideration. For the 
phthalates and many other groups of chemicals, it is highly relevant to consider the effects of combined 
exposure to compounds with similar mechanisms of action or similar effects in vivo. However, before that 
approach can be included in risk assessment, it is necessary to investigate how the compounds act in 
combination and to find appropriate prediction models for mixture effects.  
DEHA is a non-phthalate plasticizer, which is used as a substitute for DEHP. The hypothesis that DEHA 
may modulate the effects of DEHP when these compounds are administered in combination was based on 
the fact that DEHP and DEHA share a common metabolite, 2-EH, when hydrolyzed in the gut to their 
monoesters, MEHP and mono(2-ethylhexyl) adipate (MEHA). The studies on combined exposure to DEHP 
and DEHA did not show any modulating effects of DEHA on the reproductive effects of DEHP, as exposure 
to DEHP + DEHA in combination had similar effects as exposure to DEHP alone (Paper I, II, III).  
The lack of modulating effect of DEHA is in accordance with the general consideration that it is the 
monoester metabolite MEHP and not the other hydrolysis product 2-EH, which is responsible for the 
reproductive toxicity of DEHP. For example, rat pups exposed to MEHP exhibited testicular toxicity similar 
to that observed with DEHP, whereas no toxicity was present with 2-EH-exposure103. As these studies did 
not include a group exposed to DEHA alone, they did not reveal whether DEHA (or 2-EH) affects e.g. fetal 
testicular testosterone production. However, a previous study by our group showed that perinatal DEHA 
exposure did not affect anogenital distance, nipple retention, sperm production or reproductive organ weights 
in rats at doses up to 800 mg/kg bw/day 104. 
The combination study on DEHP and DINP showed increased effects of DEHP and DINP administered in 
combination compared to the effects of each compound alone (Paper I and poster in Appendix Y). As the 
study included only one dose level per compound, it could not be determined whether the effects were dose 
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additive, but clearly there was an accumulating effect. This supports the idea of recalculating TDIs by taking 
into account the contribution of other reproductive toxic phthalates.  
Furthermore, exposure to other chemicals than phthalates with similar effects may also need to be 
considered. A study on rats exposed to BBP and the herbicide Linuron from GD 14-18 showed that these two 
compounds induced cumulative antiandrogenic effects compared to the effect of each compound alone105. 
Animals in the BBP plus Linuron combination group had reduced fetal testosterone and progesterone levels, 
reduced neonatal and adult anogenital distance, increased infant and adult number of nipples/areolae and 
reduced reproductive tissue weight, while these effects were less marked in the animals exposed to the 
individual componds. Interestingly, malformations of male external genitalia were only observed in the 
combination group and not for BBP or Linuron alone 105. Studies in rats on mixtures of chemicals with 
similar antiandrogenic actions performed by our group have demonstrated dose-additivity in rats. A 
combination of three AR antagonists induced marked feminization of male pups. In contrast, the same doses 
of each chemical alone did not give as marked effects (Hass et al. in press). A mixture of four chemicals with 
dissimilar mechanisms of action (AR antagonists, a 5α-reductase inhibitor and DEHP) also induced higher 
levels of antiandrogenic effects than expected for each compound alone (unpublished). No mixture studies 
on different types of phthalates have been published previously to those included in this thesis (Paper I). 
6.5.5 Implications for risk assessment 
As long as it is unknown how many chemicals have similar effects or similar mode of action and whether 
they contribute to the total “antiandrogenic load” to humans, it is difficult to approach this problem in risk 
assessment. Instead, it may be reconsidered whether it is at all relevant to use the concept of a threshold dose 
for single chemicals below which no effects can be anticipated. In vivo as well as in vitro studies have shown 
that combined exposure to endocrine disrupting compounds at doses or concentrations below no-observed 
effect levels or no-observed effect concentrations can induce statistically significant effects when 
administered in combination 106;107(+ Hass et al. in press, Metzdorff et al., submitted). An alternative to the 
use of TDIs based on NOAELs for single chemicals could be the determination of a TDI for a group of 
chemicals with similar effects. For single chemicals, TDIs could be determined as a weighted fraction of the 
TDI for the group. However, these alternatives require added knowledge on the antiandrogenicity of a 
multitude of chemicals.  
At present, the possibilities of detecting antiandrogenic endocrine disrupters using the current OECD 
regulatory guidelines are limited. The current studies showed reductions of the AGD at GD 21 or PND 3 for 
the chemicals that reduced fetal testicular testosterone levels, but not for the chemicals not affecting fetal 
testosterone. As the AGD is also reduced by antiandrogenic compounds with different mechanisms of action, 
measurement of AGD would be highly relevant as a standard endpoint in test guidelines in which animals are 
exposed in late gestation. Recent updates of the OECD two-generation test guideline studies do include the 
assessment of AGD in the second, but not the first, generation of rat offspring exposed to test chemicals, and 
only if triggered by findings in the first generation 108. The current studies further support that antiandrogenic 
chemicals alter AGD in fetal rats at GD 21, and it is therefore relevant to measure AGD at GD 21 in e.g. the 
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OECD guideline 414, which investigates prenatal developmental toxicity following chemical exposure from 
GD 7 to 21 similarly to our studies. 
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7 Conclusions and summary 
In summary, the studies described in Paper I to VII have elaborated on a number of topics related to 
chemically induced reduction of fetal testosterone production. New knowledge revealed in the studies is 
listed here together with comments on the perspectives of these findings: 
 
Phthalates 
o DINP and DIBP have similar effects on fetal testicular development and testosterone levels as the 
known reproductive toxicant DEHP. This indicates a similar mechanism of action and points to a 
similar adverse effect pattern for these phthalates. There is thus a reason for concern for use of DINP 
and DIBP as substitutes for DEHP or DBP, and alternative substitutes need to be developed. 
Furthermore, the observation of an accumulating effect when exposing rats to a mixture of DEHP 
and DINP indicates that risk assessment should take into account the collective contribution of 
exposure to several reproductive toxic phthalates.  
o The studies have elaborated on the temporal development of the testicular histopathological effects 
of DEHP, supporting the findings described for DBP by other investigators. 
o DEHA is a non-phthalate plasticizer, which is used as a substitute for DEHP. The hypothesis that 
DEHA may modulate the effects of DEHP when these compounds are administered in combination 
was based on the fact that DEHP and DEHA share a common metabolite, 2-EH, when hydrolyzed in 
the gut to their monoesters, MEHP and MEHA. The studies showed no modulating effects of DEHA 
on the reproductive effects of DEHP. 
o New insights have been made regarding phthalate mechanism of action. Reduced levels of factors 
involved in steroid synthesis cause the testosterone-reducing effect of DEHP and DIBP. This is 
similar to the alterations described for DBP by other authors. Based on literature studies and 
indications from in vivo studies, it is suggested that the phthalate mechanism of action may involve 
the nuclear receptors SF1, PPARγ and PPARα 
o As the evidence for involvement of PPARs or other nuclear receptors in the mechanism of action of 
phthalates is rather weak, further studies are needed. In particular, cell-based studies may be able to 
reveal whether PPARα- or PPARγ-activating or –inhibiting compounds affect steroid synthesis. If 
these receptors are indeed involved in the testosterone-reducing effects of phthalates, reporter gene 
assays such as those employed in the current studies may be valuable tools for screening chemicals 
for similar mode of action as phthalates and may thus reveal other chemicals with potentially 
harmful effects. In an in vitro screening battery testing the interaction of chemicals with e.g. the AR, 
estrogen receptor and thyroid receptor it would be relevant to include test of PPARγ and PPARα 
interaction. 
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Prochloraz 
o Immunohistochemical studies on expression levels of factors involved in steroid synthesis elaborated 
on the mode of action of prochloraz, a fungicide that both acts as an antagonist to the androgen 
receptor and reduces fetal testosterone production. Reduced testosterone levels following prochloraz 
exposure is in part due to an inhibition of CYP17, a central enzyme in steroidogenesis. The 
observation of increased immunostaining intensity for CYP17 in Leydig cells of prochloraz-exposed 
fetuses may be a response to the inhibited steroid synthesis and emphasizes the importance of 
CYP17 in the mode of action of this compound.  
o The expression of 17βHSD type 10 was reduced in Leydig cells of prochloraz exposed fetuses. As 
this enzyme counteracts the degradation of testosterone and promotes dihydrotestosterone 
production, the lowered expression points to yet another mechanism leading to the observed 
antiandrogenic effects. Alternatively, the reduced expression may be a due to increased activity of 
the enzyme as a compensatory action towards the antiandrogenic effect of prochloraz. Enzyme 
activity measurements would be relevant in order to reveal whether the low expression of 17βHSD 
type 10 is an effect or a cause of the low testosterone levels. 
o A number of structurally comparable fungizides are abundantly used at present although their 
possible endocrine effects have not been determined. Further studies may reveal whether some of 
these compounds also act as antiandrogens. 
Parabens 
o Human exposure to parabens via personal care products and cosmetics is relatively high and 
knowledge on their possible adverse effects is lacking. Certain studies have shown that some of the 
parabens are estrogenic and are able to reduce testosterone levels and semen production of rats. Our 
preliminary study did not reveal any reduction of anogenital distance or testosterone levels in male 
fetal rats exposed to 100 mg/kg bw/day of butylparaben via oral dosing of the dam. Further studies 
are needed to determine whether higher doses of parabens or other routes of exposure may induce 
antiandrogenic effects in rats.  
o We examined whether parabens are able to activate or antagonize the activation of PPARα or PPARγ 
in a reporter gene assay. Butylparaben and propylparaben were shown to be weak agonists as well as 
weak antagonists of PPARα and PPARγ in vitro. Further studies may reveal whether the interaction 
of parabens with PPARs can interfere with normal physiological processes in testes or other tissues. 
Risk assessment of endocrine disrupters 
o At present, regulatory test guidelines for chemical safety are unable to detect all types of endocrine 
disruption. The analysis of chemically induced changes in fetal testosterone levels seems to be 
highly relevant, because low testosterone in late gestation is associated with adverse effects later in 
life. A reduced anogenital distance (AGD) around the day of birth is a typical sign of antiandrogenic 
effects of chemicals, why this parameter would be relevant to include in future test guidelines.  
o Prochloraz is an example of a compound with comparable antiandrogenic effects to the phthalates 
but dissimilar mechanism of action. It is plausible that mixtures of chemicals with similar effects but 
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dissimilar mechanisms of action lead to more severe effects than observed for each chemical alone. 
If future testing of chemicals reveals that several compounds interfere with e.g. fetal testosterone 
production by various mechanisms, the combined effect of exposure to even low doses of these 
chemicals may give rise to concern.  
o It is presently unclear whether human exposure to endocrine disrupting chemicals is related to the 
increasing incidence of male reproductive disorders. As certain groups of infants have been exposed 
to extremely high levels of phthalates during treatment in neonatal intensive care units, future studies 
giving information on their reproductive function later in life may be valuable for the evaluation of 
the risk associated with perinatal phthalate exposure of humans. 
o It is not evident whether phthalates or other compounds interfering with fetal testosterone production 
or –function are related to the testicular dysgenesis syndrome observed in humans. Each chemical 
alone may be present in human tissues at too low levels to cause any adverse reproductive effects. 
However, there is a reason for concern that several chemicals have antiandrogenic effects and that 
the increasing incidence of male reproductive dysfunction is due to combined exposure to 
antiandrogens. It is therefore highly relevant to be able to detect chemicals with antiandrogenic 
effects by use of adequate test guidelines and subsequently to be able to reduce human exposure to 
antiandrogens by regulatory initiatives. 
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Corrections:  
 
Paper I, Fig. 4A: Anogenital distance is indicated in mm on the y-axis, but these values are in fact arbitrary 
units, which must be multiplied by 0,165 in order to get the actual anogenital distance. 
 
Paper II, Table I: Presence of chords with enlarged diameter: 0% of animals (0% of litters) affected in the 
control group, not 100% of litters. 
 
Paper VI, Fig. 2B: Testosterone and progesterone was not measured in testes, but in the media of incubated 
testes. 
 
Paper V: Animals & dosing: 32 mated rats were used in four blocks of eight, and not 24 as indicated. 
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Steroidogenesis in fetal male rats is reduced by DEHP and DINP,
but endocrine effects of DEHP are not modulated by
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Abstract
The plasticizer di(2-ethylhexyl)phthalate (DEHP) exhibits antiandrogenic effects in perinatally exposed male rats. Di(2-ethylhexyl) adi-
pate (DEHA) and diisononyl phthalate (DINP) are currently being evaluated as potential substitutes for DEHP, but similarities in structure
and metabolism of DEHP with DEHA and DINP have led to the hypothesis that similarities in action may also exist. Pregnant Wistar rats were
gavaged during gestation and lactation with vehicle, DEHP (300 or 750 mg/kg bodyweight per day), DINP (750 mg/kg bodyweight per day),
DEHP (750 mg/kg bodyweight per day) in combination with DEHA (400 mg/kg bodyweight per day), or DEHP (300 mg/kg bodyweight per
day) in combination with DINP (750 mg/kg bodyweight per day). DINP and DEHP were both shown to reduce testicular testosterone pro-
duction ex vivo and testosterone levels in testes and plasma of male fetuses at gestation day 21, indicating a similar mechanism of action for
DINP and DEHP. Additionally, plasma LH levels in male fetuses were elevated. Neonatal anogenital distance was reduced and the number of
nipples at postnatal day 13 increased in DEHP-exposed male offspring. Serum inhibin B levels were significantly reduced in DEHP-exposed
prepubertal male offspring, and in a few adult males. No modulating effects of DEHA on the endocrine effects of DEHP were detected,
but a tendency towards an accumulating effect of DEHP and DINP in combination on suppression of testosterone synthesis was seen.
© 2003 Elsevier Inc. All rights reserved.
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1. Introduction
The plasticizer di(2-ethylhexyl)phthalate (DEHP) has
been recognized as an endocrine disrupter inducing adverse
effects in androgen responsive tissue following perinatal
exposure of male rats [1]. Di(2-ethylhexyl) adipate (DEHA)
and diisononyl phthalate (DINP) are currently being eval-
uated as potential substitutions for DEHP, but due to sim-
ilarities in structure and metabolism of DEHP and DEHA,
and of DEHP and DINP, it may be hypothesized that sim-
ilarities in action may also exist. In the present studies,
antiandrogenic effects in male rats perinatally exposed to
DEHP alone or in combination with DEHA or DINP were
investigated in late gestation, prepuberty or adulthood.
Antiandrogenic effects of phthalates have been suggested
to be due to a reduced androgen availability in target organs
causing malformations of male reproductive organs and low
adult sperm counts [1,2]. Neither DEHP, di-n-butyl phtha-
late (DBP) or their monoester metabolites were able to an-
∗ Corresponding author. Tel.: +45-3395-6562; fax: +45-3395-6001.
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tagonize the androgen receptor [1,3]. Suppression of fetal
androgen production by environmental chemicals has also
been hypothesized of underlying the disorders comprising
the ‘testicular dysgenesis syndrome’ in humans, i.e. testic-
ular germ cell cancer, cryptorchidism, hypospadias and low
sperm counts [4].
DEHP and DEHA are hydrolyzed in the gut to mono(2-
ethylhexyl) phthalate (MEHP) and mono(2-ethylhexyl)
adipate (MEHA), respectively, and have the metabolite 2-
ethylhexanol (2-EH) in common (Fig. 1A). In vivo studies
on MEHP have shown adverse effects on male reproductive
development similar to those observed after DEHP expo-
sure, effects which are not seen following 2-EH exposure
alone [5,6]. On the other hand, 2-EH exhibits maternal and
fetal toxicity when administered to pregnant rats [7]. Studies
on DEHA have not shown any adverse effects on the repro-
ductive system but rather developmental toxicity (prolonged
gestation period, smaller pup size, high incidence of postna-
tal death) when administered to pregnant dams [8], effects
resembling those observed with 2-EH. If 2-EH is also re-
sponsible for part of the effects of DEHP on the male repro-
ductive system, DEHA may hypothetically augment DEHP-
0890-6238/$ – see front matter © 2003 Elsevier Inc. All rights reserved.
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Fig. 1. (A) Metabolism of di(2-ethylhexyl) phthalate (DEHP) and di(2-ethylhexyl) adipate (DEHA) to 2-ethylhexanol (2-EH) and mono(2-ethylhexyl)
phthalate (MEHP) or mono(2-ethylhexyl) adipate (MEHA) and (B) structure of diisononyl phthalate (DINP).
induced changes in male reproductive endpoints when the
two compounds are administered in combination, even
though DEHA does not produce these effects on its own.
Some studies on DINP (Fig. 1B) have shown effects on
androgen responsive tissues (nipple retention, testes atro-
phy, epididymal agenesis) in males [2], but in other studies
DINP was reported as having no adverse reproductive ef-
fects [9]. The malformations observed with perinatal DINP
exposure point to a similar mechanism of action as DEHP,
and modulating effects of DINP on DEHP-induced changes
may be hypothesized when the compounds are administered
together.
In the present studies, male offspring of dams exposed
to DEHP, or DEHP in combination with DEHA were ex-
amined in late gestation, prepuberty and adulthood. Among
the examined parameters were effects on androgen depen-
dent development (anogenital distance and nipple retention),
ex vivo testicular testosterone production, blood levels of
testosterone, inhibin B, luteinizing hormone (LH), and fol-
licle stimulating hormone (FSH). In addition, DEHP and
DINP and a combination of the two were investigated for
effects on fetal testosterone and LH levels.
2. Materials and methods
2.1. Test compounds
DEHP, di(2-ethylhexyl) phthalate, CAS no. 117-81-7, pu-
rity 99%, was from Aldrich 20,115-4. DEHA, di(2-ethylhe-
xyl) adipate, CAS no. 103-23-1, purity 99%, was from Ald-
rich 29,118-8. DINP, diisononyl phthalate, CAS no. 28553-
12-0, purity >99%, was from Aldrich 37,666-3. The vehicle
was peanut oil obtained from the Royal Veterinary Agricul-
ture Pharmacy, Copenhagen, Denmark or from Sigma.
2.2. Animals and dosing
2.2.1. Experiment 1
This study was designed to investigate hormonal ef-
fects in male rat fetuses exposed to DEHP, DINP or a
combination of DEHP and DINP. Thirty-two dams were
randomized into four groups dosed with either vehi-
cle (peanut oil), 300 mg DEHP/kg bodyweight per day,
750 mg DINP/kg bodyweight per day, or with 300 mg DEHP/
kg bodyweight per day plus 750 mg DINP/kg bodyweight
per day. Male fetuses were sacrificed on gestation day
(GD) 21, and blood and testes were collected for hormone
analyses. The dose of 750 mg DINP/kg bodyweight per
day was the same as used by Gray et al. [2]. The dose of
300 mg DEHP/kg bodyweight per day was selected in order
to obtain submaximal effects on hormone levels compared
to the dose of 750 mg DEHP/kg bodyweight per day used
in Experiment 2 and by Parks et al. [1]. Additionally, these
doses were not expected to cause maternal toxicity when
administered in combination.
2.2.2. Experiment 2
This study was designed to investigate effects of com-
bined exposure to DEHP and DEHA in male rats in late
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gestation and early postnatally. Forty-eight time-mated Wis-
tar rats (Mol:WIST, SPF, Taconic M&B, Denmark) were
housed in pairs and randomized into three groups with sim-
ilar body weight distributions. The day following mating
was designated GD 1, and postnatal day (PND) 1 was the
day following birth. The animals were dosed with either ve-
hicle (peanut oil), 750 mg DEHP/kg bodyweight per day, or
750 mg DEHP/kg bodyweight per day in combination with
400 mg DEHA/kg bodyweight per day from GD 7 to PND
17. On GD 21, eight randomly selected dams per group
were anesthetized in CO2/O2 and decapitated, and fetuses
were removed and decapitated. Blood and testes from male
fetuses were collected for hormone analyses. The remaining
eight dams per group were housed in individual cages at GD
21, and anogenital distance at PND 3 and nipple retention
at PND 13 were assessed in all male offspring as previously
described [8]. The dose of 750 mg DEHP/kg bodyweight
per day was the same as in the study by Parks et al. [1]. The
dose of 400 mg DEHA/kg bodyweight per day was selected
as this was the highest dose not causing postnatal death
of offspring or maternal toxicity in the study by Dalgaard
et al. [8]. These doses were not expected to cause maternal
toxicity when administered in combination.
2.2.3. Experiment 3
This study was designed to investigate effects in pre-
puberty and adulthood in male rats perinatally exposed
to DEHP and DEHA in combination. Eighty time-mated
Wistar rats were randomized into four groups receiving
either 0, 300 or 750 mg DEHP/kg bodyweight per day, or
750 mg DEHP/kg bodyweight per day in combination with
400 mg DEHA/kg bodyweight per day from GD 7 to PND
17. Three randomly selected males per litter from 10 litters
per group were sacrificed at PND 22, and further one or
two males per litter were sacrificed at PND 190. Blood
from all males, and testes from one male per litter at PND
190 were collected for hormone analyses. The doses were
the same as in Experiment 2 but with an additional dose of
300 mg DEHP/kg bodyweight per day in order to investigate
dose-effect relations.
2.3. Hormone analyses
2.3.1. Ex vivo testosterone production
The left testes from two randomly selected fetuses per
litter were placed in 1 ml ice-cold Dulbecco’s Modified Ea-
gle Medium (DMEM)/F12 with 15 mM HEPES, 365 mg/l
l-glutamine plus 0.1% bovine serum albumin. The testes
were incubated at 34 ◦C for 3 h, were then placed on ice,
centrifuged at 4000× g for 10 min, and the supernatant was
collected and stored at −80 ◦C until analysis of testosterone
content.
2.3.2. Extraction of testicular testosterone
One testis from one randomly selected male per litter of
fetal or adult rats was placed in an empty tube and imme-
diately frozen in liquid nitrogen and stored at −80 ◦C until
analysis. Testosterone was extracted by two consecutive di-
ethylether extraction procedures and stored at −80 ◦C until
analysis.
2.3.3. Extraction of plasma and serum testosterone
Blood was centrifuged at 4000 × g for 10 min at 4 ◦C.
Pools of plasma from fetuses and serum from 22- and 190-
day-old males was kept at −80 ◦C until analysis of testos-
terone, LH, FSH or inhibin B content. Steroids were ex-
tracted from blood samples by solid-phase extraction using
IST Isolute C18 SPE columns of 100 mg.
2.3.4. Hormone analyses
Testosterone content in incubation media, testes and blood
was analyzed with a Delfia Testosterone Time-resolved fluo-
roimmunoassay (A050-201, PerkinElmer, Wallac Oy, Turku,
Finland). Serum LH and FSH levels were analyzed at Turku
University, Finland. Rat FSH immunoreactivity was deter-
mined by a two-site immunofluorometric assay recognizing
both the -subunit and the -subunit of the FSH molecule
[10]. Rat LH was measured using the time-resolved fluo-
rimetric assay (Delfia, Wallac OY, Turku, Finland) as de-
scribed by Haavisto et al. [11]. Inhibin B was measured us-
ing an Inhibin B ELISA assay (MCA1312KZZ, Oxford Bio-
Innovation, Oxford, UK) recognizing both the B-subunit
and the -subunit of inhibin B.
2.4. Statistics
Non-processed and logarithmically transformed data
were examined for normal distribution and homogeneity
of variance. Anogenital distance and nipple data were an-
alyzed by ANOVA using litter means. Anogenital distance
data were also analyzed by ANCOVA with body weight as
a covariate. All other data were analyzed by ANOVA using
single animal data nested within litter, which was the statis-
tical unit. Litter was included in the analysis of variance as
an independent, random factor (SAS Analyst: mixed pro-
cedure, SAS version 8, SAS Institute Inc, Cary, NC, USA).
Dunnett’s tests were performed to determine differences
between treated and control group means. Additionally, in-
teraction effects were determined on data from Experiment
1 in a factorial analysis with the factors DEHP and DINP
at levels − or +. Calculation of Pearson’s r was followed
by a t-test of the hypothesis r = 0. Asterisks indicate a
statistically significant difference compared to controls ∗:
P < 0.05; ∗∗: P < 0.01; ∗∗∗: P < 0.001.
3. Results
3.1. Fetal testosterone and LH levels, Experiment 1
In the DEHP+DINP combination study, statistically sig-
nificant reductions in testicular testosterone production and
in testicular testosterone content were observed in DEHP,
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Fig. 2. Testicular testosterone production (A), testicular testosterone con-
tent (B), plasma testosterone (C) and plasma LH (D) in 21-day-old male
rat fetuses exposed to vehicle, 300 mg DEHP/kg bodyweight per day, or
750 mg DINP/kg bodyweight per day or 300 mg DEHP/kg bodyweight per
day in combination with 750 mg DINP/kg bodyweight per day from GD
7 to GD 21 (Experiment 1). Values are means± S.E.M. (A) Two testes
from each of seven to eight litters per group, n = 14–16 testes per group;
(B) one to two testes from each of six to ten litters per group, n = 6–11
testes per group; (C) pools of plasma from 1 to 2 litters, n = 5–7 sam-
ples per group; (D) pools of plasma from 1 to 2 litters, n = 3–7 samples
per group. Asterisks indicate a statistically significant difference from
controls ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
Fig. 3. Testicular testosterone production (A), testicular testosterone con-
tent (B), plasma testosterone (C) and plasma LH (D) in 21-day-old
male rat fetuses exposed to vehicle, 750 mg DEHP/kg bodyweight per
day, or 750 mg DEHP/kg bodyweight per day in combination with
400 mg DEHA/kg bodyweight per day from GD 7 to GD 21 (Experiment
2). Values are means± S.E.M. (A) Two testes from each of six to eight
litters per group, n = 14–19 testes per group; (B) one testis from each
of six to eight litters per group, n = 6–8 testes per group; (C) pools of
plasma from one to two litters, n = 2–6 samples per group; (D) pools
of plasma from one to two litters, n = 3–5 samples per group. Asterisks
indicate a statistically significant difference from controls ∗∗P < 0.01,
∗∗∗P < 0.001.
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DINP and DEHP+DINP treated animals compared to con-
trols (Fig. 2A and B). A similar tendency was seen for
plasma testosterone, although the reduction was only statis-
tically significant for the DEHP+DINP combination group
(Fig. 2C). Plasma LH levels were elevated, and again the
difference was only statistically significant for the DEHP+
DINP combination group compared to controls (Fig. 2D).
No statistically significant differences in hormone levels
were observed between the DEHP + DINP group and the
groups receiving DEHP or DINP alone. A factorial statis-
tical analysis revealed no statistically significant interaction
between the effects of DEHP and DINP.
3.2. Fetal testosterone and LH levels, anogenital distance
and nipples, Experiment 2
In Experiment 2, on fetal and early postnatal effects of
DEHP + DEHA in combination, male offspring of DEHP-
Fig. 4. Neonatal anogenital distance at PND 3 and number of nipples
at PND 13 in male rats exposed to vehicle, 750 mg DEHP/kg bodyweight
per day, or 750 mg DEHP/kg bodyweight per day in combination with
400 mg DEHA/kg bodyweight per day from GD 7 to GD 21 (Experiment
2). Values are means± S.D., n = 35 males from six to seven litters per
group. Asterisks indicate a statistically significant difference from controls
∗P < 0.05, ∗∗P < 0.01.
treated and DEHP + DEHA-treated rats showed a reduced
ability to produce testosterone on GD 21. Testosterone pro-
duction in testes incubated for 3 h ex vivo was statistically
significantly reduced in the DEHP and DEHP + DEHA
groups compared to controls (Fig. 3A). Similarly, statisti-
cally significant reductions in testicular testosterone content
were observed in DEHP treated and DEHP+DEHA treated
male fetuses compared to controls (Fig. 3B).
Testosterone levels in plasma from male fetuses were sta-
tistically significantly reduced in the DEHP and DEHP +
DEHA groups compared to controls (Fig. 3C). In addition,
a statistically significant increase in plasma LH content was
measured in DEHP treated fetuses compared to controls
(Fig. 3D). Due to limited amount of plasma from DEHP +
DEHA treated fetuses, LH was not measured in that group.
Anogenital distance at PND 3 was significantly reduced in
the DEHP-exposed males and in the males exposed to DEHP
plus DEHA (Fig. 4A). The statistical analysis using birth
weight as a covariate gave similar results and birth weight
had no significant influence on the anogenital distance.
The number of nipples was significantly increased at PND
13 in males exposed to DEHP, but not in males exposed
to DEHP plus DEHA (Fig. 4B). The effect of DEHP and
DEHA in combination did not differ significantly from the
effect seen with DEHP alone.
3.3. Testosterone, inhibin B, FSH and LH levels at PND
22 and 190 (Experiment 3)
In Experiment 3 on prepubertal and adult effects of
DEHP + DEHA in combination, serum inhibin B levels
were significantly reduced in 22-day-old males exposed to
750 mg DEHP/kg bodyweight per day compared to controls
(Fig. 5A). The average inhibin B level in animals exposed
to 300 mg DEHP/kg bodyweight per day appeared lower
than in controls and higher than in animals exposed to
750 mg DEHP/kg bodyweight per day, indicating a dose-
dependent effect. Inhibin B levels were similar in the group
receiving 750 mg DEHP/kg bodyweight per day and in the
group receiving DEHP in combination with DEHA. On
PND 190, no differences in inhibin B levels between groups
were observed (Fig. 6C). No correlation existed between
inhibin B levels measured in males from the same litters on
PND 22 and PND 190 (data not shown).
A tendency towards increased serum FSH levels with in-
creasing DEHP dose was observed on PND 22 (Fig. 5B).
However, no statistically significant differences between the
four groups were detectable, likely due to the large varia-
tions between animals within each group.
Serum LH levels were not significantly different between
groups on PND 22, but while LH levels varied only lit-
tle within control litters, half the litters in the high-dose
DEHP group had several-fold higher LH levels than con-
trols (Fig. 5C). Five of the litters with the highest LH levels
in the exposed groups were also the litters with the highest
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Fig. 5. Serum hormone levels at PND 22 in male rats exposed to either vehicle, 300 or 750 mg DEHP/kg bodyweight per day, or 750 mg DEHP/kg bodyweight
per day in combination with 400 mg DEHA/kg bodyweight per day from GD 7 to PND 17 (Experiment 3). (A) serum inhibin B, (B) serum FSH, (C)
serum LH, (D) serum testosterone. Values are means±S.E.M. (A and B), or single measurements (C and D) on serum pooled from three males per litter
(n = 8–10 samples per group), where lines designate median values. Asterisks indicate a statistically significant difference from controls ∗P < 0.05.
FSH levels. The litters with very high serum LH and FSH
levels also had low serum inhibin B levels and high or nor-
mal serum testosterone levels. A correlation between serum
LH and serum FSH (Pearson’s r = 0.61, P < 0.001) and an
inverse correlation between serum FSH and serum inhibin
B (Pearson’s r = −0.51, P < 0.001) were observed.
No significant differences in serum testosterone levels be-
tween groups were detectable on PND 22 (Fig. 5D). When
considering serum testosterone levels and testicular testos-
terone content at PND 190, a pattern comparable to the re-
duced testosterone levels in gestation was seen, with the
strongest tendency observed for the DEHP+DEHA combi-
nation group (Fig. 6A and B), although no statistically sig-
nificant differences were found.
4. Discussion
4.1. Endocrine effects of DEHP and DINP
The study on gestational DINP exposure (Experiment
1) revealed for the first time an inhibitory effect on fe-
tal testicular testosterone production as well as testicular
testosterone content, and a tendency to reduced plasma
testosterone level. The observed reduction of ex vivo
testosterone production, testicular testosterone content and
plasma testosterone in 21-day-old fetuses receiving DEHP
in utero confirmed previous findings by Parks et al. [1]. In
agreement with the reported lower antiandrogenic potency
of DINP than DEHP [2], 750 mg/kg bodyweight per day of
DINP reduced testosterone to levels comparable to those
observed with the lower dose of 300 mg/kg bodyweight per
day of DEHP (Fig. 2A–C). Also in the DEHP + DEHA
combination study (Experiment 2), testosterone levels in
the DEHP group and the DEHP + DEHA group were re-
duced significantly compared to controls. Abnormalities
of androgen-dependent tissues paralleled the reduction in
testosterone levels: anogenital distance was significantly
reduced and the number of nipples was increased in males
exposed to DEHP. These effects have been observed in
other studies of prenatal DEHP exposure [1,2], and are
likely to be causally linked to the low testosterone levels.
It appears that testosterone levels in fetuses are affected in
more animals than develop abnormalities later on.
Concomitantly with the decrease in testosterone level, a
significant increase in plasma LH was observed in males re-
ceiving 750 mg DEHP/kg bodyweight per day (Experiment
2), a finding not previously described in studies on prenatal
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Fig. 6. Serum testosterone (A, n = 13–16 males per group), testic-
ular testosterone content (B, n = 9–10 males per group) and serum
inhibin B (C, n = 10 males per group) at PND 190 in male
rats exposed to either vehicle, 300 or 750 mg DEHP/kg bodyweight
per day, or 750 mg DEHP/kg bodyweight per day in combination with
400 mg DEHA/kg bodyweight per day from GD 7 to PND 17 (Experiment
3). Values are means± S.E.M.
phthalate exposure. A similar elevation in plasma LH was
seen in the DINP study (Experiment 1), although the effect
was only statistically significant for the DEHP + DINP
combination group in that study. This observation indicates
the presence of a functional feedback loop from the gonads
to the hypothalamus and pituitary on GD 21 under the
current experimental conditions. Plasma LH levels do not
normally start rising until GD 21 [12], although Leydig cell
responsiveness to LH appears at GD 19. At this age plasma
testosterone has already started peaking independently of
LH action. Apparently, the increase in plasma LH was not
sufficient to re-establish testosterone production at GD 21,
indicating that the functional defect induced by DEHP may
either be found within the Leydig cell, or that LH action
has been modulated by other factors. Changes in the ac-
tivity or expression of steroidogenic enzymes following
phthalate exposure have been found in rat studies on fetal
DBP exposure [13,14]. However, it is not evident whether
such changes are due to direct interactions of phthalates
with Leydig cells, or to indirect effects caused by phthalate
interference with Sertoli cell function and production of
paracrine factors acting on Leydig cells. Experiments on
Leydig tumor cells indicate that MEHP may have direct ef-
fects on Leydig cell lipid metabolism and progesterone syn-
thesis [15,16]. Previously, phthalate effects were ascribed
mainly to interference with Sertoli cell function [17,18],
but the current evidence suggests that also the Leydig cell
population is targeted in the fetus.
At PND 22 (Experiment 3), serum inhibin B levels were
significantly lower in the high-dose-DEHP and DEHP +
DEHA exposed groups compared to controls, but serum
testosterone, LH and FSH levels did not differ significantly
between groups. A correlation between serum levels of LH
and FSH for individual animals was observed at PND 22,
in addition to an inverse correlation between serum levels
of FSH and inhibin B. In a few exposed animals, a charac-
teristic pattern of high serum levels of LH, FSH and testos-
terone concomitantly with low serum inhibin B levels was
observed. Akingbemi et al. [19] have found the opposite
effect: serum testosterone and LH levels were significantly
lower on PND 21 and 35 in the offspring of rats treated
with 100 mg DEHP/kg bodyweight per day from GD 12 to
GD 21. In the offspring of rats exposed to similar doses dur-
ing lactation as well as in utero (GD 12 to PND 21) serum
testosterone was slightly reduced on PND 21 but not on
PND 35 [19]. Due to the nature of pubertal development,
endocrine effects at this age may indicate a time-shift in the
developmental process, whereas the tendencies to effects on
adult serum inhibin B and testosterone levels (Fig. 6A–C)
may suggest long-term effects on testicular function. The
significantly reduced serum inhibin B level in prepubertal
DEHP-exposed males indicates a reduced Sertoli cell num-
ber or function, and is in accordance with the presumption
that phthalates disrupt the FSH response, and that the FSH
level in neonatal life determines Sertoli cell number [20].
Serum inhibin B levels and testes weights (Majken Dal-
gaard, personal communication) were unaltered in most of
the DEHP exposed adults, indicating that recovery of Sertoli
cell number or function had occurred since prepuberty in
most animals. However, a group of five adult males had very
low serum inhibin B levels (below 70 pg/ml), and three of
these males were reported as having atrophic testes (Majken
Dalgaard, personal communication). In addition to these ef-
fects in few animals, the tendency to reduced mean testos-
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terone levels in serum and testes of adult males, mainly in
the DEHP + DEHA combination group, may point to per-
manent functional defects also in males without testicular
atrophy.
4.2. Effects of combined exposure
No modulating effect of DINP on the effects of DEHP
can be inferred on the basis of these data, as fetal testos-
terone levels were not significantly lower with exposure to
DINP in combination with DEHP than with DEHP or DINP
alone. However, a tendency indicating an accumulating ef-
fect of DEHP and DINP in reducing steroidogenesis could
be observed (Fig. 2A–C). Factorial statistics revealed no in-
teraction effect, indicating that the effect of the combination
was in agreement with what could be expected from addi-
tion of the DINP and the DEHP doses.
No statistically significant differences in endocrine ef-
fects were observed between rats exposed to DEHP and rats
exposed to DEHP in combination with DEHA. A shortfall
of these studies is the lack of a group receiving DEHA
alone. However, as the effects in the exposed groups were
quantitatively similar, it was concluded that DEHA does
not modulate the effects of DEHP. If, on the other hand, the
applied 750 mg DEHP/kg bodyweight per day suppresses
fetal testosterone levels maximally, detection of further sup-
pression by DEHA may be difficult. Selecting dose levels
based on dose response curves will be necessary to fully es-
tablish whether combination effects may be seen. Previous
studies have shown no effect of gestational and lactational
DEHA exposure (up to 800 mg/kg bodyweight per day) on
male reproductive development [8]. In that study, prepuber-
tal and adult testicular testosterone content and prepubertal
serum LH level were unaffected by DEHA, and no changes
in anogenital distance, number of nipples, histopathology
or weights of reproductive organs were observed. The lack
of modulating effect of DEHA on the endocrine effects of
DEHP in this study strengthens the conclusion that DEHA
does not induce antiandrogenic effects. In the literature, no
evidence for testicular toxicity of the metabolite 2-EH was
found [7].
In summary, these studies reveal that DINP has a suppress-
ing effect on fetal testosterone levels in prenatally exposed
male rats similarly to the effect observed with DEHP. Corre-
spondingly, fetal plasma LH levels were increased in DEHP-
exposed males. As expected, neonatal anogenital distance
was reduced and the number of nipples increased in DEHP-
exposed males. The extensive endocrine effects of DEHP
in late gestation were absent in prepuberty and adulthood,
except for a reduced serum inhibin B level in 22-day-old
males, and in a few adult males. Administration of DEHA
or DINP in combination with DEHP did not significantly
modulate the endocrine effects of DEHP, although a ten-
dency to an accumulating effect in suppressing testosterone
synthesis was seen in the DINP and DEHP combination
study.
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Abstract
This study aimed to characterize the effects of di(2-ethylhexyl) phthalate (DEHP) on the fetal rat testes and relate them to the effects
seen in adults. Histopathological effects in fetal testes were examined with immunohistochemistry for anti-Mu¨llerian hormone (AMH), 3-
hydroxysteroid dehydrogenase, smooth muscle actin (SMA), proliferating cell nuclear antigen (PCNA), histone H3 and vimentin. Additionally,
testicular apoptosis levels were assessed in fetal, prepubertal and adult rats. As the plasticizer di(2-ethylhexyl) adipate (DEHA) has similarities
with DEHP in chemical structure and metabolism, we investigated if the testicular effects of DEHP were modulated by co-administration
with DEHA.
Wistar rats were gavaged during gestation and lactation with vehicle, DEHP (300 or 750 mg/kg/day), or DEHP (750 mg/kg/day) in combi-
nation with DEHA (400 mg/kg/day), and male offspring were examined at gestation day (GD) 21, postnatal day (PND) 22, 26 and 190.
In fetal testes, Leydig cells were found in large clusters containing AMH positive Sertoli cells. At GD 21, seminiferous chords appeared
enlarged with an apparently increased number of gonocytes. However, proliferation of gonocytes did not appear increased. A few animals
had a high number of TUNEL positive apoptotic cells in degenerating seminiferous tubules at PND 22 and 190, whereas most exposed
animals had low levels of germ cell apoptosis at GD 21, PND 22 or PND 26, as evaluated by DNA laddering, TUNEL staining, Caspase-
3 immunohistochemistry and Caspase-3 activity measurement. No differences between DEHP and DEHP + DEHA exposed groups were
observed.
© 2004 Elsevier Inc. All rights reserved.
Keywords: Phthalate; Toxicity; Male reproduction; In utero; Programmed cell death; Pathology; Endocrine disrupters
1. Introduction
Phthalates are extensively used in consumer plastic prod-
ucts, and human exposure is considerable. Certain phthalates
are known to induce adverse effects in androgen respon-
sive tissues (cryptorchidism, hypospadia, decreased sperm
counts, decreased weights of reproductive organs) following
perinatal exposure of male laboratory animals [1–3]. Stud-
ies concerning pathogenesis of effects have been performed
with dibutyl phthalate (DBP) [4–6]. The current study aims
to test if similar early testicular effects are seen with di(2-
ethylhexyl) phthalate (DEHP), which is among the phthalates
∗ Corresponding author. Tel.: +45 72347562; fax: +45 72347698.
E-mail address: ol@dfvf.dk (O. Ladefoged).
most abundantly found in the environment [7]. It is essential
to evaluate the effects of perinatal exposure, as the perinatal
period is particularly sensitive to hormonal influences and as
infants are exposed to phthalates in considerable doses [7].
Following acute DEHP or MEHP treatment, germ cell
apoptosis is induced in adult and prepubertal rat testes by
disruption of interaction between Sertoli cells and germ cells
[8,9]. Also reduction of the intratesticular testosterone level
has been shown to induce germ cell apoptosis in adult or pre-
pubertal rats [10,11]. Observations of reduced testosterone
levels and germ cell alterations in testes of fetal rats exposed
to DEHP during gestation [3,12] have led to the hypothesis
that perinatal DEHP treatment may induce apoptosis of fetal
germ cells. Due to reports of low testosterone levels also post-
natally, apoptosis levels were assessed in fetal, prepubertal
0890-6238/$ – see front matter © 2004 Elsevier Inc. All rights reserved.
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and adult rat testes. Apoptosis measurements following peri-
natal phthalate exposure have not previously been described
in the literature.
The plasticizer di(2-ethylhexyl) adipate (DEHA) shares
similarities in chemical structure and metabolism with DEHP,
and a comparable profile of effects on the male reproductive
system may be suspected. DEHA does not appear to induce
adverse effects on the reproductive system but rather devel-
opmental toxicity when administered to pregnant dams [13].
As the developmental toxicity of DEHA as well as DEHP
may be ascribed to their common metabolite 2-ethylhexanol
(2-EH) [14,15], it may be hypothesized that 2-EH is also
responsible for some aspects of reproductive toxicity. Thus,
DEHA may hypothetically augment DEHP-induced changes
in male reproductive endpoints when the two compounds are
administered in combination, even though DEHA does not
produce these effects on its own.
The aim of the current study was to characterize DEHP-
induced early testicular effects by evaluation of testicular
histopathology and immunohistochemical studies at gesta-
tion day (GD) 21, whereas the study by Jarfelt et al. [2] fo-
cuses on the adult effects of DEHP and DEHA. A second
aim was to examine apoptosis levels at GD 21, postnatal day
(PND) 22, 26 and 190. The application of methods in which
the apoptosis-specific Caspase-3 enzyme was detected in situ
(immunohistochemistry) and in whole testis homogenate (ac-
tivity measurement) were compared to methods detecting
apoptotic DNA strand breaks in situ (TUNEL staining) and
on whole tissue homogenate (DNA laddering). Furthermore,
we aimed to reveal if the testicular effects of DEHP were
modulated by administration of DEHA in combination with
DEHP.
2. Methods
2.1. Test compounds
DEHP, di(2-ethylhexyl) phthalate, CAS No. 117-81-7, pu-
rity 99%, was from Sigma-Aldrich 20,115-4. DEHA, di(2-
ethylhexyl) adipate, CAS No. 103-23-1, purity 99%, was
from Sigma-Aldrich 29,118-8. The vehicle was sterile peanut
oil obtained from the Royal Veterinary Agriculture Pharmacy,
Copenhagen, Denmark and from Sigma.
2.2. Animals and dosing
2.2.1. Experiment 1
Fourty-eight time-mated Wistar rats (HanTac:WH,
Taconic M&B, Denmark, bodyweight approximately 200 g)
were supplied at day 3 of pregnancy. The day following mat-
ing was designated GD 1, and PND 1 was the day follow-
ing birth. The dams were randomized into three groups of 16
with similar body weight distributions and housed in pairs un-
til GD 21 under standard conditions: Semi-transparent plastic
cages with pinewood bedding were situated in an animal room
with controlled environmental conditions (12 h light–dark
cycles with light starting at 6 p.m., light intensity 500 lx,
temperature 21± 2 ◦C, humidity 50± 5%, ventilation eight
air changes per h). Food (Altromin Standard diet 1324) and
acidified tap water were provided ad libitum. The animals
were dosed with either vehicle, 750 mg DEHP/kg bw/day,
or 750 mg DEHP/kg bw/day in combination with 400 mg
DEHA/kg bw/day from GD 7 to GD 21. Animals were in-
spected for general toxicity twice daily. On GD 21, eight dams
per group were anesthetized in CO2/O2 and decapitated, and
fetuses were removed and decapitated. The remaining eight
dams per group received similar doses as during pregnancy
until PND 17, and male offspring was sacrificed at PND 26.
Testes were removed from all fetuses and 26-day-old rats and
treated as described below.
2.2.2. Experiment 2
Eighty time-mated Wistar rats were randomized into four
groups of 20 receiving either 0, 300 or 750 mg DEHP/kg
bw/day, or 750 mg DEHP/kg bw/day in combination with
400 mg DEHA/kg bw/day within the same period as de-
scribed for the first study (GD 7 to PND 17). Housing con-
ditions were as described for the previous experiment. Three
males per litter were sacrificed at PND 22, and further one
or two males per litter at PND 190. Testes were removed and
treated as described below.
The doses in the combination group were selected as
the highest doses where no maternal toxicity and a low
level of developmental toxicity were seen in previous ex-
periments. In our previous dose-response study of DEHA,
400 mg DEHA/kg bw/day caused a small increase in postna-
tal death of offspring and no maternal toxicity [13]. The dose
of 750 mg DEHP/kg bw/day was similar to the dose used
by Parks et al. (2000) [1] and Gray et al. (2000) [3], while
the dose of 300 mg DEHP/kg bw/day was selected in order
to obtain submaximal effects compared to 750 mg DEHP/kg
bw/day.
2.3. Histopathology, TUNEL assay and
immunohistochemistry
Not all animals were used for histopathology, as some
randomly selected testes were collected for hormone analy-
ses [12] and gene expression studies. Fourteen to 19 testes
per group at GD 21 (i.e. 2–4 testes per litter), and 10 testes
per group at PND 22 and 26 (i.e. 1–2 testes per litter), were
fixed in neutral buffered formalin and embedded in paraffin.
10 testes per group at PND 22 and 26, and 16 testes per group
at PND 190 (i.e. 1–2 testes per litter) were fixed in Bouin’s
fixative. These testes were randomly selected from each of
the 5–8 litters per group at GD 21 and PND 26, and the 8–13
litters per group at PND 22 and 190. One section per testis
was stained with hematoxylin and eosin and evaluated for
histopathological effects in a blinded manner (GD 21 and
PND 26). Chord diameters were investigated in fetal testes
stained for smooth muscle actin (SMA) by measuring the
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diameter of tubular cross sections perpendicular to the tubu-
lar length direction. Chord diameters more than 10% larger
than the maximal chord diameter in fetal control testes were
defined as enlarged chords. In each section, all chords were
measured. As some testes (from all groups) were flattened
due to technical difficulties, chord diameter was only mea-
sured in testes of optimal quality (9–13 testes from 5 to 6
litters per group).
In order to study the apoptosis/proliferation balance at
different ages, TUNEL staining of apoptotic cells was per-
formed in addition to immunostaining for the apoptosis-
specific enzyme Caspase-3 and the proliferation markers pro-
liferating cell nuclear antigen (PCNA) and Histone H3. Ad-
ditionally, structural changes were studied using cell type
specific markers anti-Mu¨llerian hormone (AMH, Sertoli cell
specific) and 3-hydroxysteroid dehydrogenase (3-HSD,
Leydig cell specific) and the structural proteins vimentin and
smooth muscle actin.
TUNEL staining was performed on 4m sections fixed
on SuperFrost + slides (Menzel-Gla¨ser, Germany) at 37 ◦C
overnight and then deparaffinized with petroleum and ethanol
to water before the staining procedure. The TUNEL assay was
performed with ApopTag-peroxidase kit (Cat. No. S7100, In-
tergen Co, NY) following the supplier’s guidelines. Sections
from fetal testes were pretreated with 5g/ml Proteinase K
in PBS for 5 min, while sections from 22-, 26-, and 190-day-
old rat testes were microwave-pretreated in citrate buffer pH
6 for 2× 5 min at 99 ◦C.
Except for pretreatment procedures and secondary anti-
bodies, immunohistochemistry was performed using compa-
rable protocols for all antibodies on one section per testis.
Following pretreatment, sections were blocked for endoge-
nous peroxidase activity in 3% H2O2 in PBS, and blocked in
swine serum with bovine serum albumin. Sections were in-
cubated with primary antibody over night at 4 ◦C, and were
then incubated with secondary antibody for 30 min, stained in
3-amino-9-ethylcarbazole (AEC, Labvision, CA) and coun-
terstained in Meyer’s hematoxylin.
Immunohistochemical staining was performed using pri-
mary antibodies against cleaved, active Caspase-3 (Cell
Signaling Technology, MA, #9661), PCNA (clone PC10,
DAKO), phospho-histone H3 (Upstate Biotech), vimentin
(clone V9, DAKO), AMH (also called Mu¨llerian inhibit-
ing substance, MIS, DAKO), SMA (clone 1A4, DAKO) and
3-HSD (a kind gift from Dr. I. Mason, Edinburgh, UK).
Sections for PCNA staining were not pretreated, while sec-
tions for Caspase-3 or Vimentin staining were microwave
pretreated for 2× 5 min in citrate buffer pH 6 at 99 ◦C,
and sections for AMH, SMA and 3-HSD staining were
pretreated for 5 min in citrate buffer pH 6 at 99 ◦C. Sec-
tions for Histone H3 staining were pressure cooked for
10 min in citrate buffer pH 6. As secondary antibodies were
used anti-rabbit EnVision + (DAKO) for Caspase-3 and 3-
HSD staining, anti-mouse EnVision + (DAKO) for PCNA,
Vimentin and SMA staining, and rabbit anti-goat antibody
(DAKO) enhanced with anti-rabbit EnVision + for AMH
staining. Biotinylated swine-anti rabbit secondary antibody
was used for Histone H3 staining and followed by incu-
bation with AB complex. Double staining for SMA and
3-HSD was performed by simultaneous incubation with
the two primary antibodies followed by two consecutive
staining procedures: first incubation with anti-mouse EnVi-
sion + and staining for SMA with AEC, then blocking in
H2O2, incubation with anti-rabbit EnVision + and staining
with Vector SG peroxidase staining kit (Vector Laboratories,
CA).
Apoptotic TUNEL positive or Caspase-3 positive cells,
and proliferating Histone H3 positive cells were quantified
in one section per fetal testis. Interstitial and intra-tubular
positively stained cells were counted separately through-
out the entire section. At PND 22, 26, and 190, the num-
ber of TUNEL positive cells was counted in 100–200
tubules in one section per testis from 10 to 20 males per
group.
2.4. Apoptosis assessment
Caspase-3 activity was measured on one testis from 10
males per group (from 5 to 10 litters per group) at GD 21,
PND 22 and PND 26 as described by Gorman et al. [16] and
determined as nmol of substrate cleaved per gram tissue per
hour. Double determinations were made for each sample in
wells with and without inhibitor.
DNA laddering was performed as described by Staley et
al. [17] on one testis from one to three fetuses, 22- or 26-
day-old males per litter (10–19 males from 5 to 10 litters
per group). DNA was extracted using QIAGEN DNeasy tis-
sue kit and PCR was performed using ApoAlert LM-PCR
Ladder Assay Kit (Cat.No. 905-1, Clontec, CA), and Clon-
tech Advantage cDNA Polymerase Mix containing KlenTaq
DNA Polymerase, and TaqStart Antibody. Positive controls
contained calf thymus DNA, and negative controls did not
contain DNA. Results on DNA-laddering are given in arbi-
trary units, which reflect the relative fluorescence of DNA
ladders on gels, and thus are a measure of relative apoptosis
level.
2.5. Statistical analysis of apoptosis data
Statistical analyses were performed on apoptosis data.
Non-processed and logaritmically transformed data were ex-
amined for normal distribution and homogeneity of variance.
Following appropriate transformation, data were analyzed by
ANOVA using single animal data nested within litter, which
was the statistical unit. Litter was included in the analysis
of variance as an independent, random factor (SAS Ana-
lyst: mixed procedure, SAS Version 8, SAS Institute Inc,
Cary, NC, USA). Dunnett’s tests were performed to deter-
mine differences between treated and control group means.
In cases where normal distribution and homogeneity of vari-
ance was not obtained, data were additionally tested with
the non-parametric Kruskall–Wallis test (correction for litter
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effect not possible). Asterisks indicate a statistically signifi-
cant difference compared to controls (*) p< 0.05.
3. Results
3.1. Testicular histopathology, GD 21
Vacuolization of Sertoli cells, germ cell shedding and re-
duction of Leydig cell cytoplasm were observed in almost all
DEHP-exposed and DEHP + DEHA-exposed fetuses, when
evaluating one HE stained section per testis. Multinuclear
gonocytes and large Leydig cell clusters (apparently hyper-
plasia of Leydig cells) were observed in approximately half
the exposed animals at GD 21 (Table 1, Fig. 1A–C). The Ley-
dig cell clusters contained small cells with irregular nuclei
and reduced cytoplasm compared to Leydig cells in control
testes. All fetuses exposed to DEHP or DEHP + DEHA had
one or more seminiferous chords with increased diameters
compared to controls. The diameters of these enlarged sem-
iniferous chords were increased by 19–103% compared to
the maximal chord diameter measured in controls (63m).
This equals a 67–184% increase in chord diameter compared
to average chord diameter in controls (45m). Inside these
enlarged seminiferous chords, germ cells had a reduced cyto-
plasm and the number of germ cells per chord cross-section
appeared to be increased (Fig. 1C).
PCNA staining was present in most gonocytes, Sertoli
cells and Leydig cells of fetal control testes, while areas of
Leydig cell hyperplasia in DEHP exposed testes were neg-
ative for PCNA (Fig. 2A and B). The proliferation marker
Histone H3 was mainly present in peritubular cells, intersti-
tial cells and Sertoli cells, and was less abundant than PCNA
(not shown). In DEHP exposed animals, Leydig cell clusters
and seminiferous chords with an apparent increase in germ
cell number did not have increased numbers of Histone H3
positive cells (Table 1).
Staining for 3-HSD strengthened the observation of fo-
cal Leydig cell clustering instead of the localization as sin-
gle cells distributed throughout the interstitium in controls
(Fig. 2C and D). The intensity of staining did not generally
appear to be affected by treatment.
Staining for the cytoplasmic Sertoli cell marker AMH in-
dicated the presence of Sertoli cells within Leydig cell clus-
ters in DEHP and DEHP + DEHA exposed testes (Fig. 2F). In
control testes, AMH staining was located throughout seminif-
erous chords (Fig. 2E), but in chords with shedding of germ
cells AMH was found mainly peripherally (Fig. 2F bottom
right corner).
SMA staining was strong in peritubular myoid cells and
perivascular cells, and there was generally no difference in
SMA immunostaining intensity between treatment groups,
although a few exposed testes had weakly stained tubules
(Fig. 2G and H).
3.2. Testicular histopathology, PND 26
At PND 26, no germ cell shedding, multinucleated germ
cells, or vacuolization of Sertoli cells were present, and only
small areas of Leydig cell hyperplasia (smaller than the size
of a cross-section of a tubule) were observed in a few ani-
mals. Seminiferous tubules lacking spermatocytes were ob-
served at PND 26 in rats exposed to DEHP or DEHP + DEHA
(Table 1). Malformed tubules were present in 10–15% of
testis sections from the DEHP- or DEHP + DEHA exposed
rats at day 26, when examining one section per testis (Table 1).
Characteristic for these malformed structures were the ab-
sence of normal epithelial structure, and anastomoses be-
tween tubular structures within the region.
Localization of vimentin staining in Sertoli cells was eval-
uated in one section per testis, and no differences between
groups were observed in fetal or prepubertal rat testes (data
not shown). Whereas vimentin filaments in juvenile and adult
Table 1
Histopathological effects in testes of 21-day-old fetal rats and 26-day-old rats exposed from GD 7 to PND 17 to either 750 mg DEHP/kg bw/day, or 750 mg
DEHP/kg bw/day in combination with 400 mg DEHA/kg bw/day
Control DEHP 750 DEHP 750 + DEHA 400
Histopathological evaluation at GD 21
Number of animals (number of litters) 17 (7) 14 (8) 19 (5)
Vacuolization of Sertoli cells (%) 6a (14)b 100 (100) 100 (100)
Shedding of gonocytes (%) 0 (0) 100 (100) 100 (100)
Multinucleated gonocytes (%) 0 (0) 64 (75) 75 (80)
Reduced cytoplasm in interstitial cells (%) 0 (0) 100 (100) 89 (100)
Presence of chords with enlarged diameterc (%) 0 (100) 100(100) 100(100)
Leydig cell clusters/hyperplasia (%) 12 (29) 50 (63) 42 (60)
Histone H3 positive cells per section (mean±S.D.)d 80± 25 90± 17 71± 28
Histopathological evaluation at PND 26
Number of animals (number of litters) 20 (7) 20 (6) 20 (7)
Presence of malformed tubules (%) 0a (0)b 10 (17) 15 (29)
Presence of tubules lacking spermatocytes (%) 10 (29) 50 (100) 25 (57)
a Percentage of affected males of the total number of males when evaluating one section per testis.
b In parentheses are given percentage of affected litters of total number of litters when evaluating one section per testis.
c Based on 9–13 animals (from 5 to 6 litters) per group.
d Based on 6–12 animals per group.
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Fig. 1. Testicular histopathology in 21-day-old male rat fetuses exposed to vehicle (A), 750 mg DEHP/kg bw/day (B), or 750 mg DEHP/kg bw/day in combination
with 400 mg DEHA/kg bw/day (C) from GD 7 to GD 21. The number of germ cells and the chord diameter appeared increased in seminiferous chords of
DEHP- and DEHP + DEHA exposed animals. (↑) Vacuolization in Sertoli cell cytoplasm, (») multinucleated gonocyte, (*) interstitial cell hyperplasia. Scalebar:
100m.
rats extended from the Sertoli cell nucleus towards the tubule
lumen, vimentin in fetal Sertoli cells was mainly located
basally to the nucleus. In prepubertal testes, PCNA staining
did not appear to differ between groups.
3.3. Apoptosis
Statistically significant increases in apoptosis level as
measured with DNA-laddering were observed at GD 21 in
the DEHP and DEHP + DEHA groups compared to con-
trols (Fig. 4). No statistically significant differences between
groups in the intensity of bands on DNA ladders were ob-
served at PND 22. At PND 26, DNA-laddering levels in the
DEHP + DEHA combination group were statistically signif-
icantly higher than in the control group at PND 26, while
the group receiving 750 mg DEHP/kg bw/day was not sta-
tistically significantly different from the control group or the
DEHP + DEHA combination group (Fig. 4).
The number of TUNEL and Caspase-3 positive gono-
cytes and interstitial cells appeared higher in DEHP + DEHA
treated fetuses compared to controls, though the number of
positive cells per section was very low, on average five posi-
tive cells per section (Fig. 4). The number of Caspase-3 posi-
tive cells matched the number of TUNEL positive cells at GD
21, whereas very few cells were Caspase-3 positive at PND
22 compared to TUNEL (data not shown). The numbers of
TUNEL positive cells per tubule were not significantly dif-
ferent between groups at PND 22, 26 or PND 190. However,
at PND 22 as well as 190, a few animals in the treated groups
had very high numbers of TUNEL positive cells, presumably
spermatocytes (Fig. 3). At PND 22, high apoptosis levels
were seen in testes where many tubules were lacking sperma-
tocytes (Fig. 3B), and where large areas of dysgenic tubules
were present in the same section. In adults, increased numbers
of TUNEL positive cells were seen mainly in atrophic testes.
Specifically, the apoptotic cells were found in tubules with
ongoing spermatogenesis, whereas end-stage tubules lacking
spermatocytes had few TUNEL positive cells (Fig. 3D).
Caspase-3 activity was not detectable at GD 21 in testes
of controls or treated animals. No statistically significant dif-
ferences between groups in Caspase-3 activity at PND 22 or
26 were observed (not shown).
4. Discussion
The current studies aim to relate the early testicular effects
of perinatal exposure of male rats to DEHP and DEHA to the
adult effects described by Jarfelt et al. [2]. The progress of tes-
ticular lesions was studied by an evaluation of the apoptosis-
proliferation balance and immunohistochemical characteri-
zation of testicular lesions in fetal, prepubertal and adult rat
testes.
Confirming findings in studies on DBP-exposed fetuses
[4-6], histopathological effects were observed in most testes
in late gestation. Testes of DEHP and DEHP + DEHA ex-
posed fetal rats had vacuolization of Sertoli cells, shedding
of gonocytes, presence of multinucleated gonocytes, an ap-
parent increase in tubule diameter with an increased number
of gonocytes with small cytoplasm, as well as an apparent in-
crease in the number of Leydig cells with a reduced amount
of cytoplasm (Fig. 1 and Table 1).
4.1. Early origins of adult testicular effects
Staining for the Sertoli cell product AMH in testes of
DEHP-exposed fetuses revealed the presence of Sertoli cells
outside seminiferous chords in areas of Leydig cell hyper-
plasia (Fig. 2F). As described by Jarfelt et al. [2], dysgenic
areas characterized as malformed tubules within focal areas
of interstitial cell hyperplasia were observed at PND 22 and
190 in DEHP-exposed rats. In addition to Sertoli cells and a
reduced number of germ cells, Leydig cells positively stained
for 3-HSD were found inside these tubules.
It is likely that the development of dysgenic tubules is
related to the morphological changes in the interstitium ob-
served already during gestation. Fisher et al. [6] have shown
the presence of incomplete chords lined with smooth muscle
actin within dysgenic areas as early as PND 4 in rats exposed
to DBP from GD 13.5 to 21.5. They found gonocytes, Ser-
toli cells and Leydig cells within these malformed chords,
as determined by immunohistochemical staining for proteins
specific for these cell types. In this study, no dysgenic chords
were observed at GD 21 with SMA staining, and no 3-HSD
positive Leydig cells were found inside seminiferous chords.
This difference to the findings by Fisher et al. [6] indicates
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Fig. 2. Immunohistochemical staining of testes of 21-day-old male rat fetuses exposed to 750 mg DEHP/kg bw/day + 400 mg DEHA/kg bw/day from GD 7 to GD
21 (B, D, F, H). (A, C, E, and G) are control rat testes. Interstitial cells in hyperplasic areas are negative for PCNA staining and surrounded by positively stained
mesenchymal cells (B). Staining for localization of 3-hydroxysteroid dehydrogenase (3-HSD) shows positively stained Leydig cell clusters surrounded by
mesenchymal cells negative for 3-HSD (D). Staining for the Sertoli cell specific marker Anti-Mu¨llerian Hormone indicated the presence of Sertoli cells (→)
within Leydig cell clusters (F). (#) Indicates tubules with shedding of germ cells and a peripheral localization of AMH staining (F). Double staining for 3-HSD
and -smooth muscle actin (SMA, specific for peritubular and perivascular cells) shows weak SMA staining in peritubular cells of some tubules neighboring
Leydig cell clusters (H). D + H are serial sections. Scalebar: 100m.
that the dysgenic chords develop between GD 21 (our obser-
vations) and PND 4 (their observations). The development of
dysgenic tubules may indicate malfunction of the androgen-
dependent peritubular cells, though not much is known about
the role of androgens and peritubular cells in tubular forma-
tion. Fisher et al. described a reduced intensity of SMA stain-
ing at GD 19 but not at GD 15, 17 or PND 4 in DBP exposed
rats, indicating defects of peritubular myoid cells [6]. Such
reduction of staining intensity was generally not confirmed
at GD 21 in the present study with DEHP, although some ar-
eas of the testes had weaker staining than normal (Fig. 2H).
These areas were neighboring Leydig cell clusters with dis-
placed Sertoli cells, indicating that these areas may develop
into malformed chords by PND 4.
Previous studies have shown a reduction of testosterone
production by DEHP-exposed rats [3,12]. This leads to an
increase in LH [12] and may cause the assumed Leydig cell
proliferation as an attempt to compensate for the reduced
testosterone levels. In the current study, no quantification of
Leydig cells was performed, but Leydig cell number appeared
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Fig. 3. TUNEL staining of apoptotic cells in testes of 22-day old (A + B) and 190-day-old (C + D) rats exposed to 750 mg DEHP/kg bw/day from GD 7 to PND
17. The number of apoptotic germ cells (red staining) is increased in some but not all 22-day old rat testes (B). In atrophic adult testes (D), apoptosis levels are
high in tubules with some spermatogenesis (*), whereas end-stage tubules (#) have few apoptotic cells. Scalebar: 100m.
high not only in DEHP-exposed males, but also in several
controls. However, the normal testes had Leydig cells with an
“active” appearance with a large, vacuolated cytoplasm and
a large spherical nucleus, and were found in small groups or
as single cells, while Leydig cells in DEHP-exposed testes
appeared “inactive” as they were small and found in large
clusters (Fig. 1A and B). If the assumed Leydig cell hyper-
plasia in DEHP-exposed males is real, the lack of PCNA
staining (Fig. 2B) indicates that any increase in Leydig cell
proliferation rate has apparently stopped before GD 21. Cells
surrounding the PCNA-negative Leydig cell clusters had in-
tense PCNA-staining, and as these cells were 3-HSD nega-
tive they may be undifferentiated mesenchymal cells (Fig. 2B
and D). At this age, the apparent hyperplasia may thus take
Fig. 4. Apoptosis levels in testes of rats exposed from GD 7 to PND 17 to either vehicle, 300 mg DEHP/kg bw/day (DEHP 300), 750 mg DEHP/kg bw/day
(DEHP 750), 750 mg DEHP/kg bw/day + 400 mg DEHP/kg bw/day (DEHP 750 + DEHA 400). Values are means ±SD. (*) indicates statistically significant
differences from controls, p< 0.05.
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place in the undifferentiated cells, as suggested by Mylcreest
et al. [5].
The testosterone reduction may affect neighboring cells in
the testes as well as other organs. An early defect in Sertoli
cell maturation may have consequences for later spermatoge-
nesis. Alternatively, late testicular atrophy may be indirectly
caused by Leydig cell dysfunction, as low testosterone lev-
els may cause epididymal dysgenesis and secondary effects
on the testes, as suggested by Barlow and Foster [4]. Fo-
cal dysgenesis in testes may rather originate from fetal or
early postnatal development, and is possibly related to Ser-
toli cell dysfunction, as immature Sertoli cells were desribed
by Fisher et al. [6] in abnormal seminiferous tubules of adult
DBP exposed rats.
4.2. Germ cell apoptosis and proliferation from
gestation to adulthood
Despite the observed loss of contact between germ cells
and Sertoli cells in fetal testes (Fig. 1) and the reduced fe-
tal testosterone levels [12], apoptosis levels did not appear
markedly increased in the examined fetal testes. This is in
contrast to the germ cell apoptosis seen after acute phtha-
late exposure of adult or prepubertal rats [8,9]. A tendency
to increased numbers of TUNEL or Caspase-3 stained cells
within the seminiferous chords of DEHP and DEHP + DEHA
treated fetuses was confirmed by increased DNA-laddering.
However, very few of the shedded gonocytes in fetal testes
were Caspase-3 positive or TUNEL positive (Fig. 4). In fact,
the number of gonocytes appeared to be increased within
each tubular cross-section (Fig. 1C). As the number of cells
positive for the proliferation marker Histone H3 did not differ
between groups when assessed in one section per testis, any
possible increase in gonocyte number may be due to prolif-
eration at an earlier age. As apoptosis levels were found to be
low, the shedded germ cells probably die at a later age, e.g.
concomitantly with the multinucleated gonocytes, which dis-
appear before PND 10 in phthalate-exposed testes [1,4,18].
Despite the differences found with DNA-laddering, apoptosis
does not appear to be an important feature of neither DEHP
nor DEHA exposure at GD 21 at the applied doses. Oppo-
site findings in prepubertally exposed males [9], the observed
DEHP-induced disruption of contact between fetal germ cells
and Sertoli cells was apparently not related to collapse of the
structural vimentin filaments, as no differences in vimentin
structure between controls and DEHP-exposed fetal testes
were observed.
At prepuberty, testicular apoptosis levels were normal
in most DEHP-exposed rats. The few testes with increased
apoptosis level at PND 22 also contained dysgenic tubules
and tubules lacking spermatocytes. The changes seen in these
22-day-old testes may be related to adult testicular dysgene-
sis, whereas animals with apparently normal testes in prepu-
berty likely develop normally into adulthood.
Poor Sertoli cell function may cause germ cell apoptosis
[19], and as phthalates are known to disrupt Sertoli cell func-
tion [20–22], apoptosis in the degenerating testes and in dys-
genic tubules may be due to Sertoli cell dysfunction. In a study
on acute MEHP treatment of 28-day-old rats, condensation of
the structural vimentin filaments in Sertoli cells was seen 3 h
after treatment followed by an increase in apoptosis levels 6 h
after dosing [9]. In the current study, there was a general lack
of effect on vimentin structure at PND 22. Vimentin filaments
had a disorganized distribution within dysgenic tubules, but
appeared normal in other tubules at this age. The apparently
normal Sertoli cell structure in prepubertal males in the cur-
rent study may reflect recovery after the end of dosing at PND
17, or a gradual adjustment to the effects of chronic perina-
tal phthalate exposure. If the effect of prepubertal (in this
case lactational) exposure to DEHP is indeed degenerative as
shown in studies on 28-day-old MEHP-exposed rats [9,23],
any possible increase in cell death may be reversible due to
the rapid turnover of cells in the testicular epithelium and
therefore absent in most animals at the examined ages PND
22 and 26, i.e. 4–8 days after the end of lactational exposure.
In adults, apoptosis levels were increased in a few testes
with atrophic seminiferous epithelium, whereas no statisti-
cally significant difference was seen between group means.
The ongoing apoptosis in adult testes with atrophic seminifer-
ous epithelium may indicate that spermatogenesis does occur
to some degree, and that new spermatocytes keep appearing
only to undergo apoptosis. Conversely, the most degenerated
testes with mainly Sertoli cell-only tubules had a relatively
low number of apoptotic cells.
A tendency to an apoptosis-inducing effect of DEHA was
seen with DNA-laddering in prepubertal rats at PND 26, as
apoptosis levels were higher than controls in the combination
group, but not in the DEHP group. This may be a random
finding, as this is not seen at PND 22, and as TUNEL data
on the contrary pointed towards lower apoptosis levels in the
exposed groups. Unfortunately, these studies lack a group
receiving DEHA alone for comparison with the control and
the combination groups. However, our previous studies have
shown no testicular histopathological changes or malforma-
tions of reproductive organs in male rats gestationally and
lactationally exposed to DEHA (up to 1200 mg/kg bw/day)
[13].
In conclusion, apoptosis did not appear to be an impor-
tant element of the testicular effects of perinatal exposure to
DEHP or to DEHP in combination with DEHA in fetal testes,
but in prepubertal and adult testes, apoptosis was involved in
the degeneration of seminiferous tubules. Histopathological
effects were observed in most testes in late gestation, although
only a few prepubertal and adult testes were severely affected.
DEHP has similar effects to those described for DBP by oth-
ers [4,6]: At GD 21, Leydig cells were found in large clusters
containing displaced Sertoli cells, and seminiferous chords
were enlarged and appeared to have an increased number of
centrally located gonocytes, although gonocyte proliferation
was not increased at this age. Focal dysgenesis in testes likely
originates from fetal or early postnatal development, whereas
general testicular atrophy may be due to either dysfunctional
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Sertoli or Leydig cells or be secondary to effects of andro-
gen deficiency in other reproductive organs. No significant
differences between DEHP and DEHP + DEHA exposed rats
were detected.
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Abstract
Di(2-ethylhexyl) phthalate (DEHP) is a well-known testicular toxicant inducing adverse effects in androgen responsive tissues. Therefore,
di(2-ethylhexyl) adipate (DEHA) is currently being evaluated as a potential substitute for DEHP. Similarities in structure and metabolism of
DEHP and DEHA have led to the hypothesis that DEHA can modulate the effects of DEHP. Wistar rats were gavaged with either vehicle,
DEHP (300 or 750 mg/kg bw/day) or DEHP (750 mg/kg bw/day) in combination with DEHA (400 mg/kg bw/day) from gestation day (GD)
7 to postnatal day (PND) 17.
Decreased anogenital distance (AGD) and retention of nipples in male offspring were found in all three exposed groups. Dosed males
exhibited decreased weights of ventral prostate and m. levator ani/bulbocavernosus. Histopathological investigations revealed alterations in
testis morphology in both juvenile and adult animals. The litter size was decreased and postnatal mortality was increased in the combination
group only, which is likely a combined effect of DEHP and DEHA. However, no combination effect was seen with respect to antiandrogenic
effects, as males receiving DEHP in combination with DEHA did not exhibit more pronounced effects in the reproductive system than males
receiving DEHP alone.
© 2004 Elsevier Inc. All rights reserved.
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1. Introduction
The increase in developmental and functional disorders of
the male reproductive tract in both humans and wildlife have
led to the hypothesis that perinatal exposure to environmen-
tal chemicals may be harmful to normal development of the
male reproductive tract by disrupting the endocrine system
[1,2]. In 1992, Carlsen and co-workers suggested a world-
wide decline in human sperm quality and it was proposed
that environmental chemicals might be partly responsible
[3,4]. Large geographical differences in semen quality have
∗ Corresponding author. Tel.: +45 7234 7562; fax: +45 7234 7698.
E-mail address: ol@dfvf.dk (O. Ladefoged).
recently been reported both in the US and in northern Europe
[5,6].
Phthalates are plasticizers that induce flexibility to
polyvinyl products in several consumer products [7]. Di(2-
ethylhexyl) phthalate (DEHP) is one of the most commonly
used plasticizer and humans are exposed via oral, inhala-
tion and intravenous routes [8–10]. DEHP and DBP are well
known testicular toxicants in rodents inducing adverse ef-
fects in androgen responsive tissues [11–13], and low sperm
counts [12,14,15]. A study by Duty and co-workers demon-
strated an association between phthalate levels and impaired
sperm quality in humans [16]. The development of the male
reproductive tract is androgen dependent and therefore vul-
nerable to antiandrogens. It is suggested that the effects of
0890-6238/$ – see front matter © 2004 Elsevier Inc. All rights reserved.
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phthalates are caused by an antiandrogenic mechanism not
involving the androgen receptor [17,18], and recent studies
report that DINP, DBP and DEHP decrease testosterone syn-
thesis in foetal testes [18–20].
Because of the antiandrogenic effects of DEHP, di(2-
ethylhexyl) adipate (DEHA) is being evaluated as a potential
substitute for DEHP. We have previously studied the repro-
ductive effects of DEHA [21]. Results showed that DEHA
induced mild developmental toxicity at 400 mg/kg bw/day,
moderate developmental toxicity from 800 mg/kg bw/day,
but no antiandrogenic effect at doses up to 1200 mg/kg
bw/day. In spite of these results, similarities in structure and
metabolism of DEHP and DEHA have led to the hypothesis
that similarities in action may exist. Therefore, the aim of the
present study was to examine whether antiandrogenic effects
of perinatal exposure to DEHP could be modulated by
DEHA. The doses in the combination group were selected as
the highest doses where no maternal toxicity and a low level
of developmental toxicity were seen in previous experiments.
In our previous dose–response study of DEHA, 400 mg
DEHA/kg bw/day caused a small increase in postnatal death
of offspring and no maternal toxicity [21]. The dose of
750 mg DEHP/kg bw/day was similar to the dose used by
Parks et al. and Gray et al. in comparable study designs
[12,18]. The dose of 300 mg DEHP/kg bw/day was selected
in order to obtain submaximal effects compared to 750 mg
DEHP/kg bw/day. As few studies on semen quality following
perinatal DEHP exposure of rats have yet been reported, we
examined semen production as well as velocity and motility
parameters. Additionally, we aimed to verify previous
findings of irreversible effects of DEHP by evaluating the
histopathology of reproductive organs and the typically
antiandrogenic effects on anogenital distance and nipple
retention.
2. Materials and methods
2.1. Chemicals
DEHP, CAS No. 117-81-7, purity 99% and DEHA, CAS
No. 103-23-1, purity 99% was obtained from Sigma–Aldrich,
St. Louis, MO. The vehicle was sterile peanut oil obtained
from the Royal Veterinary and Agriculture Pharmacy, Copen-
hagen, Denmark.
2.2. Animals and treatment
Eighty time-mated, young adult Wistar rats with a body
weight around 200 g (HanTac:WH, Taconic M&B, Den-
mark) were supplied at day 3 of pregnancy. Upon arrival,
the females were randomly distributed in pairs and housed
under standard conditions: semitransparent plastic-cages
(15 cm× 27 cm× 43 cm) with pinewood-bedding (Hanflock
H9), situated in an animal room with controlled environmen-
tal conditions (12 h light–dark cycles with light starting at 6
p.m., light intensity 500 lux, temperature 21± 2 ◦C, humidity
50± 5%, ventilation 8 air changes per hour). Food (Altromin
Standard Diet 1324) and acidified tap water were provided
ad libitum.
At gestation day (GD) 4, the females were weighed and
assigned to four groups, 20 dams per group, with similar
weight distributions. The four groups of dams were gav-
aged daily with vehicle, 300 or 750 mg DEHP/kg bw/day, or
with 750 mg DEHP/kg bw/day in combination with 400 mg
DEHA/kg bw/day in a dosing volume of 2 ml/kg bw from GD
7 to PND 17. At GD 20, the females were housed individually.
They were observed twice a day for signs of toxicity. Body
weight was recorded on GD 4 and daily during the dosing
period.
From GD 21, animals were inspected twice a day at 8 a.m.
and 4 p.m. and time of birth was recorded. After delivery,
body weights of dams and individual pups were recorded.
Pups were counted, sexed and checked for anomalies. Pups
found dead were investigated for macroscopic lesions, when
possible. The day following delivery was designated PND 1
for the pups. Litter size was not standardized.
One male and one female from each litter were kept after
weaning at PND 21, to investigate sexual maturation, sperm
quality and histopathology of testes at adulthood. These pups
were selected randomly and housed in pairs of the same sex
and exposure status. Three to five pups per litter were sacri-
ficed by decapitation following CO2-anaesthesia at PND 22
for histopathological investigation of the testes. The rest of
the pups and dams that had not given birth were sacrificed
as well at PND 22 and examined for macroscopic lesions.
The number of uterine implantation sites was counted in the
dams.
2.3. Postnatal development
Body weight of the offspring was registered in the pre-
weaning period at PND 3 and 13. In order to examine femi-
nization of males, anogenital distance was measured and the
presence of nipples was examined. Anogenital distance was
measured in the offspring on PND 3. On PND 13, the pups
were examined for the presence of either areolas or nipples,
described as a dark focal area (with or without a nipple bud)
located where nipples are normally present in female off-
spring. No distinction was made between the retention of an
areola or a nipple.
Age of sexual maturation was investigated by recording
the day of vaginal opening in the females and cleavage of
the balano-preputial skinfold in the males. The latter was
done by observing when the prepuce, which is fused to
the glans penis until the onset of puberty, could be fully
retracted.
2.4. Sperm analysis
Sexually mature males (PND 190) were anaesthetised by
CO2/O2 and decapitated. The epididymides were removed
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and the cauda of the right epididymis was used for motility
analysis. The cauda of the left epididymis was frozen in liquid
nitrogen for later sperm count. Sixteen animals per group
were used, one to two males per litter.
2.5. Sperm motility
The epididymis was trimmed of fat and cut at the corpus-
cauda region. Cauda was placed in a petri dish containing 3 ml
warm (37 ◦C) Medium 199 Hanks & Hepes (Invitrogen Life
Technologies, Denmark), supplemented with 0.5% bovine
serum albumin (crystallised and lyophilised; Sigma, MO).
Spermatozoa were obtained from the distal cauda where the
tubular diameter is widest. Under the dissecting microscope,
the cauda was held by forceps and several stabs were made
into the tubules. The petri dish was placed in an incubator for
5 min. Cauda was removed and the sperm sample was diluted
10 times (in medium 199, supplemented with 0.5% bovine
serum) and re-placed in the incubator for 10 min, to allow
dispersion of spermatozoa. Sperm samples was loaded into
a 100m flat cannula (HTR 1099, Fercom, Denmark) and
analysed by computer assisted sperm analysis (CASA; HTM-
IVOS version 12 Hamilton Thorne Research, Beverly, MA,
US). Minimum 20 fields were recorded at 60 Hz under ×4
dark field illumination, and the images were video recorded
for later analysis.
The standard set up was used during analysis and
tracking errors were deleted through the edit and playback
features. Twelve fields (minimum 200 sperm cells) were
analysed for each sperm sample. The samples were blinded
to the observer. The parameters evaluated in this study
were: percent motile and percent progressive spermatozoa,
curvilinear velocity (VCL) and amplitude of lateral head
displacement (ALH) that describe the vigour of the sperma-
tozoa, and some progressive parameters such as average path
velocity (VAP), straight line velocity (VSL) and straightness
(STR).
2.6. Sperm count
Cauda of the left epididymis was thawed at room
temperature, trimmed of fat, weighed and homogenised in
1 ml Triton X-100. The homogenate was stored at 5 ◦C and
treated with ultrasonic sound for 21/2 min the following
day. Distilled water (100l) was placed into a stain reaction
vial containing DNA-specific fluorescent stain (Supra
Vital IDENT Stain Kit, HTR) and vortexed. One hundred
microlitres of the sperm homogenate was added, vortexed,
followed by incubation for 2 min at room temperature. After
subsequent vortexing, 3.5l was loaded into a 20m deep
counting chamber (20 Micron, LEJA, Fercom, Denmark).
Before the sample was placed in the HTM-IVOS, it was
allowed to settle for 2 min. Samples were analysed using
10× UV fluorescent objective and IDENT OPTIONS set A.
Ten fields were analysed for each sample and three counts
were performed for each suspension. Counts were averaged
and data are presented as number of sperm per gram
cauda.
2.7. Organ weight, histopathology and
immunohistochemistry
All males underwent a thorough autopsy. The following
organs were excised and weighed in PND 22 males and adult
males: brain, liver, kidneys, adrenals, testes, epididymides,
seminal vesicles, ventral prostate, bulbouretal glands, and
levator ani/bulbocavernosus muscles. Caput of the left epi-
didymis, ventral prostate, and seminal vesicles were fixed
in formalin, embedded in paraffin and examined by light mi-
croscopy after staining with haematoxylin and eosin. In PND
22 males, histopathological investigations were performed in
one testis from each of around 20 males per group, represent-
ing 10 litters. Ten testes were Bouin’s fixed, and 10 testes were
formalin fixed. The other reproductive organs were investi-
gated in 10 males representing 10 litters per group. In adult
males, reproductive organs including testis were investigated
in 14–16 adult males representing 14–16 litters per group. All
testes from adults were Bouin’s fixed. Sections were blinded
to the observer with respect to dose groups.
For immunohistochemistry one section per testis were pre-
treated for 5 min in citrate buffer pH 6 at 99 ◦C, and incubated
simultaneously with the two primary antibodies against 3-
hydroxysteroid dehydrogenase (3-HSD, a kind gift from Dr.
I. Mason, Edinburgh, UK) and smooth muscle actin (SMA,
clone 1A4, DAKO, Denmark) over night at 4 ◦C. This was
followed by two consecutive staining procedures: first incu-
bation with anti-mouse EnVision+ and staining for SMA with
AEC, then blocking in H2O2, incubation with anti-rabbit En-
Vision+ and staining with Vector SG peroxidase staining kit
(Vector Laboratories, CA).
2.8. Statistical analysis
The litter was generally considered the statistical unit and
differences were considered statistically significant when p-
values were lower than 0.05. Pregnancy data and postnatal
development were analyzed using ANOVA, when the data
showed normal distribution and homogeneity of variance.
When relevant, body weight or litter size was included as a
covariate in the analyses and a nested design adjusting for
litter effects was used. For post-hoc pairwise comparisons
Dunnett’s test was used. For data not fulfilling the conditions
for ANOVA, non-parametric analysis of variance or Fisher’s
exact test were performed. The SYSTAT PC-version software
package (Systat 1990) was used for these statistical analyses.
One to four males per litter from ten to sixteen litters per
group were used to analyse sperm quality at PND 190, and
terminal body weight and organ weights in PND 22 and PND
190 males. Non-processed and ln-transformed data were ex-
amined for normal distribution and homogeneity of variance.
In order to adjust for litter effects, litter was included in the
analysis of variance as an independent, random, and nested
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factor (proc mixed, SAS version 8, SAS Institute Inc., Cary,
NC, USA). Organ weights were analysed using treatment as
one main factor and age as another main factor and body
weight was used as a covariate. When an overall significant
treatment effect was observed, two-tailed comparison was
performed using least square means. In cases where nor-
mal distribution and homogeneity of variance was not ob-
tained, data were additionally tested with the non-parametric
Kruskall–Wallis test. Macroscopic lesions and testis effects
were analysed using Fisher’s exact test. The combination
group was compared to the 750 mg DEHP group in order
to investigate the possible modulating effect of DEHA.
3. Results
3.1. Pregnancy data, postnatal growth and development
Pregnancy and litter data are summarized in Table 1. No
clinical signs of toxicity were observed in the dams during
the dosing period. Maternal weight gain from GD 7 to 21 was
decreased in dams treated with DEHP alone or with DEHP in
combination with DEHA when compared to the control dams.
However, the difference was only statistically significant for
the group exposed to the combined dosing. Maternal body
weight on PND 1 and during the lactation period was similar
among groups.
The number of pups per litter and the birth weight of live
pups were decreased in litters exposed to DEHP and DEHA
in combination. Birth weight was also significantly decreased
in pups exposed to 750 mg DEHP. The postimplantation-
perinatal loss (i.e. number of implants minus number of
live pups at birth) was statistically significantly increased
in litters exposed to 750 mg DEHP and in litters exposed
to DEHP and DEHA in combination. Postnatal mortality
seemed higher in all exposed groups, but the difference was
only statistically significant in litters exposed to DEHP in
combination with DEHA. The number of pups dying post-
natally were 1 of 94 (1.1%), 5 of 102 (4.9%), 10 of 139
(7.2%), and 28 of 113 (24.8%) in the control group, 300 mg
DEHP, 750 mg DEHP, and the combination group, respec-
tively. There were 3 litters with total loss of pups in the
group exposed to DEHP and DEHA in combination. These
litters consisted of 2, 2 and 6 pups, i.e. 10 dead pups in total,
while the other 18 dead pups were distributed among 9 other
litters.
The anogenital distances on PND 3 were significantly de-
creased in the male pups in all exposed groups compared to
the control group (Table 1). The male offspring displayed
decreases of 14, 17, and 21% in the 300 mg DEHP, 750 mg
DEHP, and 750 mg DEHP plus 400 mg DEHA groups, re-
spectively. There was no significant difference in male AGD
between the 750 mg DEHP dose group and the combined dose
group. The mean AGD for control female pups was 2.38 mm
(51% of AGD in control male pups).
On PND 13, the mean number of areolas/nipples was sta-
tistically significantly increased in male offspring from lit-
ters in all exposed groups (Table 1). The mean number of
areolas/nipples in the litters exposed to DEHP and DEHA
in combination was significantly lower than the mean val-
ues for the litters exposed to the same dose of DEHP alone.
The distribution of individual exposed males in relation to
number of nipples is shown in Fig. 1. In the control group,
90.9% of the males had 0 areolas/nipples and the rest had
only 1. In male offspring exposed to 750 mg DEHP, only
around 10% had 0 or 1 nipple, while around 40% had 6–10
Table 1
Reproductive parameters in rats dosed by gavage with DEHP or DEHP in combination with DEHA from GD 7 to PND 17
Control DEHP (300 mg) DEHP (750 mg) DEHP (750 mg) + DEHA (400 mg)
Number of litters 12 11 15 15
Maternal weight gain GD 7 to 21 (g) 77.3 ± 15.8 70.1 ± 19.9 65.0 ± 10.8 60.7 ± 17.0*
Maternal weight, PND 1 (g) 233.6 ± 16.0 231.3 ± 18.2 228.9 ± 16.3 228.3 ± 15.4
Pregnancy length (days) 22.7 ± 0.4 22.8 ± 0.4 22.8 ± 0.4 22.9 ± 0.5
Birth weight, (g)
Males 5.93 ± 0.27 6.03 ± 0.43 5.54 ± 0.55* 5.39 ± 0.69*
Females 5.75 ± 0.36 5.81 ± 0.54 5.30 ± 0.55* 5.11 ± 0.54*
Male pups per litter (%) 56 ± 28 61 ± 14 46 ± 23 57 ± 22
Litter size, at birth 10.4 ± 3.2 9.3 ± 2.9 9.3 ± 3.6 7.5 ± 2.9*
Postnatal death, mean 0.11 ± 0.33 0.45 ± 0.93 0.53 ± 0.99 1.87 ± 1.64**
Postimplantation-perinatal-loss (%)a 6.7 ± 12.0 12.9 ± 14.1 15.3 ± 12.0* 20.0 ± 15.9**
AGD in males, PND 3 (mm) 4.63 ± 0.14 3.97 ± 0.57** 3.83 ± 0.36** 3.67 ± 0.29**
Body weight, PND 13 (g)
Males 24.0 ± 2.4 26.0 ± 2.6 23.5 ± 3.7 24.7 ± 3.9
Females 24.3 ± 3.2 25.8 ± 2.9 22.6 ± 3.6 24.2 ± 3.0
Nipples in males, PND 13 (number) 0.1 ± 0.2 3.9 ± 2.7** 5.2 ± 1.7** 3.9 ± 2.4**,+
a (No. implantations− litter size at birth)/no. implantations.
∗ p< 5% compared to control group.
∗∗ p< 1% compared to control group.
+ p< 5% compared to group dosed with 750 mg DEHP/kg bw/day.
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Fig. 1. Areolas/nipples at PND 13 in male rats exposed to either vehicle,
DEHP or DEHP in combination with DEHA from GD 7 to PND 17. Values
represent the percentage of male offspring in each group with either 0–1,
2–3, 4–5, 6–7 or 8–10 areolas/nipples.
nipples. The distribution in male offspring exposed to 300 mg
DEHP or 750 mg DEHP plus 400 mg DEHA seems rather
similar with 26-32% having 0–1 nipple and 25–36% having
6–10 nipples.
The age of sexual maturation was similar among groups
(data not shown).
3.2. Sperm quality
Fig. 2 shows the number of sperm per gram cauda
epididymis. No statistically significant reduction in the
number of sperm cells was observed, and no statistically
significant reductions were found when investigating any
of the sperm motility and velocity parameters compared to
the control group. Sperm quality data could not be analysed
by a parametric statistical procedure, as the group dosed
with 300 mg DEHP had three males with severely reduced
sperm number when compared to the control group (Fig. 2).
Furthermore, these three males plus two males dosed with
750 mg/kg also had a severely reduced percentage of motile
sperm compared to the control group (Fig. 3), as well as
considerable reductions in all other sperm motility and
velocity parameters tested (data not shown). In order to
investigate the effect on the remaining males, the severely
affected dosed outliers were excluded from the statistical
analyses. No statistically significant effects were observed.
Fig. 2. Sperm number in cauda epididymis in adult male rats exposed to
vehicle, DEHP or DEHP in combination with DEHA from GD 7 to PND
17. Values are single animal data, n= 16.
Fig. 3. Sperm motility in adult male rats exposed to vehicle, DEHP or DEHP
in combination with DEHA from GD 7 to PND 17. Values are single animal
data, n= 16.
3.3. Macroscopic ﬁndings, terminal body weight, organ
weights, immuno- and histopathology
A low incidence of malformations related to the re-
productive system was observed in the groups exposed to
DEHP or DEHP in combination with DEHA, as listed in
Table 2. Microophtalmia was found in one male receiving
the high dose of DEHP and two males in the combination
group, while hydronephrosis was found in control animals
as well as the exposed groups (data not shown). However,
no statistically significant differences were found between
the exposed groups compared to the control group for any
of the observed malformations.
No treatment-related effects on body weight, brain, liver,
kidneys or adrenals weights were observed at PND 22 or
190 (Tables 3 and 4). In the statistical analysis of ventral
prostate, m. levator ani/bulbocavernosus and paired testes
weight, an interaction between dose and age was observed.
Hence, in PND 22 males, a statistically significant decrease
in paired testes weight after receiving 750 mg DEHP was ob-
served, while no decrease in m. levator ani/bulbocavernosus
or vental prostate weights were observed (Table 3). This was
in contrast to PND 190 males, where statistically signifi-
cant decreases in weights of ventral prostate and m. leva-
tor ani/bulbocavernosus were found in all exposed groups
(Table 4).
No effect was observed on testis, epididymis and seminal
vesicle weights at PND 190. These data could not be analysed
by a parametric statistical procedure, as a few of the PND 190
males in the 300 mg DEHP and 750 mg DEHP groups had
very small testes and epididymides (Table 4). Additionally,
one of the males in the group dosed with 300 mg DEHP had
atrophic seminal vesicles. In order to investigate the effect
on the remaining males, the severely affected dosed outliers
were excluded from the statistical analyses. No statistically
significant effects were observed.
Haematoxylin and eosin staining of control testes from
PND 22 and PND 190 males are presented in Fig. 4 A and D,
respectively. In testes from males dosed with DEHP alone or
DEHP in combination with DEHA, normal testis tissue with
small foci of malformed tubules surrounded by interstitial
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Table 2
Total number of PND 22 and 190 males with macroscopic reproductive effects after exposure to DEHP or DEHP and DEHA in combination from GD 7 to
PND 17
Control DEHP (300 mg) DEHP (750 mg) DEHP + DEHAa
Number of PND 22 males 31 30 29 27
Number of PND 190 males 16 16 16 16
Small testis or lack of one testis 4 3
Small/malformed epididymis 4 3
Malformed seminal vesicles or spongious tissue in
m. levator ani/bulbocavernosus
3 1
Cryptorchid testis 2
Hypospadiab 1
Abcesses in the uro-genital system 2
a The mixture contained 750 mg DEHP and 400 mg DEHA/kg bw/day. Statistically significantly different compared to the control group (p< 0.05).
b Only investigated in PND 22 males.
Table 3
Terminal body weight and organ weights at PND 22 after pre- and postnatally exposure to DEHP or DEHP and DEHA in combination
Control DEHP (300 mg/kg) DEHP (750 mg/kg) DEHP + DEHAa n
Body weight (g) 45.8 ± 3.9 51.4 ± 5.9 45.0 ± 5.9 47.8 ± 6.2 30
Brain (g) 1.45 ± 0.055 1.47 ± 0.12 1.43 ± 0.075 1.45 ± 0.064 10
Liver (g) 1.73 ± 0.24 1.95 ± 0.30 1.73 ± 0.19 1.76 ± 0.19 10
Paired kidneys (mg) 512 ± 66 564 ± 89 512 ± 95 538 ± 81 10
Paired adrenals (mg) 22.0 ± 7.2 22.5 ± 6.9 19.5 ± 3.9 23.3 ± 6.4 10
Right testis (mg) 127 ± 13 134 ± 18 120 ± 23 120 ± 24 20
Left testis (mg) 128 ± 12 135 ± 18 117 ± 26 122 ± 24 30
Paired testes (mg) 256 ± 26 269 ± 37 235 ± 42* 240 ± 49 20
Left epididymis (mg) 25.9 ± 5.0 28.2 ± 7.8 21.3 ± 5.9 21.2 ± 4.2 10
Ventral prostate (mg) 29.9 ± 5.4 30.5 ± 5.8 23.8 ± 6.6 28.4 ± 5.5 10
Seminal vesicles (mg) 24.9 ± 7.3 30.6 ± 8.2 23.7 ± 5.3 26.8 ± 6.3 10
M. levator ani/bulbocavernosus (mg) 39.2 ± 7.3 42.3 ± 9.5 34.6 ± 7.6 37.8 ± 6.0 10
a The mixture contained DEHP 750 mg/kg and DEHA 400 mg/kg. Data represents mean±S.D. before exclusion of outliers.
∗ Statistically significantly different compared to the control group (p< 0.05).
Table 4
Terminal body weight and organ weights at PND 190 after pre- and postnatal exposure to DEHP or DEHP and DEHA in combination
Control DEHP (300 mg/kg) DEHP (750 mg/kg0 DEHP + DEHAa
Body weight (g) 423 ± 33 421 ± 49 416 ± 29 428 ± 28
Brain (g) 1.95 ± 0.063 1.99 ± 0.13 2.06 ± 0.032 2.03 ± 0.069
Liver (g) 12.1 ± 1.3 12.3 ± 1.7 11.7 ± 0.99 12.6 ± 1.3
Paired kidneys (g) 2.17 ± 0.13 2.19 ± 0.22 2.23 ± 0.23 2.26 ± 0.25
Paired adrenals (mg) 47.5 ± 6.5 42.4 ± 10 45.9 ± 6.1 47.0 ± 11
Right testis (g)b 1.84 ± 0.15 1.65 ± 0.64c 1.71 ± 0.47c 1.88 ± 0.15
Left testis (g)b 1.91 ± 0.14 1.67 ± 0.56c 1.84 ± 0.16 1.89 ± 0.17
Paired testis (g)b 3.76 ± 0.29 3.32 ± 1.1c 3.55 ± 0.49 3.78 ± 0.32
Left epididymis (mg) 624 ± 46 556 ± 170d 594 ± 76d 633 ± 89
Ventral prostate (mg)b 584 ± 120 468 ± 120* 464 ± 88* 485 ± 98*
Seminal vesicles (g) 1.64 ± 0.31 1.39 ± 0.50d 1.56 ± 0.29 1.40 ± 0.27
M. levator ani/bulbocavernosus (g)b 1.25 ± 0.21 1.06 ± 0.20* 1.02 ± 0.14* 1.05 ± 0.16*
a The mixture contained DEHP 750 mg/kg and DEHA 400 mg/kg. Data represents mean±S.D. before exclusion of outliers; n= 16 in all groups.
b An interaction between age and dose was observed. Therefore the two age groups were analysed separately.
c Two males from this group were severely affected by dose, considered as statistically outliers. When these were excluded from the analysis, no statistically
significant differences were observed when compared to the control group.
d One male from this group were severely affected by dose, considered as a statistically outlier. When this male was excluded from the analysis, no statistically
significant differences were observed when compared to the control group.
∗ Statistically significantly different compared to the control group (p< 0.05).
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Fig. 4. Examples of testis effects in rats perinatally exposed to DEHP alone or DEHP in combination with DEHA. (A–C) 22-day-old males; (D–F) 190-day-old
males. (A) and (D) are control testes; (B), (C), (E), and (F) are testes from males exposed to either DEHP (300 or 750 mg/kg) or DEHP (750 mg/kg) in
combination with DEHA (400 mg/kg) – similar effects were seen in all three exposed groups. Foci containing malformed tubules (*) often surrounded by
interstial cell hyperplasia () were observed at both PND 22 (B) and PND 190 (E) in all exposed groups but not in controls. A tendency to an increased
incidence of seminiferous tubules with fewer spermatocytes and slightly disorganised seminiferous epithelium were observed in exposed males at PND 22 (C),
but not at PND 190. However, 4 PND 190 males dosed with 300 mg/kg and 2 PND 190 males dosed with 750 mg/kg had severely atrophic seminiferous tubules
(#) (end-stage tubules, where only Sertoli cells were left) (F). Staining: haematoxylin and eosin.
cell hyperplasia was found, (Fig. 4 B and E). These mal-
formed tubules had disorganized seminiferous epithelium,
decreased spermatogenesis, and tubular anastomoses. The in-
cidence was lower at PND 190 compared to PND 22 (Table 5).
Double staining with SMA and 3-HSD indicated that Ley-
dig cells were present inside malformed tubules at PND 22
and 190 (Fig. 5 A–C).
At PND 22, tubules lacking spermatocytes and slightly
disorganised tubules were observed in both control and dosed
testes although with a higher but non-significant incidence in
the exposed groups (Table 5 and Fig. 4 C). These differences
were not found in adults. At PND 190, severely atrophic testes
with end-stage tubules (tubules with a total lack of germ cells
and only Sertoli cells present) and diffuse Leydig cell hyper-
plasia were observed in four males exposed to 300 mg DEHP
and two males dosed with 750 mg DEHP of which one was
cryptorchid (Tables 2 and 5, Fig. 4 F). Four of these six males
also had small epididymides.
Table 5
Histopathological effects in testes of PND 22 and 190 males after exposure to DEHP or DEHP in combination DEHA from GD 7 to PND 17
Number of affected males/total number of investigated males and in percent (%) Control DEHP (300 mg) DEHP (750 mg) DEHP + DEHAa
Foci with malformed tubules and interstitial cell hyperplasia
PND 22 0/19 (0) 6/21 (29)* 5/18 (28)* 3/21 (14)
PND 190 0/14 (0) 3/16 (19) 2/15 (13) 5/16 (31)*
PND 22 + 190 0/33 (0) 9/37 (24)* 7/33 (21)* 6/37 (16)*
Slight disorganisation, lack of spermatocytes
PND 22 5/19 (26) 9/21 (43) 9/18 (50) 8/21 (38)
PND 190 0/14 (0) 0/16 (0) 0/15 (0) 0/16 (0)
Severely atrophic testes
PND 22 0/19 (0) 0/21 (0) 0/18 (0) 0/21 (0)
PND 190 0/14 (0) 4/16 (25) 2/15 (13) 0/16 (0)
Total number of males with effects on testes histology
PND 22 5/19 (26) 14/21(67)* 12/18 (67)* 10/21 (48)
PND 190 0/14 (0) 7/16 (44)* 4/15 (27) 5/16 (31)*
PND 22 + 190 5/33 (15) 21/37(57)* 16/33 (48)* 15/37 (41)*
a The mixture contained 750 mg DEHP and 400 mg DEHA/kg bw/day. In PND 22 males n= 18–21. In PND 190 males n= 14–16. In PND 22 about 10 testes
were Bouin’s fixed and the rest formalin fixed. In PND 190 males all testes were Bouin’s fixed.
∗ p< 5% compared to the control group. Fisher’s exact test.
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Fig. 5. Immunohistochemical characterization of dysgenic tubules in testes of young and adult male rats exposed to 750 mg DEHP/kg bw/day from GD 7 to
PND 17. (A–C) Double immunostaining for -smooth muscle actin (grey staining) and 3-hydroxysteroid dehydrogenase (3-HSD, red staining) showing
localization of Leydig cells inside seminiferous tubules in (A) 26-day-old rat testis; (B and C) 190-day-old rat testis, counterstained with Meyer’s Hematoxylin.
Control rat seminiferous tubules resemble the tubules neighboring dysgenic areas in these photos. Arrow indicates Leydig cells inside seminiferous tubules.
Scalebar: 100m.
At PND 22, no histopathological effects were observed
in the epididymis, seminal vesicles, or the prostate, except
for one male exposed to 750 mg DEHP, where a decrease in
epithelium height from a cylindric to a cuboidal epithelium
was observed in the proximal section of the epididymis. At
PND 190, four males with testis effects (two males dosed
with 300 mg DEHP and one male in each group dosed with
either 750 mg DEHP or 750 mg DEHP in combination with
400 mg DEHA) had mild histopathological changes in the
prostate consisting of a general lack of eosinophilic secrete in
acini or a mild regional lymphocyte infiltration of the stromal
tissue (data not shown).
When summarizing the numbers of males with any effects
on the reproductive system, i.e. macroscopic and histological
effects combined, the incidences were: 5 affected males of
47 males in the control group (10%), 22 affected of 46 males
in the 300 mg DEHP group (48%), 17 affected of 45 males in
the 750 mg DEHP group (38%), and 17 affected of 43 males
in the 750 mg DEHP plus 400 mg DEHA group (40%). The
total number of affected males was statistically significantly
higher in all exposed groups compared to controls.
4. Discussion
The results of this study demonstrate that prenatal and
lactational DEHP exposure can alter reproductive system de-
velopment in male rats. Male offspring of dams exposed to
300 and 750 mg DEHP and a combination of 750 mg DEHP
and 400 mg DEHA from GD 7 to PND 17 exhibited decreases
in AGD, retention of nipples and decreases in the weight of
ventral prostate andm. levator ani/bulbocavernosus. Further-
more, permanent alterations in testis histopathology were ob-
served. Additionally, sperm counts, motility and velocity, as
well as testis and epididymis weights were severely affected
in a few animals.
4.1. Effects on dams and pup development
The lower maternal weight gain during gestation in dams
from the combined dose group may not be an indication
of maternal toxicity, since maternal body weights after
delivery were similar among groups. The low weight gain
may rather be due to dams having fewer pups with a
significantly decreased birth weight (Table 1). The number
of pups per litter at birth was significantly decreased in
litters exposed to DEHP in combination with DEHA and the
post implantation loss was significantly increased. The high
incidence of postnatal mortality in the combined group could
be a combined effect of both DEHA and DEHP. We have
previously found that DEHA induced weak developmental
toxicity at 400 mg/kg bw/day and moderate developmental
toxicity at 800 and 1200 mg/kg bw/day [21]. In the current
study, it appeared that DEHP alone caused a trend towards a
dose related increase in postnatal mortality, and a significant
increase in postimplantation-perinatal loss in the 750 mg
DEHP group was observed. Findings on reduced pup
survival after in utero phthalate exposure have previously
been reported for DEHP [14] and DBP [13] at doses of
750 mg/kg bw/day.
The AGD was significantly decreased in all exposed
groups in a dose-related manner, also when correcting for
body weight, which is in agreement with studies on DEHP
by Moore et al. [14] and Parks et al. [18]. The effect on AGD
was most severe in the group receiving the combined dose
of DEHP and DEHA, though there was no significant dif-
ference in AGD between the 750 mg DEHP dose group and
the combined dose group. The development of external geni-
tals is affected by dihydrotestosterone (DHT). The reduction
of AGD may be secondary to low DHT levels caused by a
reduction in prenatal testosterone production, as shown in
studies on 19–21-day-old foetal males exposed to DEHP in
utero [18,19].
More areolas/nipples were present at PND 13 in males
in all three exposed groups compared to the control group.
The distribution in male offspring in the 300 mg DEHP dose
group and in the 750 mg DEHP plus 400 mg DEHA dose
group were almost similar (Fig. 1). The lower number of
areolas/nipples in the combined exposure group compared
to the 750 mg DEHP group may be explained by the high
postnatal mortality in the combination group, as the most
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severely affected males may be dead at PND 13, the day
when number of nipples is counted.
4.2. Effects on sperm quality
Effects on sperm counts, motility and velocity parameters
were observed in 3 males exposed to 300 mg/kg DEHP and
2 males exposed to 750 mg/kg DEHP and these 5 males all
had atrophic testes. The fewer living sperm cells probably ac-
count for the decreased percentage of motile sperm. Effects of
DEHP on sperm count have previously been demonstrated in
other studies where animals were exposed either perinatally
[14,22] or in adulthood [15,23]. These findings may either be
a result of the effect of DEHP on Sertoli cells that nurse the
developing spermatozoa, or on the epididymides, where the
maturation of sperm cells takes place.
4.3. Histological effects
At PND 22, slightly disorganised tubules and lack of sper-
matocytes was observed in both controls and dosed males
(Fig. 4 C). These findings probably reflect variability among
animals in the timing of the first spermatogenic cycle. The
incidence was increased in the dosed groups compared to the
control group and even though this increase was not statis-
tically significant, it may reflect a delay in spermatogenesis
in these young males, caused by the DEHP induced testes
effects observed in late gestation (see accompanying paper
[24]). Correspondingly, levels of serum inhibin B, a marker
of Sertoli cell function, were significantly reduced at PND
22 in these males, possibly reflecting delayed Sertoli cell
maturation as reported in Borch et al. [19]. The statistically
significant decrease in paired testis weight in the high dose
DEHP group at PND 22 supports this presumed delay in the
progress of testicular maturation.
Six adult males from the DEHP groups had severely at-
rophic testes with degeneration of the seminiferous epithe-
lium. The highly abundant effects described in fetuses [24]
are in contrast to the very few affected adult testes. This gives
rise to speculations of why some testes appear to recover,
and others continue an inappropriate development. It is well
known that fetal Leydig cells are affected by phthalates in ad-
dition to fetal Sertoli cell/germ cell interactions [18,20,25].
Early Sertoli cell dysfunction may cause the later spermato-
genic failure, and indeed serum inhibin B is affected in prepu-
bertal males exposed to DEHP as well as in adult males with
atrophic testes. It is possible that Sertoli cells in the most af-
fected testes in prepuberty never mature completely, leading
to the observed dysfunction of spermatogenesis and testicular
atrophy in adults. On the other hand, the testicular atrophy
may also be secondary to effects on the epididymis, as fe-
tal Leydig cell dysfunction resulting in reduced testosterone
production will likely affect the development of androgen
dependent organs. This is demonstrated by the observed at-
rophy of a few epididymides, in addition to the statistically
significant reduction of the weights of the ventral prostate
and m. levator ani/bulbocavernosus in all exposed groups at
PND 190 (Table 4).
Interestingly, Barlow and Foster have recently studied the
progress of effect of DBP from foetal age until adulthood after
in utero exposure. They observed that DBP-induced testic-
ular lesions progressed in severity from PND 45 to 70, and
suggested that the testicular atrophy induced by DBP was
secondary to epididymal obstruction [24]. Also, in utero ex-
posure to linuron induced obstruction of testicular fluid out-
flow following epididymal malformations causing testicular
atrophy that was much more profound at PND 56 compared
to PND 35 [26]. In the current study, four of the six males
with atrophic testes also had small epididymides. Unfortu-
nately, epididymal histology could be evaluated in only one
of the small epididymides, as the remaining epididymides
were sampled for semen analyses. In this epididymis, the
ductular lumen was decreased and contained no sperm. In the
current study, none of the examined testes had dilated sem-
iniferous tubules as seen by Barlow & Foster in prenatally
DBP exposed rats at PND 45 but not at PND 70. If dilation
of seminiferous tubules was indeed an early step in the ob-
served seminiferous tubules degeneration, this would likely
not be seen at our examination at PND 190. The hypothesis
of epididymal obstruction is confirmed by the examination at
PND 22, in which we observed one epididymis with dilated
ductular cross sections with flattened epithelium.
Persisting Leydig cell dysfunction was generally not seen
in the current study, where testosterone levels were normal in
prepubertal animals and most adults, but low in males with
atrophic testes. The observed Leydig cell hyperplasia in the
atrophic testes may be caused by elevated LH levels as an
attempt to compensate for the low testosterone levels.
Areas of malformed tubules surrounded by focal areas
of interstitial cell hyperplasia were found in the otherwise
normal testes of males dosed with DEHP or with DEHP in
combination with DEHA. The incidence was lower at PND
190 compared to PND 22, which is likely due to the dysgenic
tubules becoming surrounded by an increasing volume of
normally growing testis tissue during puberty and adulthood.
Leydig cells were found inside the dysgenic tubules, as also
reported by Fisher et al. in a study on neonatal males exposed
in utero to DBP [27]. As discussed in the accompanying paper
[24], the dysgenic areas probably originate from foetal or
early postnatal life.
4.4. Are the antiandrogenic effects of DEHP modulated
by DEHA?
Based on the result in this study, no modulating effect of
DEHA on the antiandrogenic effects of DEHP was observed.
However, the litter size at birth was significantly decreased
and postnatal pup mortality increased in the combination
group only. These effects are likely reflecting the develop-
mental toxicity of DEHA as seen at 800 mg/kg DEHA in our
previous dose–response study [27]. By combining DEHA
with DEHP, DEHP seems to advance this developmental
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toxicity of DEHA. Including a dose group receiving DEHA
alone in our study design would have strengthened the con-
clusions in the current study. Even though the effect on AGD
seemed more pronounced in the combined dose group, the
difference to the 750 mg DEHP group was not statistically
significant. In addition, the other endpoint for antiandrogenic-
ity, nipple retention, was even less affected in the combination
group compared to the high dose of DEHP, further indicating
that DEHA does not increase the antiandrogenic effect of
DEHP. These findings confirm previous studies in our lab-
oratory where perinatal exposure up to 1200 mg DEHA/kg
bw/day did not reduce the AGD in male offspring [21]. Gen-
erally, DEHA does not increase the incidence or severity of
effects on organ weights, sperm analysis and histopathology.
Variability in responsiveness from animal to animal seen
in this study was rather remarkable, as some individuals in
the exposed dose groups were severely affected, while oth-
ers were more or less unaffected. Also Gray et al. reported
large animal-to-animal variation after in utero exposure to
DEHP [11]. We examined all males from each litter macro-
scopically, but we may have reduced the chance of seeing
all effects by using each type of tissue for many parameters
(histopathology, semen quality, hormone analyses). The af-
fected animals in our study could thus represent a minimum
of effects.
In summary, adverse effects of DEHP as shown by others
have been confirmed in this study. Testicular atrophy, reduced
weights of reproductive organs, reduced anogenital distance
and an increased number of nipples/areolas were found in
perinatally exposed males. Dysgenic tubules containing Ley-
dig cells were found within otherwise normal DEHP-exposed
testes. The litter size was decreased and postnatal mortality
was increased in the combination group only, which is likely
a combined effect of DEHP and DEHA. However, no combi-
nation effect was seen with respect to antiandrogenic effects,
as males receiving DEHP in combination with DEHA did not
exhibit more pronounced effects in the reproductive system
than males receiving DEHP alone.
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Abstract
Diethylhexyl phthalate (DEHP) is widely used as a plasticizer in consumer products and is known to disturb the development
of the male reproductive system in rats. The mechanisms by which DEHP exerts these effects are not yet fully elucidated, though
some of the effects are related to reduced fetal testosterone production.
The present study investigated the effects of four different doses of DEHP on fetal testicular histopathology, testosterone production
and expression of proteins and genes involved in steroid synthesis in fetal testes.
Pregnant Wistar rats were gavaged from GD 7 to 21 with vehicle, 10, 30, 100 or 300 mg/kg bw/day of DEHP. In male fetuses
examined at GD 21, testicular testosterone production ex vivo and testicular testosterone levels were reduced significantly at the
highest dose. Histopathological effects on gonocytes were observed at 100 and 300 mg/kg bw/day, whereas Leydig cell effects were
mainly seen at 300 mg/kg bw/day. Quantitative RT-PCR revealed reduced testicular mRNA expression of the steroidogenesis related
factors SR-B1, StAR, PBR and P450scc. Additionally, we observed reduced mRNA expression of the nuclear receptor SF-1, which
regulates certain steps in steroid synthesis, and reduced expression of the cryptorchidism-associated Insl-3.
Immunohistochemistry showed clear reductions of StAR, PBR, P450scc and PPAR protein levels in fetal Leydig cells, indicating
that DEHP affects regulation of certain steps in cholesterol transport and steroid synthesis. The suppression of testosterone levels
observed in phthalate-exposed fetal rats was likely caused by the low expression of these receptors and enzymes involved in
steroidogenesis. It is conceivable that the observed effects of DEHP on the expression of nuclear receptors SF-1 and PPAR are
involved in the downregulation of steroidogenic factors and testosterone levels and thereby underlie the disturbed development of
the male reproductive system.
© 2006 Elsevier Ireland Ltd. All rights reserved.
Keywords: Diethylhexyl phthalate; Phthalates; Anti-androgen; Prenatal; Steroid synthesis; Testosterone; PPAR; SF-1
1. Introduction
It has been suggested that the observed increas-
ing incidences of testicular cancer, hypospadia, cryp-
∗ Corresponding author. Tel.: +45 7234 7549.
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mdam@dfvf.dk (M. Dalgaard).
torchidism and reduced semen quality in recent years
may be caused by endocrine disrupting environmen-
tal compounds with adverse effects on male reproduc-
tion (Skakkebaek et al., 2001). Among the chemicals
suspected of causing these effects in humans are the
abundantly used phthalates found in plastics, paints and
other materials. Human studies have indicated associa-
tions between maternal phthalate exposure and altered
0300-483X/$ – see front matter © 2006 Elsevier Ireland Ltd. All rights reserved.
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reproductive development in their infant sons (Swan et
al., 2005). Some of the most commonly used phtha-
lates are known to induce adverse effects in the repro-
ductive system of male rats. Perinatal phthalate expo-
sure leads to anti-androgenic effects such as reduced
anogenital distance (AGD), retained nipples, hypospa-
dias, undescended testes, epididymal agenesis and low
sperm counts in male rats (Barlow and Foster, 2003;
Jarfelt et al., 2005).
The mechanisms by which phthalates exert these
effects are not yet fully elucidated. Some of the anti-
androgenic effects seen after pre- or perinatal expo-
sure of rats are likely caused by the observed reduction
in testosterone production in late gestation. Normally,
testosterone levels in male rats increase from gestational
day (GD) 17 and peak at GD 20 (Parks et al., 2000).
DEHP, di-n-butyl phthalate (DBP), diisononyl phthalate
(DINP) and diisobutyl phthalate (DIBP) have been found
to reduce testosterone levels between GD 17 and post-
natal day (PND) 2 (Borch et al., 2004; Parks et al., 2000;
Borch et al., 2006). Studies on DBP have shown reduc-
tion of fetal testicular mRNA and protein levels of a
number of factors related to testosterone production. The
factors affected by DBP include scavenger receptor B-1
(SR-B1) responsible for cholesterol uptake into Leydig
cells, steroidogenic acute regulated protein (StAR) and
peripheral benzodiazepine receptor (PBR) both involved
in mitochondrial cholesterol uptake, and the steroid-
converting enzymes P450 side chain cleavage (P450scc)
and P450c17 (Barlow et al., 2003; Lehmann et al., 2004;
Thompson et al., 2004). However, the mechanism behind
the downregulation of these factors is not known.
Whereas focus has so far been aimed at elucidat-
ing the mechanism of action of DBP, similar studies
on the mechanism of action of DEHP or other phtha-
lates have not been published so far. Liu et al. (2005)
showed by microarray analyses that DBP, DEHP, ben-
zylbutyl phthalate and dipentyl phthalate evoke a similar
pattern of changes in gene expression, indicating that
these phthalates target the same pathways in male repro-
ductive development.
In the present study, we examined the effects of
DEHP on mRNA and protein levels of factors related to
the synthesis of steroids (SR-B1, StAR, PBR, P450scc,
P450c17) at GD 21 in the testes of fetal rats exposed to
doses from 10 to 300 mg/kg bw/day of DEHP. We have
previously observed reduced fetal testosterone levels at
300 and 750 mg DEHP/kg bw/day (Borch et al., 2004)
and aimed to examine effects on steroid synthesis as well
as histopathology at lower dose levels.
Additionally, we examined the expression of Ley-
dig cell product insulin-like factor-3 (Insl-3), which is
involved in testicular descent, and two factors essential
for fetal Leydig cell differentiation, the Sertoli cell prod-
uct Desert hedgehog (Dhh) and its receptor Patched-1
(Ptc-1) in Leydig cells (Yao and Capel, 2002). A study on
prenatal flutamide exposure of rats showed downregula-
tion of testicular Dhh, Ptc-1 as well as Insl-3 expression
at GD 18 and GD 20 (Brokken et al., in preparation).
It may thus be speculated that impaired Dhh and Ptc-1
function may underlie reduced expression of Insl-3 and
steroidogenesis related factors.
The expression of the nuclear receptors steroido-
genic factor-1 (SF-1), and peroxisome proliferator acti-
vated receptors- and - (PPAR and PPAR) was
also examined. SF-1 is known to regulate the expres-
sion of genes involved in steroidogenesis, and PPARs
are nuclear receptors that among many other functions
regulate genes involved in cholesterol uptake and trans-
port (Xie et al., 2002). A role for PPARs in the testic-
ular toxicity of phthalates may be speculated, as the
most testis toxic phthalates are strong PPAR activa-
tors (reviewed by Corton and Lapinskas, 2005). Several
PPAR or PPAR activating chemicals are known to
affect steroid production in testes and ovaries of rats
and humans in vitro and in vivo. PPAR agonists such
as phthalates, ammonium perfluorooctanoate, clofibrate
and WY14,643 have been found to reduce testosterone
production in primary Leydig cell culture and in adult
rats (Biegel et al., 1995; Csaba et al., 1995; Gazouli
et al., 2002; Liu et al., 1996). Furthermore, the two
PPAR activating thiazolidinedione drugs troglitazone
and rosiglitazone reduced testosterone levels in humans
(Vierhapper et al., 2003; Bloomgarden et al., 2001). If
the effects of phthalates in rat testes are related to PPARs,
this mechanism of action may thus be highly relevant to
humans.
Testicular gene and protein expression of a number
of factors related to steroid synthesis and/or Leydig cell
function were examined in order to compare the effects
of DEHP with those observed with DBP in previous stud-
ies and to elaborate further on the mechanisms of actions
of DEHP.
2. Materials and methods
2.1. Test compounds
DEHP, di(2-ethylhexyl) phthalate, CAS no. 117-81-7,
purity 99%, was from Aldrich 20,115-4.
2.2. Animals and dosing
Forty time-mated Wistar rats (HanTac:WH, Taconic M&B,
Denmark, body weight approx. 200 g) were supplied at day 3
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of pregnancy. The day following mating was designated GD
1. The dams were randomized into five groups of eight with
similar body weight distributions and housed in pairs until GD
21 under standard conditions. Semi-transparent plastic cages
with pinewood bedding were situated in an animal room with
controlled environmental conditions (12 h light–dark cycles
with light starting at 9 p.m., light intensity 500 lx, tempera-
ture 21 ± 2 ◦C, humidity 50 ± 5%, ventilation 8 air changes/h).
Food (Altromin Standard diet 1324) and tap water were pro-
vided ad libitum. The animals were dosed with vehicle (corn
oil), 10, 30, 100 or 300 mg DEHP/kg bw/day from GD 7 to GD
21. Animals were inspected for general toxicity twice daily. On
GD 21, dams were anesthetized in CO2/O2 and decapitated, and
fetuses were removed and decapitated.
Testes were removed and sampled for gene expression,
histopathology, measurement of testosterone production ex
vivo, or measurement of testosterone content. One or two
testes per litter were placed in RNAlater (QIAGEN) and kept
at −20 ◦C until extraction of RNA and cDNA production
for use in real-time RT-PCR. One or two testes per litter
were placed in Bouin’s fixative, and one testis per litter was
placed in neutral buffered formaldehyde for histopathology
and immunohistochemistry. For measurement of testosterone
production ex vivo, one testis per litter was placed in 0.5 ml
ice-cold Dulbecco’s modified eagle medium (DMEM)/F12
with 15 mM HEPES, 365 mg/l l-glutamine plus 0.1% bovine
serum albumin and 0.1 g/l gentamicin. The testes were incu-
bated at 37 ◦C for 5 h, were then placed on ice, centrifuged
at 4000 × g for 10 min, and the supernatant was collected
and stored at −80 ◦C until analysis of testosterone con-
tent. One testis per litter was placed in an empty tube and
immediately frozen in liquid nitrogen and stored at −80 ◦C
until analysis. Testosterone was extracted by two consecutive
diethylether extraction procedures and stored at −80 ◦C until
analysis.
Trunk blood from all males was collected with heparinized
microfuge tubes and kept on ice. Pools of blood from each
group was centrifuged at 4000 × g for 10 min at 4 ◦C, and kept
at −80 ◦C until analysis of testosterone content. Steroids were
extracted from plasma samples by solid-phase extraction using
IST Isolute C18 SPE columns of 100 mg. Testosterone content
in incubation media, testes and plasma was analyzed with a
Delfia time-resolved fluoroimmunoassay (Perkin-Elmer, Wal-
lac Oy, Turku, Finland). Plasma cholesterol was measured on
one pool of plasma from each dose group using a Roche/Hitachi
analyzer system.
2.3. Gene expression
mRNA expression was measured in 1 or 2 animals per litter,
10 animals per group. Two testes from the same animal were
pooled and homogenized in RLT buffer from the RNeasy Mini
kit (QIAGEN), and total RNA was isolated using RNase-mini
kit from QIAGEN following the supplier’s protocol for animal
tissues. The quantity and quality of purified RNA was evalu-
ated by spectroscopy. cDNA was produced by Omniscript kit
(QIAGEN) from 1g total RNA using T16 primer and 18S
rRNA specific oligos.
Expression of SR-B1, StAR, P450scc, P450c17, PBR,
PPAR and PPAR was analyzed by quantitative RT-PCR
on ABI PRISM 7900 HT (Applied Biosystems) by standard
TaqMan technology using fluorescence monitoring. TaqMan
probes contain a reporter dye at the 5′-end and a quencher dye
at the 3′-end is cleaved during the PCR, and fluorescence from
the reporter dye is detected. Quantitative results were obtained
by the cycle threshold value where a signal rises above back-
ground level. Rat specific primers and TaqMan probes from
Applied Biosystems are listed in Table 1. Optimal concentra-
tions were determined for each set of probe and primers. For
each sample, 2l cDNA (2.5 ng/l) was amplified under uni-
versal thermal cycling parameters (Applied Biosystems) using
TaqMan Universal PCR master mix (Applied Biosystems) in
a total reaction volume of 20l. For each sample three sepa-
rate measurements were performed. A fourth measurement was
made when intra-assay variation was above >10%. Sample sig-
nals were quantified from standard curves and expression levels
of each gene were normalized to the level of the housekeeping
gene 18S rRNA.
Expression of Desert hedgehog (Dhh), Patched 1 (Ptc-1),
Insl-3, SF-1 and Ribosomal protein S26 (S26) was measured
by quantitative PCR (QuantiTect SYBR-Green PCR Kit, Qia-
gen) according to the manufacturer’s instructions by using the
DNA Engine Opticon system (MJ Research Inc., Waltham,
MA) with continuous fluorescence detection. Primers for Insl-
3, SF-1, Dhh, Ptc-1 and S26 are listed in Table 1. About
2l cDNA per sample was used for the amplification. Sin-
gle measurements were made for all dose groups. As the
expression of Insl-3 and SF-1 appeared to be affected by the
highest dose of DEHP, Insl-3, SF-1 and S26 were subsequently
repeated in triplicates for the control and high dose group.
Expression levels of Insl-3 and SF-1 were quantified from stan-
dard curves and normalized to the level of the housekeeping
gene S26.
2.4. Histopathology and immunohistochemistry
Sections from testes fixed in Bouin’s fixative were stained
with haematoxylin and eosin for histopathological evaluation
blinded to the observer. Immunohistochemistry was performed
on one section per testis. Following microwave pretreatment
for 2 × 5 min in either citrate or TEG buffer, sections were
blocked for endogenous peroxidase activity in 3% H2O2 in
PBS, and blocked in 1% bovine serum albumin in PBS.
Sections were incubated over night at 4 ◦C with the follow-
ing rabbit polyclonal antibodies: StAR antibody (PA1-560,
Affinity Bioreagents, Golden, CO, 1:1000), P450scc anti-
body (AB 1244, Chemicon, Temecula, CA, 1:50,000), 3-
hydroxysteroid dehydrogenase (3-HSD) antibody (a kind
gift from Dr. I. Mason, Edinburgh, UK, 1:4000), PPAR
antibody (Cell Signaling, Beverly, MA, 1:100), PBR anti-
body (SantaCruz, CA, 1:200). Sections were then incubated
for 30 min with secondary antibody (Anti-rabbit EnVision+,
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Table 1
Rat specific primer sets and TaqMan probes for quantitative RT-PCR analyses
18S
TaqMan probe 6-FAM-ACC GGC GCA AGA CGA ACC AGA G-TAMRA
Forward primer GCC GCT AGA GGT GAA ATT CTT G
Reverse primer GAA AAC ATT CTT GGC AAA TGC TT
SR-B1
TaqMan probe 6-FAM-AAA GCA TTT CTC CTG GCT GCG CAG-TAMRA
Forward primer TCT GGT GCC CAT CAT TTA CCA
Reverse primer AGC CCT TTT TAC TAC CAC TCC AAA
StAR
TaqMan probe 6-FAM-CTG ACT CCT CTA ACT CCT GTC TGC CTA CAT GGT-TAMRA
Forward primer CCC TTG TTT GAA AAG GTC AAG TG
Reverse primer TGA AAC GGG AAT GCT GTA GCT
P450scc
TaqMan probe 6-FAM-CCT TTA TGA AAT GGC ACA CAA CTT GAA GGT ACA-TAMRA
Forward primer ACG ACC TCC ATG ACT CTG CAA T
Reverse primer CTT CAG CCC GCA GCA TCT
P450c17
TaqMan probe 6-FAM-CGT CAA CCA TGG GAA TAT GTC CAC CAG A-TAMRA
Forward primer GCC ACG GGC GAC AGA A
Reverse primer CCA AGC CTT TGT TGG GAA AA
PPAR
TaqMan probe 6-FAM-CAA TCC GCC TTT TGT C-MGB
Forward primer TCA TAC TCG CAG GAA AGA CTA GCA
Reverse primer GCA CAA GGT CTC CAT GTC ATG T
PPAR
TaqMan probe 6-FAM-TAT GAC CTG AAG CTC CAA GAA TAC CAA AGT GC-TAMRA
Forward primer TGA CCC AAT GGT TGC TGA TTA C
Reverse primer GGG ACG CAG GCT CTA CTT TG
PBR
TaqMan probe 6-FAM-AAA GCC CAG CCC ATC T-MGB
Forward primer TGG TTC CCT TGG GTC TCT ACA CT
Reverse primer CAC CCC ACT GAC AAG CAT GA
S26
Forward primer AAG GAG AAA CAA CGG TCG TG
Reverse primer GCA GGT CTG AAT CGT GGT G
Insl-3
Forward primer ACG CAG CCT GTG GAC ACC
Reverse primer CAA TCC GGG GGT GTT TCA TT
SF-1
Forward primer GCT TGT CTC AAG TTC CTC ATC CTC
Reverse primer CTC GTT GCC CAA ATG CTT AT
Dhh
Forward primer AAG CAA CTT GTG CCT CTG CT
Reverse primer TCG TCC CAA CCT TCA GTC AC
Ptc-1
Forward primer TAC GTG GAG GTG GTT CAT CA
Reverse primer AAC ACC AAG GGC AAG AAA TG
DAKO, Glostrup, Denmark), stained in diaminobenzidine
(DAB+ Substrate Chromogen System, DAKO, Glostrup, Den-
mark) or 3-amino-9-ethylcarbazole (AEC, Labvision, CA), and
counterstained in Meyer’s hematoxylin.
2.5. Statistics
Non-processed and logarithmically transformed hormone
and gene expression data were examined for normal distribu-
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tion and homogeneity of variance. Normally distributed and
variance homogeneous data were analyzed by ANOVA using
single animal data. For datasets including more than one ani-
mal per litter, the litter was the statistical unit and included
in the analysis of variance as an independent, random factor
nested within treatment group (SAS Analyst, Mixed Procedure,
SAS version 8, SAS Institute Inc., Cary, NC, USA). Dunnett’s
tests were performed to determine differences between treated
groups and control group means. Asterisks indicate a statis-
tically significant difference compared to controls, *p < 0.05;
**p < 0.01; ***p < 0.001.
3. Results
Testicular histopathology was examined in one or two
testes per litter from 21-day-old fetal rats exposed to 0,
10, 30, 100, or 300 mg DEHP/kg bw/day from GD 7
to GD 21. At the two highest doses germ cells were
centrally located, the number of gonocytes appeared to
be increased, and multinucleated germ cells were present
(Fig. 1). At the highest dose level, vacuolisation of Sertoli
cell and clusters of spindle shaped Leydig cells were
observed.
We measured testosterone levels as well as testicular
gene and protein expression of factors involved in testos-
terone synthesis and Leydig cell function. Testosterone
levels were analysed in plasma as well as in testes and in
addition, the ability of the fetal testis to produce testos-
terone ex vivo was measured. Testicular testosterone
content and testicular testosterone production ex vivo
were reduced by DEHP. For both parameters, the effect
was statistically significant at the highest dose compared
to controls (Fig. 2A and B). Similarly, a clear tendency
towards reduced plasma testosterone levels was found
(Fig. 2C). However, as blood from all male fetuses in
each dose group had been pooled, an average level was
measured and no statistical analysis was possible.
In order to examine the role of cholesterol availability
for testicular testosterone synthesis, cholesterol levels
were measured in pools of plasma from all male fetuses
in each dose group. No differences between groups were
observed (data not shown).
The effect of DEHP on factors involved in steroid syn-
thesis was examined by quantitative analysis of mRNA
expression and by immunohistochemistry on GD 21
testes. The gene expression of SR-B1, StAR, PBR and
P450scc were reduced dose-dependently. The effect was
statistically significant for StAR at the two highest doses
and for SR-B1, PBR and P450scc at the highest dose
(Fig. 3A–D). Similarly, there was a tendency towards
lower transcript levels of P450c17 (Fig. 3E).
Immunohistochemical staining of testis sections from
the highest dose group were compared to controls. Cor-
Fig. 1. Testicular histopathology at GD 21 in male rat fetuses exposed
to 0 or 300 mg DEHP/kg bw/day from GD 7 to GD 21. Testes of DEHP-
exposed animals (B) had a larger number of gonocytes compared to
controls (A). Gonocytes were located centrally in the seminiferous
tubules due to vacuolization of Sertoli cell cytoplasm (>). Multinucle-
ated gonocytes (#) were present in testes of DEHP-exposed animals.
Original magnification 40×.
responding to the gene expression findings, the protein
expression of StAR, PBR and P450scc protein in Ley-
dig cells was reduced by DEHP (Fig. 4). No change in
3-HSD staining intensity was observed (not shown).
Collectively, these effects on mRNA and protein expres-
sion indicate that a general downregulation of the steroid
synthesis pathway leads to the observed low testosterone
levels.
Additionally, we examined the mRNA expression
of other factors involved in Leydig cell function. SF-
1, which regulates the expression of genes involved in
steroidogenesis, and Insl-3, which is involved in testicu-
lar descent, were both significantly reduced in the highest
dose group compared to controls (Fig. 5).
As the nuclear receptors PPAR and PPAR regulate
genes involved in cholesterol uptake and transport, we
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Fig. 2. Testosterone levels at GD 21 in male rat fetuses exposed to 0,
10, 30, 100, or 300 mg DEHP/kg bw/day from GD 7 to GD 21. (A)
Testicular testosterone content (n = 5–7 litters, two testes per litter); (B)
testicular testosterone production ex vivo (n = 5–7); (C) plasma testos-
terone (one pooled sample per group). Figures show mean ± S.E.M.
Asterisks indicate a statistically significant difference compared to con-
trols, ***p < 0.001.
also examined their expression in fetal rat testes. PPAR
immunostaining was seen in Leydig cell cytoplasm and
nuclei of control testes (Fig. 6C). Testes from the high
dose DEHP group had much weaker PPAR staining.
This weak PPAR staining was mainly located in Leydig
Fig. 3. Gene expression at GD 21 in testes of male rat fetuses exposed
to 0, 10, 30, 100, or 300 mg DEHP/kg bw/day from GD 7 to GD
21. Figures show mRNA levels normalized to the levels of 18S
(mean ± S.E.M.). Asterisks indicate a statistically significant differ-
ence compared to controls, *p < 0.05; ***p < 0.001. (A) SR-B1; (B)
StAR; (C) PBR; (D) P450scc; (E) P450c17.
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Fig. 4. Immunohistochemical staining at GD 21 of testes from male rat fetuses exposed to 0 or 300 mg DEHP/kg bw/day from GD 7 to GD 21. The
intensity of staining in Leydig cells (↑) for StAR (A and B), PBR (C and D), and P450scc (E and F) is reduced in DEHP-exposed animals (B, D
and F) compared to controls (A, C and E).
cell nuclei and almost absent in the cytoplasm (Fig. 6D).
The effect of DEHP on PPAR protein expression
was not matched by gene expression results, although
PPAR mRNA levels appeared slightly reduced at the
highest dose compared to controls (Fig. 6A). PPAR
mRNA levels were not altered by DEHP treatment
(Fig. 6B).
In order to give an overview of the observed findings,
the DEHP-induced effects on mRNA and protein expres-
sion is shown in Table 2 and for comparison it is indicated
which effects have previously been described for DBP
(Barlow et al., 2003; Lehmann et al., 2004; Thompson
et al., 2004).
4. Discussion
The current study showed reduced testicular testos-
terone production ex vivo and testicular testosterone
levels in rat fetuses exposed to DEHP in utero. The
testosterone suppressing effect was significant at 300 mg
DEHP/kg bw/day, a dose level that induces atrophy of
testes and epididymides, reduced anogenital distance and
an increased number of nipples in male rats exposed in
utero (Jarfelt et al., 2005). Recent studies have shown
reduced anogenital distance and an increased number of
nipples at doses from 10 mg DEHP/kg bw/day (Hass et
al., 2004).
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Fig. 5. Gene expression at GD 21 in testes of male rat fetuses exposed
to 0 or 300 mg DEHP/kg bw/day from GD 7 to GD 21. Figures show
mRNA levels normalized to the levels of S26 (mean ± S.E.M.). Aster-
isks indicate a statistically significant difference compared to controls,
*p < 0.05; **p < 0.01. (A) SF-1; (B) Insl-3.
Histopathological effects on gonocytes were seen at
the two highest dose levels, 100 and 300 mg DEHP/kg
bw/day. Leydig cell alterations were observed at the
highest dose, at which testosterone levels and steroido-
genic factors were also affected. The observation of
effects on gonocytes at lower doses may indicate that
DEHP disrupts pathways affecting gonocyte develop-
ment at doses which do not affect Leydig cell function.
Gene and/or protein expression of the steroidogenic
factors SR-B1, StAR and P450scc were reduced in testes
of DEHP-exposed animals, as summarized in Table 2.
These effects have previously been described for DBP,
but not for any other phthalate (Barlow et al., 2003;
Lehmann et al., 2004; Thompson et al., 2004). Further-
more, this is the first paper to describe reduced expres-
sion of SF-1 and PBR and reduced protein levels of
PPAR in fetal testes of rats exposed to any phthalate.
As SF-1 and PPARs regulate certain steps in cholesterol
transport and steroid synthesis, it may be hypothesized
Table 2
Effects of gestational exposure to DEHP (300 mg/kg bw/day) on testic-
ular mRNA or protein expression of factors involved in fetal steroido-
genesis or testicular descent in male rat fetuses
Effect of DEHP on mRNA
expression measured by
quantitative RT-PCR
Effect of DEHP on protein
expression assessed by
immunohistochemistry
SR-B1 ↓ (⇓) NA (⇓)
StAR ↓ (⇓) ↓ (⇓)
PBR ↓ (⇑) ↓ (⇓)
P450scc ↓ (⇓) ↓ (⇓)
3-HSD NA (⇓) ↔
P450c17 ↔ (⇓) NA
PPAR ↔ NA
PPAR ↔ ↓
SF-1 ↓ NA
Insl-3 ↓ (⇓) NA (⇓)
Dhh ↔ NA
Ptc-1 ↔ NA
(↓) Downregulation/decreased expression in the current study; (↔)
no significant effect of DEHP exposure in the current study; NA, not
assessed in the current study; (⇓) downregulation observed with DBP
in other studies; (⇑) upregulation observed with DBP in other studies.
that these nuclear receptors are involved in the testos-
terone reducing effect of phthalates.
Fig. 7 shows a schematic overview of the effects
of DEHP on rat fetal testes that were observed in the
present study as well as effects of DBP described in
previous studies. It is indicated which genes are reg-
ulated by SF-1 and PPARs. As it is presently unclear
which of the PPAR subtypes may be involved, we will
here refer to “PPARs” in general instead of naming each
PPAR subtype. The first step in testicular steroidogene-
sis is either uptake of cholesterol from blood or de novo
cholesterol synthesis within the Leydig cell. Choles-
terol uptake via SR-B1 is regulated by PPARs in the
liver and macrophages (Chinetti et al., 2000; Malerod
et al., 2003), and likely also in Leydig cells. PBR and
StAR cooperate in the transport of cholesterol into the
mitochondria, where P450scc converts cholesterol to
pregnenolone. The remaining enzymes in the pathway
(3-HSD, P450c17 and 17-hydroxysteroid reductase)
are all located in the cytosol. SR-B1, StAR, P450scc,
3-HSD and P450c17 are regulated by SF-1, and PBR
is regulated by PPARs (Val et al., 2003; Gazouli et al.,
2002). Reduced steroid synthesis could thus be due to
PPAR activation by DEHP, leading to downregulation
of SR-B1 and PBR, or due to effects on SF-1 leading to
reduced expression of SR-B1, StAR, P450scc, 3-HSD
and P450c17 (Fig. 7).
The observed reduction in fetal testicular PBR mRNA
expression corresponds with the observed reduction
of PBR immunostaining in Leydig cells. PBR mRNA
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Fig. 6. Gene and protein expression of PPARs at GD 21 in testes of male rat fetuses exposed to 0, 10, 30, 100, or 300 mg DEHP/kg bw/day from
GD 7 to GD 21. (A and B) mRNA levels of PPAR and PPAR normalized to the levels of 18S (mean ± S.E.M.). (C and D) The intensity of
immunostaining in Leydig cells for PPAR is reduced in DEHP-exposed animals (D) compared to controls (C).
expression was also reduced in testes of adult mice
exposed to DEHP (Gazouli et al., 2002), while reduced
PBR mRNA expression in fetal testes has not been
described previously for any phthalate. In contrast,
Lehmann et al. (2004) found increased testicular PBR
mRNA expression and reduced PBR immunostaining of
Leydig cells in DBP-exposed rats at GD 19. The differ-
ence in the age of the fetus at the time of examination
may explain the discrepancy between the gene expres-
sion results of the two studies.
As mentioned above, the nuclear receptor SF-1,
which was downregulated in the current study, is
involved in the regulation of several steroidogenic fac-
tors. Also the Insl-3 gene contains binding sites for SF-1,
indicating a role for SF-1 in the regulation of Insl-3
expression (Koskimies et al., 2002). The observed reduc-
tion in Insl-3 expression may thus be caused by an effect
of DEHP on SF-1 activity. Testicular downregulation of
Insl-3 expression was also described in a study on 18-
day-old fetal rats exposed to 750 mg DEHP/kg bw/day
(Wilson et al., 2004). In a study on male rats exposed
postnatally (PND 5–14) to DBP, an increased expres-
sion of testicular SF-1 protein was observed on PND 20,
supporting an involvement of SF-1 in the mechanism
behind phthalate effects (Kim et al., 2004).
No ligands for the orphan receptor SF-1 have
been described, but an interaction between phthalate
monoesters and the nuclear receptor SF-1 may be specu-
lated. However, Thompson et al. (2004) found no effect
of monobutyl phthalate (MBP) on SF-1 regulated tran-
scription of StAR, SR-B1 or P450c17 reporter constructs
in a reporter gene assay. As no other phthalate metabo-
lites were examined in that study, it is possible that DEHP
metabolites and other metabolites of DBP than MBP are
able to bind and activate SF-1.
In the current study, DEHP clearly reduced the
immunohistochemical expression of PPAR protein in
fetal rat testes. PPARmRNA levels were not reduced as
evidently as PPAR protein expression in Leydig cells,
although most testes had very low PPAR transcript
J. Borch et al. / Toxicology 223 (2006) 144–155 153
Fig. 7. Illustration of how phthalates may reduce testicular testosterone production and testicular descent via interaction with PPAR or SF-1. The
uptake of cholesterol and conversion to testosterone involves numerous receptors and enzymes. (↓) Indicates factors (protein and/or mRNA) which
are downregulated in fetal testes by DEHP in the current study or by DBP in other studies. The nuclear receptors PPAR and SF-1 regulate the
expression of some of these factors as indicated by the dotted arrows. SR-B1, StAR, P450scc, 3-HSD and P450c17 are regulated by SF-1, and
PBR and possibly SR-B1 are regulated by PPARs. The low testosterone production in DEHP-exposed testes may thus be due to PPAR activation
by phthalates, leading to downregulation of SR-B1 and PBR, or due to effects on SF-1 leading to reduced expression of SR-B1, StAR, P450scc,
3-HSD and P450c17. As indicated, SF-1 also regulates Insl-3, which is associated with DEHP-induced cryptorchidism. MEHP, metabolite of
DEHP, is known to bind and activate PPARs, but it is unclear whether MEHP interacts with SF-1.
levels compared to controls. This could be due to tem-
poral differences in protein and gene expression and/or
to the presence of PPAR expression in other cell types
than Leydig cells (blood, macrophages). The observed
reduction of PPAR protein levels in vivo by DEHP
corresponds with the observation in vitro that PPAR
activators downregulate PPAR protein and mRNA lev-
els by autoregulation (Camp et al., 1999). It remains to be
examined whether this low expression of PPAR upon
activation results in decreased or increased PPAR activ-
ity overall.
No clear effects on PPAR mRNA expression were
observed in fetal testes in the current study. In agree-
ment with this, Ward et al. (1998) proposed that the
testicular effects of phthalates are at least partly PPAR
independent, as DEHP-exposed PPAR knockout mice
and wild-type mice exhibited similar testis toxicity.
Another study, however, showed reduced testosterone
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levels in DEHP-exposed wild-type mice, but not in
PPAR knockout mice, indicating a role for PPAR
in effects on testosterone (Gazouli et al., 2002). Also
the specific PPAR agonist WY14,643, which does
not activate PPAR or PPAR/, was shown to sup-
press testosterone in vitro and in vivo (Gazouli et al.,
2002). Although it is not clear which PPAR subtype
may be involved in the testicular effects of phthalates,
it is conceivable that PPAR and PPAR (and possibly
PPAR/) share similar patterns of effects, and ago-
nists to either of the subtypes may affect testosterone
production.
The observed effect on SF-1 and PPAR expres-
sion on testes from GD 21 fetuses is difficult to relate
causally to the reduction of testosterone production, as
testosterone effects begin already at GD 17 (Parks et al.,
2000). Any primary effect on nuclear receptor expres-
sion should thus preferably be investigated at or before
GD 17, although the most sensitive time for detection of
effects on testosterone is around GD 21 in our rat strain
(Borch et al., 2006). Causal relations may be studied by
investigation of rapid effects of phthalate treatment. In
a study on acute DBP dosing of young rats, effects on
PPAR regulated genes were observed already after 3–6 h
(Kobayashi et al., 2003). Rapid effects on steroidogenic
factors in testes of fetal rats exposed to DBP at GD 19
were studied by Thompson et al. (2005). They described
an early drop in testicular testosterone levels within 1 h
after maternal dosing. Six hours after treatment, gene
expression of StAR, SR-B1, P450scc and P450c17 were
reduced and followed by a further drop in testosterone
levels (Thompson et al., 2005). The rapid reduction in
testosterone levels indicates direct inhibition of enzymes
involved in steroidogenesis, as the effect occurs before
measured changes in gene expression of steroidogenic
factors. The later drop in testosterone levels, however,
may be related to regulation of steroidogenic enzymes
by nuclear receptor such as PPARs and/or SF-1. Alterna-
tively, the observed changes in PPAR and SF-1 expres-
sion may be secondary to a direct effect of DEHP on
steroidogenic enzyme activity.
Reduced cholesterol availability may contribute to the
reduced testosterone production. PPAR agonists increase
the flux of cholesterol from extrahepatic tissues to the
liver, as reviewed by Xie et al. (2002). Corresponding
to this, reduced serum cholesterol was observed in adult
male rats dosed with 125–1000 mg/kg bw/day of DEHP
for 9 weeks (Dalgaard et al., 2000). However, no change
in plasma cholesterol was seen in fetuses exposed to
DEHP doses up to 300 mg/kg bw/day in this study.
The human relevance of phthalate effects observed
in rats has been debated, as hepatic PPAR-mediated
effects are not considered relevant to humans (Doull et
al., 1999). However, PPAR-mediated effects of phtha-
lates in the testes may be highly relevant to humans.
Indeed, the PPAR activating thiazolidinedione drugs
rosiglitazone and troglitazone were found to reduce
testosterone levels in normal men (Vierhapper et al.,
2003), and are known to reduce the hyperandro-
genism seen in women with Polycystic Ovary Syndrome
(Bloomgarden et al., 2001). Human testes do express
PPAR in Leydig cells and spermatocytes, but human
testicular expression of PPAR has not been adequately
investigated (reviewed by Corton and Lapinskas, 2005).
In conclusion, this study revealed for the first time that
gestational exposure to DEHP reduces nuclear receptors
SF-1 mRNA and PPAR protein levels in fetal rat testes.
Furthermore, the expression of several steroidogenic
genes (SR-B1, StAR, PBR and P450scc) was reduced by
DEHP as previously shown for DBP, indicating a similar
mechanism of action for DEHP and DBP. The inhibition
of steroidogenesis leads to low fetal testosterone lev-
els, likely causing adverse reproductive effects later in
life. Additionally, reduced testicular expression of the
cryptorchidism-associated Insl-3 gene was observed. It
is conceivable that the observed effects of DEHP on the
expression of nuclear receptors SF-1 and PPAR are
involved in the downregulation of steroidogenic factors
and testosterone levels and thereby underlie the disturbed
development of the male reproductive system.
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Abstract
Phthalates are widely used as plasticizers in various consumer products and building materials. Some of the phthalates are known
to interfere with male reproductive development in rats, and di-n-butyl phthalate (DBP), diethylhexyl phthalate (DEHP) and butyl
benzyl phthalate (BBP) were recently banned for use in toys in the EU mainly due to their reproductive toxicity. Diisobutyl phthalate
(DiBP) has similar structural and application properties as DBP, and is being used as a substitute for DBP. However, knowledge on
male reproductive effects of DiBP in experimental animals is lacking.
Methods: In the current study, four groups of pregnant Wistar rats were exposed to either 0 mg/kg bw/day or 600 mg/kg bw/day
of DiBP from gestation day (GD) 7 to either GD 19 or GD 20/21. Male offspring was examined at GD 19 or GD 20/21 for effects
on testicular testosterone production and testicular histopathology. Changes in anogenital distance (AGD) were evaluated as an
indication of feminisation of males.
Results: Anogenital distance was statistically significantly reduced at GD 20/21 together with reductions in testicular testosterone
production and testicular testosterone content. Histopathological effects (Leydig cell hyperplasia, Sertoli cell vacuolisation, central
location of gonocytes and presence of multinuclear gonocytes) known for DBP and DEHP were observed in testes of DiBP-exposed
animals at GD 20/21. Additionally, immunohistochemical expression of P450scc and StAR proteins in Leydig cells was reduced
by DiBP. At GD 19, these effects on anogenital distance, testosterone levels and histopathology were less prominent.
Conclusion: In this study, GD 20/21 rather than GD 19 appears to be the optimal time for investigating changes in anogenital
distance, testosterone levels, and testicular histopathology. DiBP has similar testicular and developmental effects as DBP and
DEHP, and although more developmental and especially postnatal studies are needed to clearly identify the reproductive effects of
DiBP, this study indicates a reason for concern about the use of DiBP as a substitute for DBP.
© 2005 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
The observed increasing incidences of testicular can-
cer, hypospadia, cryptorchidism and reduced semen
quality in recent years have been suggested to be caused
∗ Corresponding author. Tel.: +45 7234 7560; fax: +45 7234 7698.
E-mail address: mdam@dfvf.dk (M. Dalgaard).
by endocrine disrupting environmental compounds with
adverse effects on male reproduction (Skakkebaek et
al., 2001). Among the chemicals suspected of causing
these effects in humans are the phthalates, which are
abundantly used in plastics, paints and other materials.
Results from a recently published human study indicate
associations between maternal phthalate exposure and
reproductive development in their infant sons (Swan et
al., 2005). Some of the most commonly used phtha-
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lates (dibutyl phthalate (DBP), diethylhexyl phthalate
(DEHP) and diisononyl phthalate (DiNP)) are known
to induce adverse effects in the reproductive system of
male rats after prenatal exposure (Barlow and Foster,
2003; Gray et al., 2000). Some of these effects are likely
caused by a reduction in testicular testosterone produc-
tion during late gestation (Barlow et al., 2003; Borch et
al., 2004b; Parks et al., 2000).
Diisobutyl phthalate (DiBP) has not previously been
examined in fetal rats, though it is widely used and sus-
pected of having similar reproductive effects as the well-
studied DBP. Due to its similarities to DBP, DiBP can
be used as a substitute for DBP, which is presently used
in PVC, inks, paints, adhesives and cosmetics (Euro-
pean Council for Plasticisers and Intermediates web-
site, www.phthalates.com). Around 100 tons of DiBP is
used in Denmark per year mainly as softeners in plas-
tic, rubber, paint and glue, which accounts for 95% of
the use. In the US, the monoester metabolite of DiBP,
mono-isobutyl phthalate (MiBP), was found in women’s
urine in levels ranging from 0.7 ng/ml (25th percentile)
to 5.1 ng/ml (75th percentile) (Swan et al., 2005). The
exposure level of children to DiBP is unknown, but an
estimate of the total exposure to DBP in Danish children
aged 1–6 years is 400g/kg bw/day. This age group is
estimated to be the group with the highest exposure level
of DBP (Mu¨ller et al., 2003).
Since 1999 the six phthalates DEHP, DBP, BBP,
DiNP, diisodecyl phthalate (DiDP) and di-n-octyl phtha-
late (DnOP) have been temporarily banned in the EU
in the manufacture of toys and childcare articles for
children under the age of three because of their car-
cinogenic, mutagenic and reprotoxic effects. Recently,
DBP has along with DEHP and BBP been banned for
use in toys irrespective of age categories due to their
reproductive toxicity. DiNP, DiDP, and DnOP were con-
currently banned in toys that can be put in the mouth by
children.
The DiBP metabolite mono-isobutyl phthalate is
found in human blood, saliva and urine (Silva et al.,
2005). In a recent study, maternal urinary levels of MiBP
(among other phthalate monesters) were associated with
a short anogenital distance (AGD) in their infant boys
(Swan et al., 2005). Anogenital distance is a commonly
used measure of demasculinization of rats exposed to
anti-androgenic chemicals.
In the current study, AGD, testicular testosterone lev-
els, and testicular histopathology were evaluated in male
rat fetuses exposed to DiBP. The effects were examined
at gestation day (GD) 19 and GD 20/21 in order to deter-
mine the optimal time for detection of effects on fetal
testosterone production.
2. Materials and methods
2.1. Test compounds
Diisobutyl phthalate (DiBP), CAS no. 84-69-5, purity 99%,
Acros Organics, Geel, Belgium.
2.2. Animals and dosing
Twenty-four time-mated Wistar rats (HanTac:WH, Taconic
M&B, Denmark, bodyweight approximately 210 g) were sup-
plied at Day 3 of pregnancy. The day following mating was des-
ignated GD 1. The dams were randomized into four groups of
eight with similar bodyweight distributions and housed in pairs
under standard conditions. Semi-transparent plastic cages with
Tapvei aspen bedding were situated in an animal room with
controlled environmental conditions (12 h light–dark cycles
with light starting at 9 p.m., light intensity 500 lx, tempera-
ture 21 ± 2 ◦C, humidity 50% ± 5%, ventilation 8 air changes
per hour). Food (Altromin Standard diet 1324) and tap water
were provided ad libitum. Dams were dosed daily by gavage
from GD 7 to the day of autopsy with either vehicle (corn oil) or
600 mg/kg bw/day of DiBP. Animals were inspected for gen-
eral toxicity twice daily. A control group and a dosed group
were scheduled for autopsy at GD 19 and a control group and
a dosed group for autopsy at GD 21.
Dams were delivered to the animal unit in four blocks mated
on consecutive days and autopsied on consecutive days. As
two of these blocks were mixed up on arrival, some dams were
sacrificed 1 day earlier in pregnancy. Therefore, one fourth of
the fetuses autopsied at “GD 21” were only 20 days old, and
consequently named GD 20/21. As not all eight mated animals
per group were pregnant, n = 6 litters per group on GD 19 and
n = 5 litters in the control group and 6 litters in the DiBP group
on GD 20/21.
At the day of autopsy, dams were anesthetized in CO2/O2
and decapitated, and fetuses were removed. AGD was mea-
sured in all fetuses using a dissecting scope with an ocu-
lar reticle. The measurements were performed blinded with
respect to treatment group by a skilled technician who has
many years of experience in measuring AGD on PND1 pups.
Fetuses were decapitated and testes were removed and sampled
for histopathology, measurement of testosterone production ex
vivo, or measurement of testosterone content.
One or two testes per litter were placed in Bouin’s fixative,
and one or two testes per litter were placed in neutral buffered
formaldehyde for histopathology and immunohistochemistry.
One testis per litter was placed in 0.5 ml ice-cold Dulbecco’s
Modified Eagle Medium/F12 with 15 mM HEPES, 365 mg/l
l-glutamine plus 0.1% bovine serum albumin and 0.1 g/l gen-
tamicin. These testes were incubated at 37 ◦C for 5 h, were
then placed on ice, centrifuged at 4000 × g for 10 min, and the
supernatant was collected and stored at −80 ◦C until analy-
sis of testosterone content. Testosterone in supernatants was
measured without further extraction.
One testis per litter was placed in an empty tube and imme-
diately frozen in liquid nitrogen and stored at −80◦C. Steroid
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hormones were analyzed in testes after extraction with diethyl
ether. Testes were placed in vials containing 100l water,
extracted with 0.5 ml diethyl ether, and the procedure was
repeated. Following evaporation, vials were added 100 dilu-
ent 1 (zero calibrator from Perkin–Elmer Life Sciences, Turku,
Finland) and samples were vortexed and incubated for 10 min
at 45 ◦C before analysis.
2.3. Analyses of testosterone levels
Testosterone content in incubation media and testes was
analyzed with a Delfia time-resolved fluoroimmunoassay
(Perkin–Elmer, Wallac Oy, Turku, Finland). Samples and stan-
dards were measured in duplicates and the CV% were always
<20% (mean CV of 6.9%).
2.4. Histopathology and immunohistochemistry
One section per Bouin’s or formaldehyde fixed testis was
stained with H&E for histopathological evaluation and was
evaluated by an observer blinded with respect to treatment
groups. Immunohistochemistry was performed on one sec-
tion per Bouin’s-fixed testis. Following microwave pretreat-
ment for 2 × 5 min in either citrate or TEG buffer, sections
were blocked for endogenous peroxidase activity in 3% H2O2
in PBS, and blocked in 1% bovine serum albumin in PBS.
Sections were incubated over night at 4 ◦C with the follow-
ing rabbit polyclonal antibodies: steroidogenic acute regu-
lated protein (StAR) antibody (PA1-560, Affinity Bioreagents,
Golden, CO, 1:1000), P450side chain cleavage (P450scc) anti-
body (AB 1244, Chemicon, Temecula, CA, 1:50,000). Sec-
tions were then incubated for 30 min with secondary antibody
(Anti-rabbit EnVision+, DAKO, Glostrup, Denmark), stained
in diaminobenzidine (DAB+ Substrate Chromogen System,
DAKO, Glostrup, Denmark), and counterstained in Meyer’s
hematoxylin. Intensity of staining was scored as “normal” or
“reduced” staining by an observer blinded with respect to treat-
ment groups.
2.5. Statistics
Non-processed, logarithmically transformed and square
root transformed data were examined for normal distribu-
tion and homogeneity of variance. Normally distributed data
were analyzed by ANOVA using single animal data. For
datasets including more than one animal per litter, the lit-
ter was the statistical unit and included in the analysis of
variance as an independent, random factor nested within treat-
ment group. AGD data were analyzed for males and females
separately, and with cubic root of bodyweight as a covari-
ate. A Fisher’s Exact Test was used to analyze histological
changes in the testes at GD 19 and GD 20/21. SAS sta-
tistical software was used for the analyses (SAS Institute
Inc, Cary, NC, USA). Asterisks indicate a statistically sig-
nificant difference compared to controls *p < 0.05; **p < 0.01;
***p < 0.001.
3. Results
As previous studies have shown effects of DEHP,
DBP and DiNP on testosterone production, anogenital
distance and testicular histopathology in male fetal
rats, these endpoints were examined at two different
gestational ages in male rats exposed to 600 mg/kg
bw/day of DiBP.
At GD 19 and GD 20/21, testicular testosterone
content and testicular testosterone production ex vivo
were reduced in the DiBP group compared to con-
trols (Fig. 1). These effects were statistically significant
at GD 20/21 (p < 0.0001 and p = 0.0003 for testicular
testosterone content and testosterone production, respec-
tively) but not at GD 19 (p = 0.08 and p = 0.33). As
mentioned, some fetuses in the GD 20/21 group were
only 20 days old, but statistical comparison of data
from the two age groups showed no relevant differ-
ences, why all fetuses were included in the GD 20/21
group.
Corresponding to the reduced testosterone levels,
AGD was significantly reduced in DiBP dosed males
compared to controls at GD 19 and GD 20/21 (p = 0.009
and p = 0.009), indicating reduced masculinization
(Fig. 2). AGD was increased in female DiBP-exposed
Fig. 1. Testosterone levels at GD 19 and GD 20/21 in male rat fetuses
exposed to 0 mg DiBP/kg bw/day or 600 mg DiBP/kg bw/day from GD
7 to GD 19 or GD 20/21. (A) Testicular testosterone content (n = 5–6);
(B) testicular testosterone production ex vivo (n = 5–6). Figures show
mean ± S.E.M. Asterisks indicate a statistically significant difference
compared to controls ***p < 0.001.
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Fig. 2. Anogenital distance (A), bodyweights (B), and anogenital dis-
tance/cubic root of bodyweight (C), at GD 19 and GD 20/21 in male
and female rat fetuses exposed to 0 mg DiBP/kg bw/day or 600 mg
DiBP/kg bw/day from GD 7 to GD 19 or GD 20/21. Figures show
mean ± S.E.M. Asterisks indicate a statistically significant difference
compared to controls *p < 0.05, **p < 0.01.
fetuses compared to controls. This was statistically
significant at GD 20/21 (p = 0.02), but not at GD 19
(p = 0.057). We have not previously measured AGD on
animals taken by Caesarian section, and therefore have
no historical control values for fetuses. However, the
historical control data on AGD in PND1 pups show the
same difference between the sexes as we observed in
this study, i.e. males have an AGD that is approximately
twice as long as that of the females. Bodyweight was
also lower in the DiBP-exposed males and females
(statistically significant at GD 19 but not GD 20/21) and
therefore the cubic root of bodyweight was included
as a covariate in the statistical analysis in order to
take account for the influence of body size on AGD.
When analyzing AGD divided by the cubic root of
bodyweight, as shown in Fig. 2(C), we found that DiBP
dosed males had significantly lower values than controls
Table 1
Testicular histopathology in male rat fetuses exposed to 0 mg DiBP/kg
bw/day or 600 mg DiBP/kg bw/day from GD 7 to GD 19 or GD 20/21
GD 19 GD 20/21
Control DiBP Control DiBP
Clustering of small
Leydig cells
2/13 9/9*** 0/10 13/15***
Sertoli cells
vacuolisation
0/13 1/9 0/10 14/16***
Central localization of
genocytes
0/13 2/9 0/10 14/16***
Multinuclear
genocytes
1/13 0/9 1/10 10/16*
Reduced intensity of
StAR staining in
Leydig cells
0/8 4/5** 0/4 5/5**
Reduced intensity of
P450scc staining in
Leydig cells
0/8 2/5 0/4 7/7**
Numbers are single animal data on one testis from each of one to three
males per litter. There were 5 litters per group on GD 19 and 5 control
litters and 6 DiBP litters on GD 20/21.
* p < 0.05, statistically significant difference compared to controls.
** p < 0.01, statistically significant difference compared to controls.
*** p < 0.001, statistically significant difference compared to controls.
on GD 20/21 (p = 0.008) but not on GD 19, while the
dosed females had significantly higher values than
control females on both GD 19 and GD 20/21 (p = 0.005
and p = 0.032). There was no significant effect of dosing
on maternal weight gain during pregnancy, and no
difference on litter size, fetal viability, and number of
resorptions (data not shown).
DiBP-exposed animals had the histopathological
characteristics also seen with other phthalates at GD
20/21, as listed in Table 1. The number of gonocytes
appeared to be increased, and they were located cen-
trally in the seminiferous tubules due to vacuolization
of Sertoli cell cytoplasm. Leydig cells were found in
clusters and had small cytoplasm and small irregular
nuclei (Fig. 3). On GD 20/21, these effects were seen
in almost all examined testes, when examining one sec-
tion per testis. On GD 19, the effect of DiBP was mainly
on Leydig cell size and number, while Sertoli cell and
gonocyte effects were only observed in one or two of the
examined testes (Table 1).
StAR and P450scc staining intensity was reduced in
Leydig cells of DiBP-exposed animals compared to con-
trols (Table 1 and Fig. 4). This indicates reduced expres-
sion of these two proteins and thereby a reduced capacity
of the steroidogenic pathway leading to the observed
reduction in testosterone levels.
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Fig. 3. Testicular histopathology at GD 19 (A + B), and GD 20/21 (C + D), in male rat fetuses exposed to vehicle (A + C), or 600 mg DiBP/kg bw/day
(B + D), from GD 7 to GD 20/21. DiBP-exposed animals had a larger number of gonocytes, which were located centrally in the seminiferous tubules
(∧) due to vacuolization of Sertoli cell cytoplasm (#). Leydig cells (*) of DiBP-exposed animals were found in clusters and had small cytoplasm
and small irregular nuclei. (<) Multinucleated gonocytes. Original magnification 40×.
4. Discussion
The current study shows that DiBP has similar effects
as DEHP, DBP and DiNP on rat fetal testicular testos-
terone production and testicular histopathology follow-
ing exposure in utero. The proteins StAR and P450scc
involved in steroid synthesis in testes were also reduced
by DiBP as shown for other phthalates (Barlow et al.,
2003; Borch et al., submitted).
Due to the increasing knowledge on adverse
reproductive effects of some of the most widely used
phthalates, the industrial use of less well investigated
phthalates is increasing. DiBP is widely used, but only
few studies have examined its reproductive effects.
Reduced testis weight and increased testicular testos-
terone content was observed in 5-week-old rats exposed
to 2% DiBP in their diet (Oishi and Hiraga, 1980c).
On the other hand, a study in 5-week-old mice showed
that 2% dietary MiBP along with MEHP and MBP
reduced testicular testosterone levels, whereas abso-
lute testis weights was not affected (Oishi and Hiraga,
1980b). In contrast to their results with monoesters,
the same authors did not observe any effect of DiBP,
DEHP and DBP on absolute testes weights in mice (Oishi
and Hiraga, 1980a). Testicular atrophy was observed
in a study on prepubertal rats exposed to 800 mg/kg
bw/day MiBP for 6 days (Foster et al., 1981). A devel-
opmental toxicity study by the European Council for
Plasticisers and Intermediates (ECPI) showed reduced
maternal bodyweight gain and reduced fetal weight
in rats exposed to 942 mg/kg bw/day of DiBP from
GD 6 to GD 20, while no embryo-/fetotoxicity was
seen at 363 mg/kg bw/day or 88 mg/kg bw/day (Euro-
pean Counsil for Plasticisers and Intermediates web-
site, www.phthalates.com). However, that study did not
examine the early endocrine effects or late reproduc-
tive effects in male offspring. Studies with DBP have
shown that male reproductive development is affected
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Fig. 4. Immunohistochemical staining of testes from 20/21-day-old male rat fetuses exposed to 0 mg DiBP/kg bw/day or 600 mg DiBP/kg bw/day
from GD 7 to GD 20/21. The intensity of staining in Leydig cells for StAR (A + B), and P450scc (C + D), is clearly reduced in DiBP-exposed animals
(B, D) compared to controls (A, C). Original magnification 40×.
at much lower doses than those inducing teratogenicity
(Lehmann et al., 2004).
DiBP appears to disrupt fetal testicular development
as potently as the well-known testicular toxicants DEHP
and DBP, and more potently than DiNP. In Table 2, the
effects of DiBP on testicular testosterone production and
testicular testosterone levels in the current study are com-
pared to similar analyses described in the literature for
other phthalates. It should be noted that measurements
in the listed studies were made on other days of gesta-
tion and with other phthalate doses. When comparing to
our own previously published data, it is clear that the
effects observed with 600 mg/kg of DiBP at GD 20/21
in the current study are at least as marked as effects of
750 mg/kg and 300 mg/kg of DEHP and 750 mg/kg of
DiNP at the same age (Table 2). However, testosterone
values generally show some variation in our studies, as
mean control values can vary up to two-fold between
studies (Borch et al., 2004b). Also the severity and inci-
dence of histopathological effects of DiBP is comparable
to that seen with DEHP in our previous studies (Borch et
al., 2005) and is higher than the incidence of histopatho-
logical effects observed with DiNP (Borch et al., 2004a).
None of the studies by other groups have been per-
formed at GD 20/21, and direct comparison to those
studies is therefore difficult. In this study, we found more
marked effects at GD 20/21 compared to GD 19. Simi-
larly, Table 2 shows that the effect of DBP and DEHP was
more marked at the later ages of gestation in the studies
by Thompson et al. (2004) and Parks et al. (2000). The
weak effect of DiBP at GD 19 in the current study may
indicate a reduced sensitivity of our assay compared to
studies by other groups.
AGD was reduced at GD 19 and GD 20/21 in males
and increased in females exposed to DiBP. DiBP reduced
bodyweights of male and female fetuses, but when
analysing AGD data with bodyweight as a covariate,
the impact of reduced body size was taken into account.
Reduced male AGD measured in infancy is commonly
observed following exposure to anti-androgenic chem-
icals and has also been described for other phthalates
(Gray et al., 2000; Jarfelt et al., 2005). The observed
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Table 2
Overview of studies on fetal testosterone levels in phthalate exposed rats
Test
compound
Dose (mg/kg
bw/day)
Examination
day
Testicular testosterone production ex
vivo, % of control (control = 100%)
Testicular testosterone
content, % of control
Reference
BBP 1000 GD 18 13 Wilson et al. (2004)
BBP 500 GD 18 53 63 Hotchkiss et al. (2004)
DBP 1000 GD 18 10 Wilson et al. (2004)
DBP 500 GD 17 48 Thompson et al. (2004)
DBP 500 GD 18 19 Thompson et al. (2004)
DBP 500 GD 19 10 Thompson et al. (2004)
DEHP 1000 GD 18 47 Wilson et al. (2004)
DEHP 750 GD 17 44 Parks et al. (2000)
DEHP 750 GD 18 43 Parks et al. (2000)
DEHP 750 GD 20 11 Parks et al. (2000)
DEHP 750 GD 21 18 23 Borch et al. (2004b)
DEHP 300 GD 21 21 30 Borch et al. (2004b)
DiNP 750 GD 21 31 27 Borch et al. (2004b)
DiBP 600 GD 19 79 (NS) 30 Current study
DiBP 600 GD 20/21 4 9 Current study
It should be noted that different study designs, involving different strains of rats and dosing periods, were used (see relevant references). NS: no
significant difference compared to controls.
increase in female AGD has not been described previ-
ously for any phthalate, but the anti-androgenic pesticide
prochloraz has similarly been shown to increase female
AGD (Laier et al., in press). We do not know the mecha-
nisms behind this finding, but suspect that this is caused
by a hormonal imbalance in the DiBP-exposed female
fetuses. The reason why this effect has not been reported
in other phthalate studies may be that the focus of peri-
natal studies has been on the anti-androgenic properties
of the compounds, which are most marked in male off-
spring.
This study was designed to investigate whether the
effects of DiBP were comparable to DEHP, DBP, and
DINP on testosterone synthesis, AGD and histopathol-
ogy and therefore only one relatively high dose of DiBP
was used. In this study, no NOAEL can be provided for
risk assessment purposes. Among other metabolites of
phthalates, Swan et al. (2005) measured MiBP in the
urine of women in the childbearing age, indicating that
sensitive age groups are exposed to several phthalates
including DiBP. With the current study, DiBP is recog-
nized as yet an additional inhibitor of fetal steroidogene-
sis. In this study, GD 20/21 appears to be the optimal time
for investigating changes in anogenital distance, testos-
terone levels, and testicular histopathology. Based on the
current results, it appears likely that DiBP has similar
reproductive effects to DBP later in life, such as testicular
and epididymal atrophy or agenesis and reduced semen
quality. DEHP, DBP and BBP were recently banned for
use in toys in the EU due to their reproductive toxicity.
The current study provides new evidence for a similar
reproductive toxicity of DiBP, and indicates a reason for
concern about the use of DiBP as a substitute for DBP.
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Abstract
The fungicide prochloraz has got multiple mechanisms of action that may influence the demasculinizing and reproductive toxic effects of the
compound. In the present study, Wistar rats were dosed perinatally with prochloraz (50 and 150 mg/kg/day) from gestational day (GD) 7 to
postnatal day (PND) 16. Caesarian sections were performed on selected dams at GD 21, while others were allowed to give birth to pups that were
followed until PND 16. Prochloraz caused mild dysgenesis of the male external genitalia as well as reduced anogenital distance and retention of
nipples in male pups. An increased anogenital distance indicated virilization of female pups. Effects on steroidogenesis in male fetuses became
evident as decreased testicular and plasma levels of testosterone and increased levels of progesterone. Ex vivo synthesis of both steroid hormones
was qualitatively similarly affected by prochloraz. Immunohistochemistry of fetal testes showed increased expression of 17α-hydroxylase/17,20-
lyase (P450c17) and a reduction in 17β-hydroxysteroid dehydrogenase (type 10) expression, whereas no changes in expression of genes involved
in testicular steroidogenesis were observed. Increased expression of P450c17 mRNA was observed in fetal male adrenals, and the androgen-
regulated genes ornithine decarboxylase, prostatic binding protein C3 as well as insulin-like growth factor I mRNA were reduced in ventral
prostates PND 16. These results indicate that reduced activity of P450c17 may be a primary cause of the disrupted fetal steroidogenesis and that an
altered androgen metabolism may play a role as well. In vitro studies on human adrenocortical carcinoma cells supported the findings in vivo as
reduced testosterone and increased progesterone levels were observed. Overall, these results together indicate that prochloraz acts directly on the
fetal testis to inhibit steroidogenesis and that this effect is exhibited at protein, and not at genomic, level.
© 2005 Elsevier Inc. All rights reserved.
Keywords: Prochloraz; Steroidogenesis; Antiandrogen; Rat; Leydig cell
Introduction
Increased incidence of human reproductive health effects in
males such as malformed sex organs, poor semen quality and
testicular cancer have been reported in many industrialized
countries (Toppari et al., 2002). The first indication of a link to
endocrine-active chemicals has recently been published,
showing that feminization of sex organs in newborn boys was
correlated to prenatal phthalate exposure (Swan et al., 2005).
Furthermore, previous epidemiological studies have indicated a
causal connection between human exposure to pesticides and
endocrine disrupting effects such as poor sperm quality (Swan
et al., 2003) and increased incidence of cryptorchidism in sons
of gardeners (Weidner et al., 1998).
An increasing amount of chemicals have been demonstrated
to act as antiandrogens in experimental animals including the
thoroughly studied pesticides linuron, procymidone, and
vinclozolin together with diethylhexylphthalate (DEHP) and
dibutylphthalate (DBP) (Gray et al., 1999a, 1999b, 2001;
Thompson et al., 2005). Some of these antiandrogens have been
banned and substituted with alternatives, but still many
pesticides currently used in the industrialized world are
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suspected of having various endocrine disrupting effects as
shown by in vitro screening (Andersen et al., 2002).
The pesticide prochloraz is currently used in a great part of the
world within agriculture and horticulture due to its fungicidal
effects. Prochloraz has been shown to act via multiple
mechanisms of action in vitro as it antagonizes the androgen
and the estrogen receptor, agonizes the arylhydrocarbon receptor
and inhibits aromatase activity (Andersen et al., 2002; Long et
al., 2003; Mason et al., 1987). Additionally, in vivo studies on
male rats have demonstrated prochloraz to act as an antiandrogen
in the Hershberger assay, in which the lowest tested dose of 50
mg/kg was causing reduced weights of reproductive organs,
down-regulated mRNA levels of androgen-regulated genes in
prostates and increased serum LH levels (Vinggaard et al., 2002).
Developmental toxic effects of prochloraz have been
reported in two recent studies (Vinggaard et al., 2005; Noriega
et al., 2005). Perinatal exposure to 30 mg/kg prochloraz caused
delayed delivery of the pups and increased nipple retention and
reduced weights of bulbourethral glands in newborn male pups
(Vinggaard et al., 2005). Furthermore, feminized behavior of
the adult males in this study was expressed as an increased
activity level and an increased intake of sweetened water,
indicating that exposure during gestation and lactation causes
permanent adverse effects in adulthood. In agreement with
previous results reported by Wilson et al. (2004), these effects
were accompanied by a marked reduction of fetal testosterone
production and increased progesterone production, and it was
suggested that the feminization of the male offspring was at
least partly due to this mechanism of action. In male rats
exposed in utero for 5 days to 31.25, 62.5, 125, and 250 mg/kg
prochloraz, developmental effects in male pups such as reduced
anogenital distance, nipple retention, hypospadias, severe
phallus clefting and exposure of the os penis were observed
together with observations that vaginal morphology was
induced in males (Noriega et al., 2005). It was suggested that
higher doses of prochloraz produce a profile of effects that
resemble the profile produced by lower doses of androgen
receptor antagonists like flutamide and vinclozolin. Overall,
prochloraz is able to feminize male rat offspring after perinatal
exposure, but the detailed mechanisms of actions that are
involved remain to be elucidated.
Steroidogenesis and production of testosterone during
gestation are critical for function and development of the male
reproductive organs. In male rat fetuses, the antiandrogenic
profile of phthalates such as DBP is distinct from that of typical
androgen receptor antagonists such as flutamide, but they still
elicit relatively similar reproductive abnormalities such as
hypospadias and absent or deformed seminal vesicles and
ventral prostates (Mylchreest et al., 2000). However, DBP does
not seem to block the androgen receptor to a major extent but
rather interfere with the androgen synthesis resulting in
diminished testosterone production. Examination by quantita-
tive real-time RT-PCR of the expression of various genes
involved in androgen biosynthesis and signaling has formed
part of the studies on mechanisms of action lying behind the
antiandrogenic effects caused by DBP (Shultz et al., 2001;
Barlow et al., 2003). Down-regulation of mRNA expression of
scavenger receptor class B-1 (SRB1), steroidogenic acute
regulatory protein (StAR), P450 side-chain cleavage enzyme
(P450scc), 3β-hydroxysteroid dehydrogenase (3β-HSD) and
17α-hydroxylase/17,20-lyase (P450c17) by DBP in fetal testes
suggests that cholesterol uptake and transport and its further
conversion are potential mechanisms for the decreased
testosterone synthesis (Barlow et al., 2003; Lehmann et al.,
2004; Thompson et al., 2004). Consequently, it is of great
interest to investigate whether these mechanisms of action play
a role in the steroidogenic effects of prochloraz as well.
The purpose of the present study was to perform a detailed
investigation of the mechanisms of action responsible for the
prochloraz-induced effects on fetal steroidogenesis in male rat
pups. Critical genes and proteins involved directly or indirectly
in steroidogenesis and/or Leydig cell function were analyzed in
the testes and adrenals by quantitative real-time RT-PCR, and
the same method was applied to look for changes in expression
of androgen-regulated genes in prostates from male pups. These
investigations were supplemented with immunohistochemistry
of relevant proteins and with hormone analyses in order to
elucidate the mechanisms responsible for the observed effects.
Finally, hormone levels were measured in mouse Leydig cells
and human adrenocortical cells in order to find a suitable in
vitro model that qualitatively reflects the effects of prochloraz
on fetal steroidogenesis in vivo.
Methods
Test compounds
Prochloraz 99.3% pure (CAS no. 67747-09-5; N-propyl-N-[2-(2,4,6-
trichlorophenoxy)ethyl]-1H-imidazole-1-carboxamide) from Institute of Organ-
ic Chemistry (Warsaw, Poland) was used for the in vivo studies, while
prochloraz 99.4% pure from Riedel de Häen (Seelze, Germany) was used for in
vitro studies. The test compound was dissolved in peanut oil (no. P-2144) from
Sigma-Aldrich (St. Louis, USA) for in vivo studies.
Animals and exposure
Fifty-six young adult nulliparous Wistar rats (HanTac: WH, Taconic M and
B, Ejby, Denmark) were supplied at day 3 of pregnancy. The animals were
distributed, housed and handled as previously described (Vinggaard et al.,
2005). At the day after arrival, i.e. gestational day (GD) 4, animals were weighed
and assigned to 3 groups of 24, 16 and 16 rats respectively with similar weight
distributions. The rats were gavaged with 0, 50 mg/kg or 150 mg/kg of
prochloraz from gestational day 7 to postnatal day (PND) 16. In the 3 groups, 21,
16 and 14 rats, respectively, appeared to be pregnant.
Health status of dams and delivery
Time of birth and the health status of the dams were monitored as previously
described byVinggaard et al. (2005). Among the time-mated animals, 13, 8 and 6
dams from the control, 50 mg/kg and 150 mg/kg prochloraz group, respectively,
gave birth. The pups were counted, sexed and checked for anomalies. Pups found
dead were investigated macroscopically for alterations when possible. The
expected day of delivery, GD 22, was designated PND 0 for the pups.
Caesarian sections GD 21
Eight dams were randomly selected from each group for Caesarian section at
GD21. From the control, 50 mg/kg and 150 mg/kg prochloraz group,
respectively, 6, 7 and 5 dams were pregnant. The dams were weighed and
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decapitated after CO2/O2 anesthesia, uterus was taken out, and the number of
live fetuses, resorbtions and implantations was registered. Location in uterus,
sex, nipples and any anomalies were recorded. Blood was taken from the trunk
of all fetuses immediately after decapitation in heparin-coated vials for hormone
analysis, and samples were pooled from each litter for both males and females.
From each litter, one testis was taken for determination of testosterone (stored in
−80 °C freezer until analysis) and one for histopathology (fixed in Bouin's
fixative). Paired testes and adrenals were taken from litters with two or more
males and stored in RNAlater (Qiagen, Crawly, UK) for gene expression
analyses. When there were more than two males in a litter, one testis was fixed in
formalin for histopathology and immunohistochemistry, while the other testis
was analyzed for progesterone. In litters with additional males, testes were taken
and ex vivo testosterone production was determined (processed immediately).
Anogenital distance and nipple retention
Anogenital distance (AGD) was measured in the offspring at birth using a
stereomicroscope. The analysis of AGD was performed by dividing the AGD
with the cubic root of the pup body weight.
On PND 13, the pups were examined for the presence of areolas/nipples,
described as a dark focal area (with or without a nipple bud) located where
nipples are normally present in female offspring. The pups' body weights were
measured at both time points.
Section of pups PND 16
Body weights of all male pups were recorded, and they underwent a
thorough autopsy at PND 16. The following organs were excised and weighed:
liver, kidneys, adrenals, testes, epididymides, seminal vesicles, ventral prostate,
bulbourethral glands and levator ani/bulbocavernosus muscle. Additionally, the
thyroids were excised but not weighed (n = 5 to 8 males per age group per dose
group).
For each litter at PND 16, the right or left testes were alternately fixed in
Bouin's fixative, while the other was frozen for analysis of testosterone levels.
From litters with two or more males, paired testes, adrenals and liver were
weighed and stored in RNAlater for gene expression analyses. When litters had
three or more males, one testis was fixed in formalin, and one was frozen for
analysis of progesterone levels. The thyroid, adrenals, epididymides, seminal
vesicles and ventral prostate were fixed in formalin, and all fixed organs were
embedded in paraffin and examined by light microscopy after staining with
hematoxylin and eosin. Testes taken for determination of hormone levels were
stored in −80 °C freezer until analysis.
In a supplementary in vivo study with similar animals, exposure period and
other experimental conditions, 6, 7 and 8 pregnantWistar rats, respectively, were
exposed to 0, 50 and 100 mg/kg prochloraz. The ventral prostates from PND 16
males were weighed and stored in RNAlater for gene expression analyses.
Investigation of male external genitalia
The external genitalia were inspected at PND 16 in all males from all litters.
The changes were scored on a scale from 1 to 4 in order to investigate whether
male external genitals were feminized. The following criteria were used: Score
1: No effect. Normal genital tubercle, the urethral opening, is found at the tip of
the genital tubercle, and the preputial skin is intact. In the perineal area, thick fur
extends caudally from the base of the genital tubercle half the distance to the
anus. A furless area circumscribes the anus. Score 2: Mild dysgenesis of the
external genitalia: a small cavity on the inferior side of the genital tubercle and a
minor cleft in the preputial opening are observed, estimated 0.5–1.4 on an
arbitrary scale. The furless area around anus expands towards the base of the
genital tubercle, but thick fur is still present at the base of the genital tubercle.
Score 3: Moderate dysgenesis of the external genitalia: the preputial cleft is
larger, estimated 1.5–2.4 on an arbitrary scale. The urethral opening is situated
halfway down the inferior side of the genital tubercle (hypospadia). Partly
furless or thin fur in the perineal area range from the base of the genital tubercle
and caudally to the furless area circumscribing the anus. Score 4: Severe
dysgenesis of the external genitalia: The preputial cleft is large, estimated 2.5–
3.5 on an arbitrary scale. The urethral opening is situated more than halfway
from the tip to the base. At the base of the genital tubercle, a groove extending
laterally is observed (similar to control females at PND 16). Perineal area is
totally furless.
Immunohistochemistry of fetal testes
Immunohistochemical staining was performed on four to five 4 μm sections
from each GD 21 testis kept in Bouin's fixative from the control group and the
150 mg/kg prochloraz group. Following microwave pretreatment for 2 × 5 min
in either citrate or T-EG buffer, sections were blocked for endogenous
peroxidase activity in 3% H2O2 in PBS and blocked in 1% bovine serum
albumin in PBS. Sections were incubated overnight at 4 °C with rabbit
polyclonal antibodies against StAR (PA1-560, Affinity Bioreagents, Golden,
CO), P450scc (AB 1244, Chemicon, Temecula, CA), 17β-hydroxysteroid
dehydrogenase (17β-HSD) type 10 (Biotrend Chemicals, Köln, Germany), 3β-
HSD or p450c17 (both antibodies were kind gifts from Dr. I. Mason, Edinburgh,
UK). Sections were then incubated for 30 min with anti-rabbit EnVision+
(DAKO, Glostrup, Denmark), stained in DAB+ (DAKO, Glostrup, Denmark)
and counterstained in Meyer's hematoxylin. Negative controls were fetal control
testis incubated with blocking serum instead of primary antibody.
Hormone analysis
Testosterone, progesterone, LH and thyroid hormones (T3, T4 and TSH)
were analyzed in rat serum or testes at GD 21 and/or PND 16. Steroid hormones
were extracted on IST Isolute SPE columns from the serum as previously
described (Vinggaard et al., 2002; Birkhoj et al., 2004), and these hormones
together with the thyroid hormones triiodothyronine (T3) and thyroxine (T4)
were measured by time-resolved fluorescence using commercially available FIA
kits (PerkinElmer Life Sciences, Turku, Finland). LH was analyzed at Turku
University, Finland, using an immunofluorimetric assay as described by
Haavisto et al. (1993). Rat TSH was determined by an enzyme immunoassay
BioTrak from Amersham Biosciences (Uppsala, Sweden). Inhibin B was
measured using an Inhibin B ELISA assay (Oxford Bio-Innovation, Oxford,
UK) recognizing both the βB subunit and the α-subunit of inhibin B. Steroid
hormones were analyzed in testes after extraction with diethyl ether.
Decapsulated testes from neonatal and adult rats were placed in vials containing
100 and 500 μl water, extracted with 0.5 and 2.5 ml diethyl ether, respectively,
and the procedure was repeated. Following evaporation, vials were added 100
and 500 μl diluent 1 (zero calibrator from PerkinElmer Life Sciences, Turku,
Finland), respectively, and samples were vortexed and incubated for 10 min at
45 °C before analysis.
Ex vivo steroid production at GD 21 was determined as previously described
(Vinggaard et al., 2005) except that a 5 h incubation was performed.
Gene expression levels determined by real-time RT-PCR
Tissues stored in RNAlater (paired testes, adrenals and ventral prostate)
were homogenized, and total RNA was isolated using RNeasy-mini kit and
RNase-Free DNase set from Qiagen (VWR International ApS, Albertslund,
Denmark). Total RNA was eluted with 40 μl RNase-free water. RNA
concentration and quality were determined using a Nanodrop spectrophotometer
(Nanodrop Technologies, Wilmington, DE). cDNA was synthesized from 1 μg
total RNA using the Omniscript Reverse Transcription kit with T16 oligos and
an 18S rRNA primer. Samples were incubated at 37 °C for 60 min followed by
60 °C for 10 min on PTC-200 Peltier Thermal Cycler (MJ Research Inc.,
Watertown, MA, USA), and the final cDNA product was stored at −20 °C
before quantification on the ABI Prism 7900 HT Sequence Detection System
(Applied Biosystems, Applera, Stockholm, Sweden) by standard TaqMan
technology. Expression levels of the following genes were quantified in the
testis and adrenals: scavenger receptor class B-1 (SRB1), steroidogenic acute
regulatory protein (StAR), P450 side-chain cleavage enzyme (P450scc) and
17α-hydroxylase/17,20-lyase (P450c17). The androgen receptor (AR) expres-
sion levels were quantified in the epididymides. In the prostates, expression
levels were quantified for prostatic binding protein C3 (PBP C3), ornithine
decarboxylase (ODC), testosterone-repressed prostate message 2 (TRPM-2),
insulin-like growth factor I (IGF-I), complement component 3 (Compl C3) and
162 P. Laier et al. / Toxicology and Applied Pharmacology 213 (2006) 160–171
androgen receptor (AR). For each sample, 2 μl cDNA (2.5 ng/μl) was amplified
under universal thermal cycling parameters (Applied Biosystems) using
TaqMan Universal PCR Master Mix (Applied Biosystems) in a total reaction
volume of 20 μl. Three separate amplifications were performed for each gene,
and, when intra-assay variation was above 10%, additional amplifications were
performed. All genes were quantified from standard curves, and expression
levels of each target gene were normalized to the expression level of the
housekeeping gene 18S rRNA.
Expression of Desert hedgehog (Dhh), Patched 1 (Ptc-1), Insl-3 and SF-1 in
the testis was measured separately by quantitative PCR using QuantiTect SYBR-
Green PCR Kit (Qiagen) according to the manufacturer's instructions by using
the DNA Engine Opticon system (MJ Research, Inc., Waltham, MA) with
continuous fluorescence detection and normalized to the level of the
housekeeping gene ribosomal protein S26 (S26).
Sequences for each primer set are listed in Table 1.
In vitro effects in the mouse Leydig tumor cell line mLTC-1
mLTC-1 cells (ATCC-CRL-2005) established from M548OP transplantable
Leydig cell tumors carried in C57BL/6 mice were grown in 24-well culture
plates (Costar, Corning, NY, USA) using the method previously described by
Nikula et al. (1999). The cells were plated at a density of 1 × 105 cells/well, and
prochloraz dissolved in DMSOwas added to the cells in duplicates at 6.25, 12.5,
25, 50 and 100 μM. The incubation medium of control cells contained the same
amount of DMSO (0.1%) as exposed cells. After 48 h of pre-incubation, the cells
were washed with 2 ml PBS and stimulated with 0.135 IU/ml hCG (6500 IU/
mg) kindly provided by The NIDDK's National Hormone and Pituitary Program
and Dr. A.F. Parlow. After 3 h of incubation, the stimulation medium was
removed and stored at −20 °C until assayed for progesterone as described for the
plasma samples. In parallel to the hCG-stimulated cells, other cells were added a
resazurin solution to test for cytotoxicity as described (Laier et al., 2003).
Medium from these wells (100 μl) was transferred to black microtiter plates
(Costar, Corning, NY, USA) before fluorescence was measured.
In vitro effects in human adrenocortical carcinoma cell line H295R
H295R cells (ATCC, CRL-2128) established from the pluripotent human
adrenocortical carcinoma cell line were grown in 24-well culture plates
(Costar, Corning, NY, USA) containing 1 ml DMEM/F12 medium
(GibcoBRL Life Technologies, Paisley, UK) supplemented with 2.0% Nu-
serum (BD Sciences Denmark), 1% ITS + premix (containing 6.25 μg/ml
insulin, 6.25 μg/ml transferrin, 6.25 ng/ml selenium 1.25 mg/ml BSA and
5.35 μg/ml linoic acid; BD Sciences, Denmark) and supplemented with 100
U/ml penicillin, 100 mg/ml streptomycin and 250 ng/ml amphotericin B
(Fungizone) at 37 °C with a humidified atmosphere of 5% CO2/air. The cells
were plated at a density of 2 × 105 cells/well and allowed to settle 1 day
(approximately 24 h). Culture medium was removed, and new medium
containing prochloraz dissolved in DMSO was added to the cells in triplicates
at 0, 0.01, 0.03, 0.1, 0.3, 1 and 3 μM. The medium of control cells contained
the same amount of DMSO (0.1%) as exposed cells. After 48 h of incubation,
the medium was removed and stored at −20 °C until assayed for progesterone
and testosterone as described for the plasma samples. After exposure, the cells
were incubated with a resazurin solution to test for cytotoxicity towards the
H295R cells as described (Laier et al., 2003). Medium from these wells (200
μl) was transferred to black microtiter plates (Costar, Corning, NY, USA)
before fluorescence was measured.
Statistical analyses
Statistical evaluation of pregnancy data and litter data. The litter was
generally considered the statistical unit, and the alpha level was 0.05. The results
were analyzed by analyses of variance (ANOVA) using the SYSTAT PC-version
software package (Systat, 1990). In order to adjust for litter effects, litter was
included in the analysis of variance as a nested factor.
Statistical evaluation of hormone data. A one-way ANOVA was employed
for all groups and, if significant, followed by the post hoc test Dunnett's test.
Significance was judged at P b 0.05.
Statistical analysis of organ weights and morphological alterations. One to
four males per litter at PND 16 were used in the analysis of terminal body
weight and organ weights. Non-processed and ln-transformed data were
examined for normal distribution and homogeneity of variance. In order to
adjust for litter effects, litter was included in the analysis of variance as an
independent, random and nested factor (proc mixed, SAS version 8, SAS
Institute Inc, Cary, NC, USA). Organ weights were analyzed using body weight
as a covariate. When an overall significant treatment effect was observed, two-
tailed comparison was performed using least square means. In cases where
normal distribution and homogeneity of variance was not obtained, data were
additionally tested with the non-parametric Kruskal–Wallis test. The scoring of
macroscopic lesions of external genitalia was analyzed using Fisher's Exact
Test.
Table 1
Sequences of each primer set used for quantitative real-time PCR
Gene Primer set
18S
rRNA
5′-FAM-ACC GGC GCA AGA CGA ACC AGA G-TAMRA-3′
Forward, 5′-GCC GCT AGA GGT GAA ATT CTT G-3′
Reverse, 5′-GAA AAC ATT CTT GGC AAATGC TT-3′
SRB1 5′-FAM-AAA GCATTT CTC CTG GCT GCG CAG-TAMRA-3′
Forward, 5′-TCT GGT GCC CAT CAT TTA CCA-3′
Reverse, 5′-AGC CCT TTT TAC TAC CAC TCC AAA-3′
StAR 5′-FAM-CTG ACT CCT CTA ACT CCT GTC TGC CTA CAT
GGT-TAMRA-3′
Forward, 5′-CCC TTG TTT GAA AAG GTC AAG TG-3′
Reverse, 5′-TGA AAC GGG AAT GCT GTA GCT-3′
P450scc 5′-FAM-CCT TTA TGA AAT GGC ACA CAA CTT GAA GGT
ACA-TAMRA-3′
Forward, 5′-ACG ACC TCC ATG ACT CTG CAAT-3′
Reverse, 5′-CTT CAG CCC GCA GCATCT-3′
P450c17 5′-FAM-CGT CAA CCA TGG GAA TAT GTC CAC CAG A-
TAMRA-3′
Forward, 5′-GCC ACG GGC GAC AGA A-3′
Reverse, 5′-CCA AGC CTT TGT TGG GAA AA-3′
AR 5′-FAM-TCG CGATTC TGG TAT GCT GCT GC-3′
Forward, 5′-GAC ACT TGA GAT CCC GTC CT-3′
Reverse, 5′-GAG CGA GCG GAA AGT TGT AG-3′
PBP C3 5′-FAM-TCATCTAGA ATA CTG CAG CCA GAA CCA CTG G-
TAMRA-3′
Forward, 5′-CCA TCC CCA TTT GCT GCT AT-3′
Reverse, 5′-AGT CAC AGT TGA GTT AAT TGT ACC TCT AAT
AAC-3′
ODC 5′-FAM-ACT CAC TGC TGT AAC ACA CAG CCT GTG CA-3′
Forward, 5′-AAT GTG TGC AAG TAT CCC TTA CAG AA-3′
Reverse, 5′-CAC AGC TTT GTA TCATCC ACA TCT C-3′
TRPM-
2
5′-FAM-AGT TTC TGA ACC AGA GCT CAC CCT TCT ACT
TCT G-3′
Forward, 5′-CTG GTT GGT CGC CAG CTA GA-3′
Reverse, 5′-ATG CGG TCC CCG TTC AT-3′
IGF-1 5′-FAM-CAA CAC TCA TCC ACA ATG CCC GTC T-3′
Forward, 5′-GAC CAA GGG GCT TTT ACT TC-3′
Reverse, 5′-GCA GCG GAC ACA GTA CAT CT-3′
Compl
C3
5′-FAM-CGT AGT CCA CTC CAG GCT CAC AAG-3′
Forward, 5′-CAG CCT GAATGA ACG ACT AGA CA-3′
Reverse, 5′-AAA ATC ATC CGA CAG CTC TAT CG-3′
S26 Forward, 5′-AAGGAGAAACAACGGTCGTG-3′
Reverse, 5′-GCAGGTCTGAATCGTGGTG-3′
Dhh Forward, 5′-AAGCAACTTGTGCCTCTGCT-3′
Reverse, 5′-TCGTCCCAACCTTCAGTCAC-3′
Ptc-1 Forward, 5′-TACGTGGAGGTGGTTCATCA-3′
Reverse, 5′-AACACCAAGGGCAAGAAATG-3′
SF-1 Forward, 5′-GTCTGTCTCAAGTTCCTCATCCTC-3′
Reverse, 5′-CTCGTTGCCCAAATGCTTAT-3′
INSL-3 Forward, 5′-ACGCAGCCTGTGGACACC-3′
Reverse, 5′-CAATCCGGGGGTGTTTCATT-3′
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Results
Pregnancy and litter data
Prochloraz showed no effects on maternal weight during or
after birth (Table 2). Maternal weight gain from GD 7 to GD 21
was significantly decreased at 150 mg/kg, but the maternal
weight gain from GD 7 to PND 1 was not significantly affected
by prochloraz. Litter sizes, birth weight of male and female
offspring and sex ratios were unaffected. No effects were
observed on pregnancy length, postnatal death or postimplanta-
tion–perinatal loss.
Anogenital distance and nipple retention
Prochloraz affected dose-dependently the anogenital dis-
tance in both male and female offspring (Table 2, Fig. 1A). At
both 50 and 150 mg/kg, the male pups had significantly reduced
anogenital distance compared to controls, whereas female pups
had an increased anogenital distance compared to controls.
Furthermore, both doses of prochloraz resulted in an increased
number of nipples in male pups at PND 13 (Fig. 1B).
Hormone levels
Male fetuses from GD21 were sectioned, and levels of
testicular testosterone and progesterone together with plasma
testosterone, progesterone and luteinizing hormone (LH) were
analyzed (Fig. 2). Testicular levels of testosterone were
significantly decreased at both dose levels of prochloraz,
whereas levels of progesterone were significantly increased.
Data on plasma pools from each exposure group showed a
similar trend for both hormones. Testicular testosterone
production ex vivo was examined at GD 21 as well, and, in
agreement with the other data, a marked dose-dependent
reduction was observed after both the low and the high dose
prochloraz.
There was a tendency towards slightly increased LH plasma
levels after prochloraz exposure, but, as the amounts of fetal
blood were limited and only one pooled sample per group was
available, it was not possible to test the hypothesis by doing
statistical analysis. The abovementioned hormones were
analyzed in serum and testes from male pups at PND 16 as
well. A tendency towards reversed effects compared to the fetal
effects was observed, i.e. increased levels of testicular and
plasma testosterone and reduced levels of progesterone together
with decreased LH plasma levels for the prochloraz-exposed
pups (Table 3). The decrease in progesterone levels in males
turned out to be statistically significant at 50 mg/kg.
Thyroid hormone levels were measured in blood plasma of
PND 16 males and females, and a significantly reduced T4 level
in prochloraz-exposed male pups (150 mg/kg) was observed
(Table 3). However, T3 and TSH levels were not affected by
prochloraz exposure for either sex.
Dysgenesis of external genitalia
Mild dysgenesis of the external genitalia was observed in
males exposed to 50 mg/kg (mean score 1.25) and 150 mg/kg
(mean score 1.28) prochloraz. In the controls, none of the males
had scores≥2 (mean score 1.0). In the rats exposed to 50 mg/kg
prochloraz, 25% of the males had scores ≥2, and 14% of the
males had scores ≥2 in the group exposed to 150 mg/kg
prochloraz. For both prochloraz groups, these effects were
statistically significantly different from controls (Fisher's Exact
Test).
Organ weight and histopathology
Body and organ weights of PND 16 male and female rat
offspring are shown in Table 4. The number of pups (n)
included for each group in the experiment varied as body
weights and some organs were weighed for more than one pup
per litter. A significantly diminished weight of both seminal
vesicles and bulbourethral glands in male pups was observed at
both doses. Female reproductive organs were unaffected. No
dose-related histopathological effects were observed in any of
the examined organs in males from GD 21 or PND 16.
Immunohistochemistry of fetal testes
Leydig cell cytoplasm was positively stained for P450c17,
17β-HSD (type 10), StAR, P450scc and 3β-HSD at GD 21. AR
immunostaining was seen in the nuclei of Leydig cells and
peritubular cells at GD 21. The intensity of P450c17
immunostaining was clearly increased in Leydig cells of
prochloraz-exposed animals compared to controls (Fig. 3).
Table 2
Pregnancy and litter data
Control Prochloraz 50
mg/kg
Prochloraz 150
mg/kg
Number of litters 13 8 6
Maternal weight gain GD7 to
GD21 (g)
93.2 ± 9.4 95.4 ± 12.9 77.8 ± 12.6 a
Maternal weight after birth (g) 236.7 ± 15.1 234.1 ± 13.1 237.8 ± 12.8
Maternal weight gain GD7 to
after birth (g)
24.3 ± 9.4 18.6 ± 4.5 14.8 ± 11.2
Pregnancy length (days) 22.5 ± 0.5 22.9 ± 0.6 22.8 ± 0.8
Birth weight, (g) — males 6.3 ± 0.4 6.4 ± 0.4 6.5 ± 0.5
Birth weight, (g) — females 6.0 ± 0.3 6.1 ± 0.2 6.2 ± 0.5
Male pups (%) 46 ± 14 41 ± 9 44 ± 13
Litter size at birth (live pups) 10.5 ± 1.5 11.0 ± 2.4 8.5 ± 3.5
Postnatal death, mean 0.23 ± 0.60 0.13 ± 0.35 0.17 ± 0.41
Postimplantation–perinatal
loss (%) b
6.2 ± 6.8 14.1 ± 16.3 23.5 ± 27.1
AGD in males, at birth
(mm/cubic root of bw)
11.6 ± 0.4 10.9 ± 0.6 a 10.2 ± 0.8 a
AGD in females, at birth
(mm/cubic root of bw)
6.1 ± 0.21 6.3 ± 0.48 a 6.7 ± 0.40 a
Body weight, PND 13
(g)—males
28.2 ± 3.5 26.1 ± 3.9 26.9 ± 3.5
Body weight, PND 13
(g)—females
27.8 ± 3.7 25.8 ± 3.9 26.2 ± 3.6
Data represent means ± SD.
a P b 0.05 compared to control group.
b (no. of implantations − live pups at PND 6) / no. of implantations.
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Fig. 1. (A) Effects on anogenital distance in male and female rat pups (PND 1) caused by perinatal exposure to 50 and 150 mg/kg prochloraz. AGD is shown as distance
per cubic root of body weight. (B) Effects on nipple retention in prochloraz-exposed males (PND 13). The data represent the mean number ± SD of areolas in male pups
for n = 13, 8 and 6 for controls, 50 and 150 mg/kg, respectively. *P b 0.05.
Fig. 2. Following in utero exposure to 50 and 150 mg/kg prochloraz, testicular levels of testosterone and progesterone (A) were measured in fetal rat testis at GD 21.
Data are represented as litter mean ± SD for n = 6, 7 and 5 for controls, 50 and 150 mg/kg, respectively. Testicular levels of testosterone and progesterone were
measured in fetal rat testis after 5 h of incubation in cell culture medium and represented as litter mean ± SD for n = 6, 7 and 5 for controls, 50 and 150 mg/kg,
respectively (B). The data for plasma levels of testosterone and progesterone in male and female offspring (C) at GD21 represent the mean levels of total pooled
samples (one pool for each group). Plasma levels of luteinizing hormone in male and female offspring at GD21 (D) are represented as the mean levels in total pooled
samples (one pool for each group). *P b 0.05. ND: not determined.
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The intensity of immunostaining for 17β-HSD (type 10) was
reduced in prochloraz-exposed animals compared to controls
(Fig. 4). No changes were observed in the intensity or
localization of immunostaining for StAR, P450scc, 3βHSD or
AR.
Gene expression levels
Expression levels of genes involved in androgen biosyn-
thesis and signaling and/or Leydig cell function were
determined in paired testes and adrenals in male fetuses.
Prochloraz had no effect on the expression levels of the genes
SRB1, StAR, P450scc and P450c17 in testis and AR in
epididymides when compared to the housekeeping gene 18S
at GD 21 or at PND 16 (Table 5). There was a clear tendency
towards a dose-dependent up-regulation of P450c17 in fetal
adrenals (GD 21) following exposure to 50 and 150 mg/kg
prochloraz (Fig. 5). In PND 16, male pups expression of
androgen-regulated genes was investigated in ventral prostates
(Fig. 6). It was found that ODC, PBP C3 and IGF-1 mRNAs
were significantly reduced in the prostates after exposure to
50 and 100 mg/kg prochloraz. In contrast, the expression
levels of TRPM-2, Compl C3 and AR mRNAs were
unaffected.
In vitro effects on steroidogenesis
In order to look for a suitable in vitro model that reliably
detects compounds that affect steroidogenesis, a mouse Leydig
cell line (mLTC-1) and a human adrenocortical carcinoma cell
line (H295R) were investigated. In control and hCG-induced
mLTC-1 cells, prochloraz caused a dose-dependent decrease of
progesterone production (Fig. 7). Preliminary data indicate that
this effect was seen irrespective of using cholera toxin, 8-
bromo-cAMP or forskolin for stimulation of steroidogenesis
(data not shown), indicating that the effect manifests itself at a
level at or after protein kinase A activation. All stimulants
caused elevated cAMP levels and consequently protein kinase
A activation (data not shown).
H295R cells incubated with prochloraz showed a markedly
dose-dependent reduction of testosterone production compared
to control (Fig. 8). Testosterone levels were reduced by 50%
with the lowest prochloraz concentration of 0.01 μM, and the
two highest concentrations (1 and 3 μM) almost shut down the
testosterone production. Progesterone levels were significantly
increased after incubation with 0.1, 0.3, 1 and 3 μM prochloraz.
Table 3
Hormones measured at PND 16 in male and female pups after perinatal
prochloraz exposure
Testis Control 50 mg/kg 150 mg/kg
Testosterone, ng/testis 0.30 ± 0.17 0.33 ± 0.28 0.54 ± 0.67
Progesterone, ng/testis 57.1 ± 23.2 47.7 ± 14.5 50.1 ± 41.0
Plasma Sex Control 50 mg/kg 150 mg/kg
Testosterone, pg/ml M 67.7 ± 28.1 72.7 ± 74.0 123 ± 68.9
F 56.3 ± 41.2 51.0 ± 26.9 32.3 ± 26.2
Progesterone, ng/ml M 6.54 ± 1.85 3.77 ± 1.54 ⁎ 3.82 ± 1.51
F 5.15 ± 1.84 3.98 ± 3.25 2.59 ± 1.24
Luteinizing hormone
(LH), pg/ml
M 386 ± 382 225 ± 178 237 ± 207
F 1605 ± 923 1257 ± 1413 2232 ± 889
Inhibin, nmol/l M 0.88 ± 0.31 1.24 ± 0.47 1.03 ± 0.43
F 0.78 ± 0.57 0.57 ± 0.41 0.45 ± 0.36
Triiodothyronine (T3), ng/ml M 2.09 ± 0.13 2.13 ± 0.43 1.94 ± 0.11
F 1.91 ± 0.23 1.91 ± 0.19 1.87 ± 0.20
Thyroxine (T4), ng/ml M 127 ± 19.7 134 ± 27.8 97.3 ± 1.8*
F 98.6 ± 12.7 91.4 ± 5.0 88.1 ± 11.1
Thyroid stimulating hormone
(TSH), nmol/l
M 44.4 ± 20.9 47.8 ± 17.7 52.1 ± 25.7
F 28.0 ± 23.0 21.4 ± 2.10 50.3 ± 13.0
Data represent means ± SD.
One-way ANOVA.
⁎ Statistical significance compared to controls by Dunnett's t test (P b 0.05).
Table 4
Body and organ weights for prochloraz-exposed male and female pups at PND 16
n Control n Prochloraz 50 mg/kg n Prochloraz 150 mg/kg
Males
Body weights (g) 35 35.2 ± 4.3 25 32.2 ± 4.3 17 32.9 ± 4.9
Liver (g) 25 0.89 ± 0.16 15 0.85 ± 0.17 12 0.91 ± 0.19
Paired kidneys (g) 14 0.347 ± 0.053 8 0.321 ± 0.059 6 0.333 ± 0.067
Paired adrenals (mg) 25 10.5 ± 1.6 15 10.5 ± 1.5 12 10.5 ± 1.9
Right testis (mg) 35 66.0 ± 8.7 25 64.8 ± 8.7 17 61.9 ± 11
Left testis (mg) 35 66.4 ± 7.3 25 65.0 ± 8.2 17 62.6 ± 9.7
Paired epididymis (mg) 25 27.0 ± 5.3 14 25.1 ± 4.3 12 24.8 ± 4.5
Seminal vesicles (mg) 13 12.0 ± 3.1 8 8.78 ± 2.3 ⁎ 6 9.55 ± 1.5
Ventral prostate (mg) 25 16.5 ± 3.1 16 14.7 ± 3.5 12 13.0 ± 3.9
M. levator ani/bulbocavernosus (mg) 13 27.0 ± 6.3 8 22.2 ± 2.4 6 23.2 ± 1.9
Bulbourethral glands (mg) 13 2.16 ± 0.63 8 1.35 ± 0.47* 6 0.790 ± 0.59*
Females
Body weights (g) 26 34.4 ± 4.3 9 31.5 ± 4.6 11 32.6 ± 4.6
Ovaries (mg) 26 6.09 ± 0.89 9 5.81 ± 1.4 11 6.33 ± 1.7
Uterus (mg) 26 24.9 ± 2.6 9 22.5 ± 2.9 11 23.8 ± 3.9
Data represent means ± SD.
One-way ANCOVA (body weight as the covariate).
⁎ Statistical significance compared to controls (P b 0.05).
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The formation of estradiol was significantly reduced at 0.1 μM
and concentrations above showing a dose-dependently correla-
tion. Visual inspection and experiments to measure cytotoxicity
by the resazurin method showed no cytotoxicity of prochloraz
up to 3 μM.
Discussion
In agreement with previous studies, prochloraz was found to
feminize the male rat offspring by significantly reducing the
anogenital distance after gestational exposure to 50 and 150 mg/
kg. This feminization was further confirmed by the observation
of nipple retention in the male pups at PND 13. These results are
in agreement with recent results demonstrating a dose-
dependent reduction of AGD in male offspring after gestational
exposure to 125 and 250 mg/kg prochloraz (Noriega et al.,
2005). However, this effect was found only for unadjusted
AGDs, whereas significance was lost after adjustment for body
weight. In this study, the AGD was corrected by the cubic root
of the body weight, and statistical significance was obtained at
the low dose of 50 mg/kg. This dose may be close to NOEL as
Vinggaard et al. (2005) did not observe any effects on AGD
with 30 mg/kg prochloraz. The increased anogenital distance
observed in female pups may indicate an androgenic potential
of prochloraz in females. Initial in vitro studies of prochloraz
did not indicate any androgen activity mediated via AR, but the
disrupted fetal steroidogenesis causing high progesterone levels
may be the causal factor of this virilization of the females
(http://progesterone.com/provera.html).
Previously, perinatal exposure to 30 mg/kg prochloraz has
been shown to significantly affect nipple retention (Vinggaard
et al., 2005), and dose dependency has been demonstrated by
Noriega et al. (2005), who found a LOEL at a dose of 125 mg/
kg. As the exposure period in the latter study was GD 14–18
compared to our GD 7-PND 17, it suggests that the underlying
causal events for the nipple retention observed at PND 13 has
Fig. 4. (A) Immunohistochemical staining of 17β-hydroxysteroid dehydrogenase (17β-HSD) (type 10) in fetal control testis at GD 21. (B) Immunohistochemical
staining of 17β-hydroxysteroid dehydrogenase (17β-HSD) (type 10) in fetal testis at GD 21 after exposure to 150 mg/kg prochloraz.
Fig. 3. (A1–2) Immunohistochemical staining of 17α-hydroxylase/17,20-lyase in fetal control testis at GD 21. (B1–2) Immunohistochemical staining of 17α-
hydroxylase/17,20-lyase in fetal testis at GD 21 after exposure to 150 mg/kg prochloraz.
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taken place during gestation but that exposure during lactation
may result in a lower LOEL of this parameter.
The decreased maternal weight gain during gestation caused
by 150 mg/kg prochloraz suggests that prochloraz induced
maternal toxicity or decreased weight of the uterine content, i.e.
number and/or weight of fetuses or placentas or both. Neither
the maternal weight gain from GD 7 to the first day after birth
(PND 1) nor the number of offspring per litter was significantly
affected by prochloraz, but both values seem lower at 150 mg/
kg compared to control values. Therefore, the effect on maternal
weight gain during gestation most probably reflects both slight
maternal toxicity and slightly decreased litter size. But, overall,
no pronounced maternal or fetal toxicity was evident at the
selected doses.
The antiandrogenic potential of prochloraz has previously
been demonstrated as it antagonized the androgen receptor in
vitro (Andersen et al., 2002) and reduced weights of
reproductive organs in the Hershberger assay (Vinggaard et
al., 2002). These results classify prochloraz as an antiandrogen
belonging to the same class of antiandrogens as vinclozolin,
procymidone and p,p′-DDE, which primarily are considered to
exert dihydrotestosterone (DHT)-dependent effects or affect
DHT-dependent tissues (AGD, nipple retention, ventral prostate
size, hypospadias) (Gray et al., 1999a). The decreased weight of
the bulbourethral glands as well as the slightly feminized
external genitals observed in male pups at PND 16 further
supports that prochloraz affects DHT-dependent tissue. How-
ever, the significant effect on seminal vesicle demonstrates that
prochloraz also affects reproductive tissue that is considered
mainly testosterone-dependent, thus resembling the effects of
the phthalates (Gray et al., 1999a).
In male fetuses, testosterone levels were significantly
decreased in the testis, while progesterone levels were
increased. Concomitantly, fetal plasma levels of testosterone
and progesterone were reduced and increased, respectively.
Similar results have been observed previously by Noriega et al.
(2005) and Vinggaard et al. (2005) and advocate for inhibition
of the androgen biosynthesis in the Leydig cells at steps
subsequent to progesterone formation at the level of 17α-
hydroxylase/17,20-lyase, 3β-HSD and/or 17β-HSD. This was
supported by the markedly reduced ex vivo testosterone
production in fetal testis at 150 mg/kg (10-fold). Previously, a
dose of 30 mg/kg given in utero did not cause any significant
effect on ex vivo testosterone formation (Vinggaard et al.,
2005), but prenatal exposure to 250 mg/kg prochloraz given
from GD 14–18 was shown to reduce fetal testosterone
production at GD 18 (Wilson et al., 2004). Circulating levels
of LH in fetal blood plasma at GD 21 tended to be increased in
prochloraz-exposed male pups, indicating that the pituitary–
Leydig cell axis was intact and effective, giving a negative
feedback at this time point. The effects on the testicular and
plasma hormone levels observed at GD 21 in the present study
were reversible as these prochloraz-induced effects were absent
at PND 16. In contrast a tendency towards a rebound effect on
testosterone, progesterone and LH was seen.
Prochloraz has a well-documented effect on aromatase
activity and the consequent metabolism of testosterone to
estradiol (Andersen et al., 2002; Sanderson et al., 2002), but,
since preliminary data showed no effect on testicular estradiol
levels in prochloraz-exposed male fetuses, this mechanism of
action probably plays no major role in the fetal testes.
We demonstrated for the first time that the levels of the
thyroid hormone T4 in plasma at PND 16 were significantly
decreased after exposure to prochloraz. A previous study
showed that prochloraz reduced both T4 and TSH levels in
castrated, testosterone-treated rats, indicating a direct effect at
the CNS level (Vinggaard et al., 2002). In this study, TSH
levels were not affected by prochloraz, but this discrepancy
may reflect different responsiveness of castrated versus intact
rats.
In general, no visible histopathological effects in the testes
were found, but changes in the expression of two enzymes
involved in synthesis or metabolism of steroids were detected
by immunohistochemistry. In fetal testis, prochloraz induced an
increased expression of the P450c17 enzyme, which is
responsible for the hydroxylation of progesterone in the 17α-
position. This increased expression may reflect that the enzyme
activity of P450c17 is inhibited which may further explain the
accumulation of progesterone and marked reduction of
Table 5
Overview of effects of prochloraz on fetal steroidogenesis at gene and/or protein
level
Proteins involved in Leydig
cell function
Real-time RT-PCR
(mRNA level)
Immunohistochemistry
SR-B1 ↔
StAR ↔ ↔
CYP450scc ↔ ↔
3β-HSD ↔
17α-hydroxylase/17,
20-lyase
↔ ↑
17β-HSD (type 10) ↓
Dessert hedgehog (Dhh) ↔
Ptc-1 (Dhh receptor) ↔
SF-1 ↔
INSL-3 ↔
AR ↔ ↔
↔ unaffected, ↑ increased or ↓ decreased by perinatal prochloraz exposure.
Fig. 5. Adrenal gene expression of cytochrome P450c17 determined by real-
time RT-PCR in male fetal rats (GD 21) after exposure of 50 and 150 mg/kg
prochloraz. The data represent the relative values of the mRNA levels of
P450c17 and the housekeeping gene 18S.
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testosterone observed in male fetuses. Previous in vitro and in
vivo studies of imidazole drugs such as ketoconazole suggest
that the predominant effect on human adrenal and testicular
steroidogenesis involves inhibition of P450c17 by direct
interaction with the cytochrome P-450 component of the
enzymes (Ayub and Levell, 1987, 1988). This is in agreement
with the fact that we find an interaction at the protein level and
not at mRNA level in the fetal testis. However, in the adrenals,
an increased expression of P450c17 mRNAwas seen, indicating
that also steroidogenesis in adrenals was affected via a
mechanism that differs from the one in the testes. Interestingly,
current literature suggests that rat adrenals lack the expression
of P450c17 (Pelletier et al., 2001). However, mRNA levels were
clearly detectable and were significantly above the level of
quantification for the analysis, although a general low
expression was seen.
Concomitantly, immunohistochemical expression of 17β-
HSD (type 10) in fetal testis was reduced by prochloraz.
17β-HSD (type 10) is a major product of both fetal and
adult-type Leydig cells in rodents and seems preferentially
to convert 3α-androstanediol into dihydrotestosterone and
estradiol into estrone. Thus, perinatal expression of this
enzyme in fetal Leydig cells has been suggested to
contribute to protection of these cells from estrogens and
encourage androgen formation (Ivell et al., 2003; Mindnich
et al., 2004). The reduced protein expression of 17β-HSD
(type 10) may indicate an increased activity of the enzyme
that is induced as a secondary defense mechanism to
protect the testis from the lowered androgen levels caused
by prochloraz.
Although some in vivo effects of prochloraz on steroido-
genesis such as the disturbance in testosterone levels and
reduced weight of seminal vesicles may indicate a similar
mechanism of action as the phthalates, no effects of prochloraz
were observed on mRNA levels of SRB1, StAR or P450scc
responsible for cholesterol trafficking and metabolism as
reported for DBP (Barlow et al., 2003; Thompson et al.,
2004). In male rat fetuses, the decreased testicular steroidogen-
esis caused by DBP has been demonstrated to precede the
repressed transcription of StAR, Scarb1, P450scc and P450c17
and seems to be unique compared to the adrenals in which genes
required for steroidogenesis were unaffected (Thompson et al.,
2005).
The reduced expression levels of the androgen-regulated
genes ODC, PBP C3 and IGF-1 observed in ventral prostate in
PND 16 males after exposure to 50 and 100 mg/kg prochloraz
further support the antiandrogenic effects of prochloraz and may
be secondary to either AR antagonism or inhibition of
testosterone formation. These findings are in agreement with
previous results where expression of ODC and PBP C3 mRNA
was found being reduced in ventral prostates of castrated
testosterone-treated male rats treated with 50–150 mg/kg
prochloraz (Vinggaard et al., 2002). Reduced expression of
the IGF-1 gene has not previously been reported for prochloraz,
but the fungicide fenarimol has been reported to reduce IGF-1
expression levels in a Hershberger assay (Vinggaard et al.,
Fig. 7. In vitro effects of prochloraz on progesterone formation in mouse Leydig
tumor cells (mLTC-1). Black columns represent unstimulated, cells and the gray
bars represent the hCG-stimulated cells. Data represent the mean ± SD for a
representative experiment in triplicate. The statistical analysis has been applied
for the hCG-stimulated cells only. *P b 0.05.
Fig. 6. Expression levels of androgen-regulated genes (ODC, PBP C3, TRPM-2, Compl C3, IGF-1 and AR) determined by real-time RT-PCR in ventral prostate from
male rats (PND 16) after exposure to 50 and 100 mg/kg prochloraz. The data represent the values of the specific mRNA levels relative to the housekeeping gene 18S.
The y axes represent arbitrary units, and therefore mRNA levels cannot be directly compared.
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2005). In general, fenarimol and prochloraz have shown very
similar profiles regarding their effects in the Hershberger assay
(Vinggaard et al., 2005) indicating that prochloraz may also
have the potential to affect IGF-1. Additionally, the absence of
effect on TRPM-2 expression levels found in this study is in
agreement with previous findings for prochloraz and fenarimol
in the Hershberger assay (Vinggaard et al., 2005).
The effect of prochloraz on steroidogenesis was investigated
in murine Leydig tumor cells (mLTC-1) and progesterone was
measured as the endpoint as mLTC-1 cells synthesize
testosterone in very limited amounts compared to androsten-
dione and progesterone. This is suggested to be due to the lack
of isoform Type 3 of 17β-hydroxysteroid dehydrogenase/17-
ketoreductase, which is responsible for the reduction of
androstendione to testosterone (Panesar et al., 2003). Prochloraz
was found to inhibit both basal and hCG-induced progesterone
production in this cell line, the opposite effect on progesterone
of what was seen in male fetuses in vivo. The reason for the
reduced progesterone levels found in mLTC-1 cells is unknown,
but obviously prochloraz affects steroidogenesis at a step before
progesterone in these cells. It may be possible that prochloraz
has more targets of action in the steroidogenic pathway
affecting more than one step. Alternatively, the steroidogenic
pathway in this cell line may deviate in more ways from
physiological Leydig cells than we are aware of. Complemen-
tary investigation of steroidogenic effects of prochloraz was
carried out with the human adrenocortical carcinoma cell line
H295R that is an in vitro model capable of complete
steroidogenesis. The results confirmed the testosterone reduc-
tion and progesterone increase observed in vivo and ex vivo
with prochloraz and further supported that the disruptive effect
of prochloraz on steroidogenesis is primarily mediated through
a direct effect on the steroidogenic cells. Thus, this in vitro
model may be a suitable candidate assay for future screening of
compound-induced effects on steroidogenesis. Measuring
additional metabolites in the androgen biosynthesis pathway
would be advantageous with this in vitro model for better
understanding of the mechanisms of actions of prochloraz.
In conclusion, we have confirmed that prochloraz in
addition to inhibiting AR also affects fetal steroidogenesis in
male rats, suggesting that prochloraz's mechanisms of actions
cannot be compared exclusively with classical antiandrogens
such as AR antagonists or phthalates. Furthermore, an
inhibitory effect on expression of androgen-regulated genes
in ventral prostates and thyroid hormone levels was found in
neonatal males. The result obtained in vivo using hormone,
immunohistochemical and gene expression analyses together
with the in vitro data indicates that the inhibitory effect on
androgen biosynthesis of prochloraz is primarily due to
inhibition of the 17α-hydroxylase/17,20-lyase. In addition, an
effect on androgen metabolism may play a role as the protein
expression of 17β-HSD (type 10) was found being up-
regulated. These results are important for future assessment of
pesticides and other environmental contaminants with anti-
androgen potential.
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Fig. 8. In vitro effects of prochloraz on testosterone, progesterone and estradiol formation in human adrenocortical carcinoma cells (H295R). Data represent the
mean ± SD for a representative experiment in triplicate. *P b 0.05.
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Hormonal and testicular effects of DINP and DEHP in fetal male rats. 
Miniposter at 13th European Testis Workshop, April 24-28, 2004, Dunblane, Scotland, UK.  
 
Diisobutyl phthalate has comparable antiandrogenic effects to Di-n-butyl phthalate in fetal rat testis.  
Poster at 45th Annual meeting of the Society of Toxicology, San Diego, March 5-9, 2006. 
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In vitro study on PPARα and PPARγ transactivation by environmental contaminants  
 
In vivo study on butylparaben, PFOA and rosiglitazone
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Hormonal and testicular effects of DINP and DEHP 
in fetal male rats
Control DINPDEHP
INTRODUCTION: As the plasticizer DEHP (diethylhexyl phthalate) is known to be testis toxic, DINP (diisononyl 
phthalate) has been suggested as a substitution. MATERIALS & METHODS: In this study, 4 groups of 8 pregnant 
Wistar rats were dosed by gavage from gestation day (GD) 7 to 21 with either vehicle, 300 mg DEHP/kg bw/day, 
750 mg DINP/kg bw/day or with a combination of 300 mg DEHP/kg bw/day + 750 mg DINP/kg bw/day. Dams 
were euthanized at GD 21 and testes were removed from male fetuses. Testes were either used for analysis of 
testosterone production, testicular testosterone content or for histopathology. See detailed method describtion in 
Borch et al., 2003.
RESULTS & DISCUSSION: 
Testicular testosterone production 
(A), testicular testosterone 
content (B) and plasma 
testosterone content (C) was 
reduced by DEHP and DINP, and 
there was a tendecy to further 
reductions in the combination 
group. Plasma LH (D) was 
upregulated by DEHP +DINP.
DEHP is more potent than DINP, 
as the effects of DEHP was similar 
to or stronger than the effects of 
DINP, even though the DEHP dose 
was lower than the DINP dose. 
The stronger effect of the 
combination than each compound 
alone points to an additive effect.
Histopathological effects of DEHP 
appear to be more abundant than 
effects of DINP, as listed in the 
table below. Multinucleated germ 
cells were seen in most testes 
from DINP and DEHP groups. 
Leydig cell effects and chords 
with enlarged diameter and many 
germ cells were more abundant 
with DEHP than DINP exposure. 
* Chords with increased diameter 
and many germ cells
Æ Multinuclear germ cells
# Leydig cell clusters
Æ
Æ
*
*
CONCLUSIONS & PESPECTIVES: 
•DINP is less potent in inducing hormonal and testicular effects than DEHP
•Germ cell effects appear to be highly abundant. In the DINP group multinucleated germ cells appear to be an 
”early” effect present in testes without enlarged/ germ cell rich seminiferous chords or apparent Leydig cell effects
•Stronger effects are seen with combined exposure to these two similarly acting compounds. Will combination of 
very low doses of many phthalates and other compounds with similar effects have effects relevant for humans?
Borch J, Ladefoged O, Hass U, Vinggaard AM. Reproductive Toxicology 2003 (doi:10.1016/j.reprotox.2003.10.011)
Data on testicular expression of steroidogenesis genes (P450scc, P450c17, StAR, SRB1) in DEHP+DINP exposed 
rats will be available for presentation at the Testis Workshop in April.
Julie Borch, Majken Dalgaard, Anne Marie Vinggaard, Ole Ladefoged. jubo@dfvf.dk
Danish Institute for Food and Veterinary Research, Mørkhøj Bygade 19, 2860 Søborg, Denmark.
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Multinuclear germ cells 0% 100% 83% 95% 
Enlarged seminiferous chords 
containing many germ cells 
0% 68% 22% 76% 
Hyperplasia of Leydig cells with 
reduced cytoplasma 
18% 72% 52% 70% 
 
 
Diisobutyl phthalate has comparable anti-androgenic effects to Di-n-butyl phthalate in rat fetal testis
Majken Dalgaard, Julie Borch, Stine Broeng Metzdorff, Marta Axelstad, Anne Marie Vinggaard 
Danish Institute for Food and Veterinary Research, Mørkhøj Bygade 19, DK-2860 Søborg, Denmark
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Fig 4. Testosterone levels at GD 19 and 20/21 in male rat fetuses. A) 
Testicular testosterone content B) Testicular testosterone production ex 
vivo (n=5-6). Figures show mean ±SEM. Asterisks indicate a statistically 
significant difference compared to controls ***:p<0.001.
Anogenital distance / cubic root of BW
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
1,6
GD 19,
male
GD 20/21,
male
GD 19,
female
GD 20/21,
female
m
m
/
g
_
-
3
Control
DiBP
**
*
**
Fig 3. Anogenital distance /cubic root of bw at GD 19 and 20/21 in male 
and female rat. Figure show mean ±SEM. Asterisks indicate a 
statistically significant difference compared to controls *p<0.05; **p<0.01. 
Fig 5. Expression of SR-B1, PBR, StAR, P450scc and 
P450c17 at GD19 and GD20/21 in testis relative to 
18SrRNA. Data for mRNA levels are arbitrary and 
represent means ± SEM (n=5-9). *p < 0.05; **p < 0.01; 
***p < 0.001
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Introduction
PHTHALATES are widely used as plasticizers in various consumer
products and building materials. Some of the phthalates are known to 
interfere with male reproductive development in rats, and di-n-butyl 
phthalate (DBP), diethylhexyl phthalate (DEHP) and butyl benzyl 
phthalate (BBP) were recently banned for use in toys in the EU due to 
their reproductive toxicity. Diisobutyl phthalate (DiBP) has similar 
structural and application properties as DBP, and is being used as a 
substitute for DBP. However, DiBP has not been as widely 
investigated in experimental animals as DBP. 
Diisobutyl phthalate (DiBP) (see fig 1.) has not previously been 
examined in fetal rat testis, though it is widely used and suspected of 
having similar reproductive effects as the well-studied DBP. Due to it’s 
similarities to DBP, DiBP can be used as a substitute for DBP, and is 
presently used in PVC, inks, paints, adhesives and cosmetics. Around
100 tons of DiBP is used in DK per year mainly as softeners in plastic, 
rubber, paints and glue, which account for 95% of the use. In the US, 
the monoester metabolite of DiBP, mono-isobutyl phthalate (MiBP), 
was found in women’s urine in levels ranging from 0.7 ng/mL (25th
percentile) to 5.1 ng/mL (75th percentile) (Swan et al., 2005). The 
exposure level of children to DiBP is unknown, but an estimate of the 
total exposure to DBP in Danish children aged 1-6 years is 400µg/kg
bw/day. This age group is estimated to be the group with the highest 
exposure level of DBP (Müller et al., 2003).
Since 1999 the six phthalates DEHP, DBP, BBP, DiNP, diisodecyl
phthalate (DiDP) and di-n-octyl phthalate (DnOP) have been 
temporarily banned in the EU in the manufacture of toys and childcare 
articles for children under the age of three because of their 
carcinogenic, mutagenic and reprotoxic effects. Recently, DBP has 
along with DEHP and BBP been banned for use in toys irrespective of 
age categories due to their reproductive toxicity. DiNP, DiDP, and
DnOP were concurrently banned in toys that can be put in the mouth 
by children.
Objectives
• To investigate if DiBP has comparable antiandrogenic effects to DBP 
after prenatal exposure. 
• To determine the optimal time for detection of effects on fetal
testosterone production.
Materials and Methods
• Pregnant Wistar rats were gavaged from GD 7 to GD 19 or GD 20/21
• Doses: Vehicle (corn oil) or 600 mg DiBP/kg bw/day
• Male fetuses were examined at GD 19 or GD 20/21
• AGD in males and females was measured
• Testicular testosterone level and production were investigated
• Quantitative RT-PCR: investigation of mRNA expression of the 
steroidogenic factors SR-B1, PBR, StAR, P450scc, and P450c17 (see 
fig 2.).
• Immunohistochemical studies of StAR, and P450scc protein levels in
fetal testes.
Fig 1. Structure of  diisobutyl
phthalate
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Fig 2. The steroidogenic pathway
Fig 7. Testicular histopathology at GD 19 (A+B) and 
20/21 (C+D) in male rat fetuses exposed to vehicle 
(A+C) or 600 mg DiBP/kg bw/day (B+D) from GD 7 to 
GD 19 or 20/21. DiBP-exposed animals had a larger 
number of gonocytes, which were located centrally in 
the seminiferous tubules (^) due to vacuolization of 
Sertoli cell cytoplasm (#). Leydig cells (*) of DiBP-
exposed animals were found in clusters and had small 
cytoplasm and small irregular nuclei. > Multinucleated 
gonocytes. Original magnification 40x.
Fig 6. Immunohistochemical staining of testes from 
20/21-day-old male rat fetuses exposed to 0 or 600 
mg DiBP/kg bw per day from GD 7 to GD 20/21. The 
intensity of staining in Leydig cells for StAR (A+B) 
and P450scc (C+D) is clearly reduced in DiBP-
exposed animals (B, D) compared to controls (A, C). 
Original magnification 40x.
Conclusions
•Based on the current results, it appears likely that DiBP has similar 
reproductive effects to DBP, such as testicular and epididymal atrophy 
or agenesis, and reduced semen quality.
• DiBP has similar testicular and developmental effects as DBP and 
DEHP, indicating a reason for concern about the use of DiBP as a 
substitute for DBP.
• In this study, GD 20/21 appears to be the optimal time for 
investigating changes in anogenital distance, testosterone levels, and 
testicular histopathology. At the m-RNA level, effects on factors 
involved in steroidogenesis seems more detectable at GD 19.  
Results
•AGD in males was significantly reduced at GD 20/21 and AGD 
in females was significantly increased at GD 19 and 20/21 after 
DiBP exposure (Fig 3) 
•At GD 19 and GD 20/21, testicular testosterone content and 
testicular testosterone production ex vivo were reduced in the 
DiBP group compared to controls (Fig 4)
• Gene expression levels of SR-B1, StAR, P450scc and P50c17 
were decreased at GD 19 and GD20/21. No effect was 
observed on PBR mRNA (Fig 5)
• Reduced immunohistochemic staining intensity of the two 
proteins StAR and P450scc was seen with DiBP (Fig 6)
•DiBP exposed animals had the histopathological 
characteristics also seen with other phthalates at GD 20/21. The
number of gonocytes appeared to be increased, and they were 
located centrally in the seminiferous tubules due to vacuolization 
of Sertoli cell cytoplasm. Leydig cells were found in clusters and 
had small cytoplasm and small irregular nuclei (Fig. 7) Supported by a grant from the Nordic Council of Ministers and the Danish Medical Council (grant no. 22-03-0198 and 2107-04-0006).
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In vitro study on PPARα and PPARγ transactivation by environmental 
contaminants 
Peroxisome proliferators activated receptors (PPARs) are a family of nuclear receptors (α, γ1, γ2, 
and δ, previously called β), which are present in many tissues. PPARs have mainly been examined 
for their involvement in fatty acid metabolism in liver, where PPARα is involved in the catabolism 
of fatty acids, and PPARγ promotes storage of fatty acids 1. PPARs promote the uptake of 
cholesterol in hepatic cells, and may thereby reduce the cholesterol content of extrahepatic tissues. 
PPARγ ligands are used as hypolipidemic and anti-diabetic drugs. PPARs also play a role in the 
immune system, and PPARγ ligands have also been found to have an anti-tumor effect (breast, 
prostate), and have been tested in clinical trials for prostate cancer treatment 2. 
The natural ligands for PPARs have not been identified, although many endogenous compounds 
have been found to bind the receptors with varying affinity. Whether any of the various potential 
ligands may be a true natural ligand depends on the affinity of the ligand as well as the 
physiological concentration of the compound in various cell types. 15-deoxy-delta12,14-
prostaglandin J2 has been suggested as an endogenous ligand for PPARγ, while mono- and 
polyunsaturated fatty acids, long-chain fatty acyl-CoAs as well as eicosanoids have been suggested 
as natural PPARα ligands 3. The anti-diabetic drugs thiazolidinediones are high-affinity exogenous 
PPARγ ligands and the hypolipidemic fibrates are specific PPARα ligands 3.  
Additionally, several environmental contaminants have been found to be PPAR ligands in vitro. 
Peroxisome proliferation is a common toxicological response, which is related to chemically 
induced alteration of hepatic function. Several environmental contaminants have been described as 
peroxisome proliferators based on their hepatic effects, but have not been tested for PPAR 
interaction in vitro. Certain perfluorinated compounds, e.g. perfluorooctanoate (PFOA) and 
perfluorooctanesulfonate (PFOS), which are used for surface treatment and emulsification, are 
known to be peroxisome proliferators. PFOA has been found to activate PPARα in vitro, whereas 
the interaction of PFOS with PPARs has not been examined 4;5. Additionally, metabolites of the 
abundantly used phthalates, which are present in PVC and other consumer products, are known to 
activate all types of PPARs 6. Certain pesticides have also been reported to activate PPARs 7.  
In addition to the hepatotoxic effect, some exogenous PPAR agonists including PFOA and 
phthalates are found to be testicular toxicants and/or suppress steroid synthesis in testes and ovaries 
of experimental animals 8-10. Certain phthalates reduce testosterone production in rats, and it has 
been suggested that phthalate exposure is related to reproductive disorders in humans 11. As various 
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thiazolidinedione drugs also affect steroid synthesis in vitro and in vivo in animals and humans, it 
may be hypothesized that PPARs are somehow involved in chemically-induced inhibition of steroid 
synthesis, as reviewed by Corton & Lapinskas 10.   
Human blood levels of PFOA, PFOS and similar compounds have increased since the 1970s, but 
due to their accumulation in the environment, these compounds have recently been phased out by 
the manufacturer and blood levels are now levelling out 12. Humans are exposed to high levels of 
phthalates mainly via food, as phthalates present in the environment end up in e.g. water, fish, and 
plants, but to some extent children are also exposed via mouthing of toys or via inhalation of dust 
containing phthalates 13. 
In addition to phthalates and perfluorinated compounds, studies have shown testosterone-reducing 
and reproductive toxicity of parabens, which are widely used in moisturizers and cosmetics. Rat 
studies showed reduced testosterone levels and sperm production when orally exposed to 
butylparaben or propylparaben, while methylparaben and ethylparaben did not affect hormone 
levels or sperm production 14-16. As humans may be exposed to high levels of these chemicals, it is 
essential that their toxicological profiles are examined thoroughly. Parabens are absorbed from skin 
and the gastrointestinal tract, hydrolysed, conjugated and excreted via urine and can be detected in 
urine of humans from the general population 17. Parabens were also found in human breast tumors, 
and as parabens act as weak estrogens, this finding has led to concern for their involvement in 
breast cancer development 18;19.  
Prochloraz is a fungicide with antiandrogenic effects in rats and multiple mechanisms of action 
including antagonism of the androgen receptor and inhibition of fetal testosterone synthesis 20.  
In the current study, propylparaben, propylparaben, PFOA, monoethylhexyl phthalate (MEHP), and 
prochloraz were evaluated for their ability to interfere with PPARα and PPARγ activation or 
antagonism in a reporter gene assay along with the PPARα ligand WY14,643 and the PPARγ ligand 
rosiglitazone. 
 
MATERIALS AND METHODS: 
Test compounds: Rosiglitazone (BRL 49653), cas no. 122320-73-4, was from Cayman Chemicals 
(cat no 71740). WY 14,643, cas no. 50892-23-4, was from Calbiochem (cat no 681725). 
Propylparaben, cas no. 94-26-8, purity 99+%, was from Acros, Belgium. Propylparaben, cas no. 94-
13-3, purity 99+%, was from Acros, Belgium. Perfluorooctanoate (PFOA), cas no. 335-67-1, purity 
96%, was from Acros, Belgium. Monoethylhexyl phthalate (MEHP), cas no. 4376-20-9 was from 
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Accustandard, New Haven, CT. Prochloraz, ca no. 67747-09-5, purity 99.3%, was from Institute of 
Organic Chemistry, Warsaw, Poland. Test compounds were dissolved in DMSO (Sigma) to 
concentrations of 1 mM (Rosiglitazone) or 30 mM (other compounds). NIH-3T3 cells and plasmids 
containing the PPAR respondent UAS-TK-luc reporter as well as gal4-DBD_mPPARαLBD and 
gal4-DBD_mPPARγLBD expression vectors were kindly provided by S. Mandrup, University of 
Southern Denmark. 
NIH-3T3 cells were maintained in phenol-free DMEM/F12 (Gibco, Paisley, UK) with 10% 
charcoal-filtered calf serum (Biological Industries Ltd, Israel) and 1% PSF at 37°C in 5% CO2/air. 
To examine the effect of different compunds on ligand-induced PPAR transactivation, cells were 
transiently transfected with the reporter construct 4xUAS-TK-luc and vectors expressing either 
PPARα or PPARγ. As positive controls WY14,643 was selected as a potent ligand for PPARα and 
rosiglitazone as a potent ligand for PPARγ.  
On day 1 of the experiment, cells were counted and transferred to 96-well cell-culture plates 
(PerkinElmer, Massachusetts, USA) at a density of 7000 cells per well. After 20 hours, cells were 
transfected with UAS-TK-luc reporter plasmid and either gal4-DBD_mPPARαLBD or gal4-
DBD_mPPARγLBD expression vectors using FuGene ® (Roche, Mannheim, Germany) as a 
transfection reagent. One hour before transfection, medium was changed; FuGene and serum-free 
medium was mixed using 4.5 µl FuGene in 10 µl medium per well and added to a mixture of the 
plasmids with a total cDNA content of 75 ng per well. Plasmids were mixed in a 1:2 ratio for gal4-
DBD_PPARαLBD and 4xUAS-TK-luc and a ratio of 1:1 for gal4-DBD_mPPARγLBD and 
4xUAS-TK-luc. These ratios and cDNA concentrations had been selected as the optimal for each 
receptor giving the highest activation level compared to other plasmid ratios and DNA contents. 
The FuGene-cDNA mixture was incubated for 30 minutes before being added to the cells.  
5 h after transfection, media was removed and new media containing test compounds was added 
and left for incubation over night (22 h). Concentrations of test compounds ranged from 0.3 to 100 
µM and the maximal concentration of the solvents DMSO or ethanol were below 0.3%, which had 
previously been found not to be cytotoxic. Cells were lysed in a lysis buffer containing 25 mM 
trisphosphate, pH 7.8, 15% glycerol, 1% Triton X-100, 1mM DTT, and 8 mM MgCl2, followed by 
shaking for 15 min. Luciferase activity was measured directly using a BioOrbit Galaxy luminometer 
by automatic injection of 40 µl substrate containing 1 mM luciferin and 1 mM ATP in lysis buffer 
and the chemiluminiscense generated from each well was measured ova a 1 s interval after an 
incubation time of 2 s. 
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In the agonist assay, the luciferase activity levels induced by test compounds were compared with 
the luciferase activity level in wells containing media only. Results are shown as fold induction 
compared to the activity levels obtained with the specific ligands. In the antagonist assay, the test 
compounds were added to wells together with either 30 µM WY14,643 (PPARα assay) or 1 µM 
rosiglitazone (PPARγ assay). Results are shown as percentage activation compared to the activity 
level obtained with the same concentrations of WY14,643 or rosiglitazone alone. 
Each plate included three wells for each concentration of test compounds, 12 wells of the negative 
control (media only) and 12 wells per plate of positive controls (WY14,643 or rosiglitazone). All 
assays were performed in triplicates and if variation between the runs was too large, a fourth or fifth 
run was performed. Results are shown as mean +/- SD of the three independent experiments.  
Cytotoxicity was measured after incubation with test compounds using Alamar Blue ® (BioSource, 
Camarillo, CA)  to assess the proliferation of cells. Cells were grown under similar conditions as for 
the reporter gene assay, except that black 96-well microtiterplates (Costar, Corning, NY) were used. 
Alamar Blue was then added to media in a final concentration of 10%. Fluorescence levels increase 
as Alamar Blue is reduced by active cells, and the measured fluorescence thus reflects the number 
of living cells. After the addition of Alamar Blue, fluorescence levels were monitored for 4 h using 
a Victor2, 1420 Multilabel counter (PerkinElmer, Massachusetts, USA). Flourescence levels were 
increasing approximately linearly from 2 to 4 h incubation time, and the cytotoxcity at different 
concentrations of test compounds were compared after 3 h of incubation. Results are shown as 
mean +/- SD of the three independent measurements. 
Statistical analysis was performed using SAS Enterprise guide 3.0 (SAS Institute Inc). Non-
processed and ln-transformed data were tested for homogeneity of variance and normal distribution. 
Using the appropriate transformation, data were analyzed by one-way analysis of variance 
(ANOVA) followed by Dunnett’s post hoc test. 
 
RESULTS: 
Transactivation of PPARα and PPARγ was examined in reporter gene assays. For the determination 
of agonism, transactivation of PPARα and PPARγ was assessed by adding different concentrations 
of test compounds to cells transiently transfected with expression plasmids for either mouse PPARα 
or mouse PPARγ and a reporter containing the PPAR response element coupled to the luciferase 
gene (UAS-TK-luc). 
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Concentration-response curves for the control ligands WY14,643 and rosiglitazone were 
determined in order to select concentrations relevant for the determination of antagonism. Sub-
maximal activation (60 to 75 % of the maximal observed activity) on the steep linear part of the 
curve was obtained with 30 µM WY14,643 and 1 µM rosiglitazone (Fig. 1). These concentrations 
were applied for antagonist assays, in which the positive control ligands were added together with 
the test compounds. The concentration-response curve for rosiglitazone only included 
concentrations up to 10 µM as higher concentrations resulted in high concentrations of DMSO 
(above 0.3%), which were cytotoxic to the cells. 
Butylparaben and propylparaben were weak activators of PPARα with lowest observed effect 
concentrations (LOEC) of 30 µM and 100 µM, respectively, and transactivated PPARγ from 10 and 
100 µM, respectively (Fig. 2). Both parabens activated PPARα approximately 2-fold at 100 µM. 
Maximal induction of PPARγ by 100 µM of butylparaben was approximately 4-fold, while 100 µM 
propylparaben activated PPARγ 2-fold. PFOA was a strong activator of PPARα from 30 µM with a 
maximum of 15-fold activation at 100 µM (Fig. 2A). PFOA was a weaker activator of PPARγ from 
30 µM with a maximum of 4-fold activation at 100 µM (Fig. 2B). MEHP activated PPARα from 3 
µM and PPARγ from 10 µM (Fig. 2). MEHP was a much stronger activator than the other 
compounds with a maximal activation at 100 µM of 28-fold for PPARα and 49-fold for PPARγ. 
Prochloraz reduced the luminescence level compared to controls in both the PPARα- and the 
PPARγ-assay (Fig.2). This may either indicate cytotoxicity or antagonism of a “background” 
activation of PPARs by factors present in the media. 
In the antagonist assays, test compounds were added concomitantly with the relevant control ligand. 
Propylparaben, propylparaben, and prochloraz reduced the luciferase activity measured in the 
PPARα as well as the PPARγ assay (Fig. 3). However, the Alamar Blue assay revealed cytotoxicity 
at high concentrations of these compounds (Fig. 4). As the concentration-response curves for the 
PPARα and PPARγ antagonist assays were very similar to the curves in the Alamar Blue assay, this 
indicates that the alterations in the antagonist assays were in part due to cytotoxicity. On the other 
hand, some degree of antagonism probably occurs, since low luminescence levels were seen at low 
(non-cytotoxic) concentrations of propylparaben in the PPARγ antagonist assay and at relatively 
low concentrations of prochloraz in the PPARα as well as the PPARγ antagonist assays (Fig. 3). 
The highest concentrations of MEHP and PFOA increased the measured luciferase activity in the 
PPARα antagonist assay, but also in the Alamar Blue assay, indicating that the compounds 
stimulated the proliferation of cells (Fig. 3A and 4). In the PPARγ antagonist assay, PFOA did not 
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alter luciferase activity, whereas MEHP reduced luminescence at 30 µM. This likely reflected the 
cytotoxicity of MEHP, as the Alamar Blue assay showed that MEHP was cytotoxic at 30 µM, but 
stimulated cell proliferation at 100 µM.  
Also 30 µM WY14,643 increased measured fluorescense in the Alamar Blue assay to 
approximately 120% of the level observed in wells containing media only (data not shown). This 
indicates stimulation of cell proliferation. When 30 µM WY14,643 or 1 µM rosiglitazone were 
added to wells together with test compounds in the Alamar Blue assay, the results were similar to 
the results without these control ligands (data not shown). As the activation by PFOA, MEHP, 
WY14,643 and rosiglitazone observed in the PPAR agonist assays was several-fold, it is clear that 
this was not solely due to the stimulation of cell proliferation. 
Results are collected in Table 1 and compared to findings described in the literature.   
DISCUSSION: 
This is the first study to describe parabens as being PPAR ligands. The transactivation of PPARα 
and PPARγ by butylparaben and propylparaben is weaker compared to the activation seen with 
compounds such as MEHP and PFOA. Both compounds appeared to be slightly stronger activators 
of PPARγ than PPARα as judged by their lowest observed effect concentrations and their maximal 
fold-induction, but this may also reflect a higher sensitivity of the PPARγ assay in general. The 
cytotoxicity observed with high concentrations of butylparaben and propylparaben may in fact lead 
to an underestimation of the potency of these compounds. Analysis of paraben interaction with 
PPARs using other (not cell-based) methods may therefore reveal higher potency than observed 
with these cells.  
The concentration-response curves show that butylparaben and prochloraz antagonize the activation 
of PPARγ obtained with rosiglitazone, and prochloraz also antagonizes the activation of PPARα by 
WY14,643. The impact of this antagonism on the physiological function of endogenous PPAR 
ligands is unknown. PPARs influence various physiological pathways including reproductive 
hormone synthesis, fatty acid metabolism, insulin function, immunology, cancer development, the 
central nervous system and the cardiovascular system 2. Therefore, the observation that parabens are 
PPAR ligands indicates that these compounds may have multifaceted effects – beneficial or 
adverse. Other parabens than those investigated in the current study are abundantly used as well and 
further studies may reveal whether they also activate PPARs. 
Several studies have described the activation of PPARα and PPARγ by MEHP and PFOA. The 
activation of PPARs by PFOA and MEHP in the current study is comparable to results described by 
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other authors. As listed in Table 1, PPARα activation is obtained at a higher concentration of PFOA 
in the current study than in the study by Maloney & Waxman (1999) indicating a higher sensitivity 
in their assay compared to ours. On the other hand, PPARγ activation by PFOA could not be 
detected in that study, but was seen in our assay. Furthermore, our assay detects PPARα and PPARγ 
activation by MEHP at low concentrations compared to the other studies listed. Additionally, very 
high fold-induction levels for both PPARα and PPARγ activation is obtained with MEHP in our 
assay compared to results reported by others 5;21-23 (Table 1). Collectively, this assay appears to be 
quite sensitive and appropriate for screening of chemicals for PPARα and PPARγ interaction.  
However, the control ligands as well as some of the tested compounds stimulated the proliferation 
of the NIH-3T3 cells, a finding that may be related to their PPARα and PPARγ activation. In order 
to eliminate the influence of stimulation of cell proliferation by chemicals, it may be relevant to use 
an alternative cell line that is not stimulated by these compounds.  
Future studies may reveal to which degree antagonism of PPARα or PPARγ activity by 
environmental contaminants may affect the function of PPARα or PPARγ-dependent tissues. 
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A B 
Fig. 1. Concentration-response curves for transactivation of (A) PPARα and (B) PPARγ by 
WY14,643 and rosiglitazone, respectively. NIH-3T3 cells transiently transfected with a PPAR 
responsive luciferase reporter gene vector and vectors expressing either mouse PPARα or PPARγ 
were exposed for 22 hours to test compounds. The measured luciferase activity reflected the 
activation of PPARs by the test compounds. Results are shown as fold induction, i.e the receptor 
activity obtained with the respective ligands divided by the activity measured when no ligand was 
present. Data represent means +/- SD of triplicates. 
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Fig. 2. Transactivation of (A) PPARα and (B) PPARγ by butylparaben, propylparaben, PFOA, 
MEHP and prochloraz. Results are shown as fold activation, i.e the activity level obtained with the 
respective compounds divided by the activity level measured when no ligand was present in the 
media. Data represent mean +/- SD of 3 independent experiments. 
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A 
B 
Fig. 3. Butylparaben, propylparaben, PFOA, MEHP and prochloraz were tested for (A) PPARα and 
(B) PPARγ antagonism. Compounds were added together with either 30 µM WY14,643 or 1 µM 
rosiglitazone to transfected cells and the ability of test compounds to antagonize the ligand-induced 
response was assessed. Results are shown as the receptor activity obtained with test compounds plus 
the specific ligands as a percentage of the activity level obtained with the specific ligands alone. Data 
represent mean +/- SD of 3 independent experiments. 
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Fig. 4. Cytotoxicity of butylparaben, propylparaben, PFOA, MEHP and prochloraz in NIH-3T3 
cells measured by Alamar Blue assay. Propylparaben, propylparaben and prochloraz were cytotoxic 
at 30, 30, and 10 µM, respectively, whereas the highest dose of PFOA and MEHP increased the 
number of proliferating cells after 22 hours of incubation. Results are shown as fluorescence levels 
obtained in wells with test compounds relative to wells containing media only. Data represent 
means +/- SD of triplicates from one experiment. 
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Table 1. Comparison of transactivation of PPARα and PPARγ by environmental contaminants in 
different studies. 
 mPPARα  mPPARγ 
 LOEC MOEC Maximal 
effect (fold 
induction)  
LOEC MOEC Maximal 
effect (fold 
induction) 
Butylparaben, 
current study 
30 µM 100 µM 2 10 µM 100 µM 4 
Propylparaben, 
current study 
100 µM 100 µM 2 100 µM 100 µM 2 
PFOA,  
current study 
30 µM 100 µM 15 30 µM 100 µM 4 
PFOA, Maloney 
and Waxman 
1999 5 
0.5 µM  10 µM 17 - - - 
MEHP,  
current study 
3 µM 100 µM 28 10 µM 100 µM 49 
MEHP, Maloney 
and Waxman 
1999 5 
5 µM 20 µM 4 5 µM 100 µM 4 
MEHP, Hurst & 
Waxman 2003 22 
0.5 µM 6 µM 2 3 µM 30 µM 4 
MEHP,  
Lampen 2003 23 
40 µM #  250 µM 6 30 µM # 250 µM 6 
MEHP,  
Bility 2004 21 
10 µM 200 µM 11 30 µM 100 µM 2.5 
LOEC: lowest observed effect concentration 
MOEC: maximal observed effect concentration  
# EC2x, i.e. concentration inducing 2-fold activation  
¤ human PPAR 
 
  
 
  
In vivo study on butylparaben, PFOA and rosiglitazone  
 
METHODS: As studies have indicated that Butylparaben, PFOA or Rosiglitazone may reduce testosterone 
levels in young or adult rats, we aimed to reveal whether these chemicals affect fetal testosterone production 
and AGD at GD 21. Four groups of 8 pregnant Wistar rats were gavaged with either vehicle or 100 mg 
butylparaben/kg bw/day, 20 mg PFOA/kg bw/day or 1 mg rosiglitazone/kg bw/day from GD 7 to 21. Study 
design and analysis methods were similar to those described in Paper V, as the study on DIBP was made in 
parallel, i.e. using the same control group and similar treatments of animals and tissues.  
RESULTS: The applied doses of PFOA, butylparaben or rosiglitazone did not affect anogenital distance or 
testicular testosterone production in male fetuses, indicating that these chemicals are not antiandrogenic by 
perinatal exposure at these dose levels (data not shown, see also Table 5 in the Result section of the thesis). 
These doses were chosen as they were shown to reduce testosterone production in young or adult rats in 
studies by other groups. Testicular histopathology, immunohistochemical staining intensity and mRNA 
levels for factors involved in steroidogenesis were comparable between the exposed groups and the control 
group (data not shown, see also Table 6 and 7 in the Result section of the thesis).
 
 
  
 
 
 
 
